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ABSTRACT OF THE DISSERTATION
Siderophore Pathways and Non-traditional Antibiotic Strategies in Multi-drug Resistant
Acinetobacter baumannii
by
Tabbetha J. Bohac
Doctor of Philosophy in Chemistry
Washington University in St. Louis, 2019
Professor Timothy A. Wencewicz, Chair
The rise of antibiotic resistance is driving exploration of non-canonical antibiotic
approaches, including neutralization of virulence factors. Multi-drug resistant (MDR) Gramnegative pathogens, including Acinetobacter baumannii, are of particular concern because of the
small number of clinically useful antibiotics available for use. Here we both expand upon the
existing knowledge of two of the siderophores of A. baumannii, acinetobactin and fimsbactin, and
utilize this knowledge to synthesize novel compounds for the inhibition of pathogenic A.
baumannii in whole cell assays.
Furthering the current knowledge of the natural siderophore systems of A. baumannii, we
were able to investigate the interaction of acinetobactin with transport proteins, as well as examine
the role of the fimsbactin siderophores in iron acquisition. Specifically, we report a crystal
structure of siderophore binding protein BauB bound to holo-acinetobactin along with fluorscence
quenching assays of acinetobactin and preacinetobactin analogs to BauB. Additionally, we isolate
fimsbactin from A. baumannii and show the importance of balance between concentrations of
siderophores. Further, we explore the cooperative relationship between siderophores fimsbactin A
and fimsbactin F.
xv

With this fundamental knowledge in hand, we report a new method for blocking iron
acquisition in MDR A. baumannii as an antivirulence strategy using rigid oxazole analogs of the
known siderophore pre-acinetobactin. In addition, we report the synthesis fimsbactin mimics and
confirm utilization of siderophore uptake pathways in model A. baumannii systems. Moreover, the
fully functional fimsbactin mimics possess a synthetic handle for the coupling of antibiotics
allowing for simple incorporation into studies aimed at Trojan horse antibiotic delivery
mechanisms.
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Chapter 1: Introduction – Siderophores of
Acinetobacter baumannii

1

1.1 Preface
This chapter was written by T. Bohac. Section 1.4 was adapted in part from [Bohac, T. J.,
Fang, L., Giblin, D. E. & Wencewicz, T. A. ACS Chemical Biology, Manuscript accepted]. TJB
isolated Fimsbactin A, performed characterization, BauB fluorescent quenching binding studies
and BauB displacement assays. LF performed all growth curves. DEG performed all DFT
calculations. TAW served as principal investigator and oversaw experimental design.

1.2 Multi-Drug Resistant (MDR) Pathogens
The Center for Disease Control (CDC) and World Health Organization (WHO) have
identified MDR pathogens as a serious threat to the health and well-being of the nation and the
World.1 If not addressed, this threat is predicted to grow, as deaths due to antimicrobial resistance
are projected to surpass cancer as the leading cause of death world wide by 2050 and account for
the loss of 10 million lives per year.2 In addition to the physical and emotional costs associate with
the loss of lives, by 2050, the total loss in global GDP due to antimicrobial resistance is projected
to be greater than $100 trillion.2 Even though MDR is projected to have a devastating impact
worldwide, many pharmaceutical companies are pulling out of antibiotic research and shutting
down whole research divisions due to the lack of profitability in antibiotics. Furthermore, due to
the rapid evolution of resistance mechanisms, resistant strains are rendering antibiotics ineffective
over shorter periods of time, limiting the profit window. Thus, the burden of research has fallen to
academic and non-profit institutions to develop solutions to combat antibiotic resistance through
the identification of novel antimicrobial compounds with novel mechanisms of action. This goal
serves as the motivation for the work described in this dissertation, which seeks to expand the
fundamental knowledge of how pathogenic bacteria function and then utilize this knowledge to
synthesize novel potential therapeutic applications to combat the rise in antibiotic resistance.
2

While resistance amongst pathogenic bacteria seems to be growing globally, there are a
handful of pathogens that are multidrug resistant; that is resistant to three or more current antibiotic
classes (MDR). These pathogens make up the “ESKAPE” pathogens as they escape from treatment
with traditional antibiotics; these pathogens include Enterococcus faecium, Staphylococcus
aureus,

Klebsiella

pneumoniae,

Acinetobacter

baumannii,

Pseudomonas

aeruginosa ,

and Enterobacter species.3 Over 63% of A. baumannii infections (over 7000 annually) are MDR
and cause 500 deaths annually in the United States alone.1 Due to its highly resistant nature of this
Gram-negative bacteria, A. baumannii will be the focus for the work in this dissertation.

1.3 Iron Acquisition Pathways
Iron is of vital importance for almost all forms of life. The unique chemistry of iron,
specifically in the single electron interconversion of ferrous and ferric iron, is instrumental in a
plethora of biological processes including, but not limited to, nitrogen fixation, DNA biosynthesis
and oxygen transport.4 Thus, iron is essential for the proliferation of cell growth, which is
especially true in the case of an infection where a pathogenic bacteria is attempting to survive,
grow, and spread within a host environment. In the instance of an infection, one of the host’s first
line of defense is to sequester nutrients, such as iron, away from the pathogen through a process
called nutritional immunity, in hopes to starve out the pathogen. 5 This effect is observed in a
marked decrease in the concentration of iron in the human serum during times of infection,
reaching levels on the order of 10-24 M.6 In order for pathogenic bacteria to survive in host
environments, bacteria have evolved numerous acquisition methods for obtaining iron. These
methods are highlighted in this section.
Iron Acquisition from Heme

3

About 75% of total iron in mammals is bound to heme, thus making heme an attractive
target for bacteria from which to acquire iron.7 To access heme iron, pathogenic bacteria produce
small heme-binding proteins called hemophores that are then secreted from the bacteria, where it
can then bind heme. Upon successful binding of heme, the hemophore-heme complex is then
transferred to specific heme-binding receptor proteins. These proteins differ in Gram-positive and
Gram-negative pathogens. Near iron transporter (NEAT) proteins are located on the cell wall of
Gram-positive pathogens and are responsible for the transfer of heme through the peptidoglycan
and cytoplasmic membrane into the cytosol.7 However, since this dissertation is focused on the
Gram-negative pathogenic bacteria A. baumannii¸ we will focus this section on the iron acquisition
from heme by Gram-negative bacteria - specifically heme acquisition system A (HasA)-type
hemophores. The HasA/HasR from S. marcescens is the most well studied hemophore system of
Gram-negative pathogens and, thus, serves as a good model for iron acquisition from heme
pathways.4
HasA-type hemophores possess the ability to bind heme from a plethora of hemoproteins
such as myoglobin, hemoglobin and hemopexin.8 The iron acquisition pathway from heme in
Gram-negative bacteria is depicted in Figure 1.1. Upon the binding of heme, HasA-type
hemophores then complexes with HasR, a TonB-dependent outer membrane receptor transport
protein, and transfers the heme into the periplasm.9,10 To facilitate transport and acquisition of
heme from the periplam to the cytosol, substrate binding proteins (SBP) aid in trafficking the
substrates, in this case heme, to the inner membrane. Most of the common substrate binding
proteins that facilitate the transport of heme are characterized as cluster A, class III SBPs. 11 The
SBP then docks to inner membrane ABC transporter proteins which facilitate the transport of the
heme-iron into the cytosol. Once in the cytosol, the heme-iron complex then binds a heme
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oxygenase enzyme, in most cases, a nicotinamide adenine dinucleotide phosphate hydrogen
(NADPH)-dependent oxygenase. These enzymes oxidize the heme ring and release iron which is
then utilized by the bacteria.4 The heme is then degraded or effluxed out of the cell by enzymes to
prevent toxicity to the bacteria.7
Transferrin and Lactoferrin Iron Acquisition
Some pathogenic bacteria may utilize iron from host glycoproteins, transferrin and
lactoferrin. One difference being iron acquisition from host glycoproteins, the large size of
glycoproteins prohibits their transfer across the outer membrane, and thus iron must be removed
directly from the glycoprotein in the extracellular space. The acquisition pathway is depicted in
Figure 1.2. The pathway commences with the Fur-regulated bipartite system of Ton-B-dependent
outer member receptor protein TbpA (transferrin)/LbpA (lactoferrin) and surface-associated
lipoprotein TbpB (transferrin)/LbpB (lactoferrin).13,14 While TbpA/LbpA and TbpB/LbpB can
both bind holo proteins, it is thought that TbpA/LbpA are also able to bind the apo forms of
transferrin/lactoferrin. Therefore, it is hypothesized that a TbpB/LbpB-holo-hTf-TbpA/LbpA
complex is formed and responsible for the transport of free iron across the outer member, although
there currently is no fully elucidated mechanism.4,14 Once the free iron reaches the periplasm, a
periplasmic binding protein (PBP) specifically ferric-binding protein FbpA is responsible for the
facilitating of iron(III) across the periplasmic space.15 FbpA then delivers the iron(III) to ABC
transporter, FbpBC, which shuttles the free iron to the cytoplasm for use by the pathogenic
bacteria.
Free Inorganic Iron Transport
Many pathogenic bacteria are capable of transporting ferrous iron through a TonBindependent manner using a ferrous iron transport system, Feo.16 The Feo system possesses a
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feoABC operon, comprised of three genes.4 Once to the periplasm, free elemental iron can be
actively transported into the cytoplasm for use by the bacteria. To help facilitate this process, it
has been seen that bacteria can secrete reductase enzymes into the extracellular space with the role
of converting ferric iron into ferrous which can then be transported. 4
Siderophores
An additional mechanism for iron acquisition by pathogenic bacteria, and the focus of this
dissertation, is the utilization of small iron-chelating secondary metabolites called siderophores,
greek for “iron-carrier”. While there are over 500 siderophores known and characterized, with a
plethora more yet to be discovered, all siderophores can be classified into four distrinct broad
classes based upon their iron-binding moieties: catechols, hydroxamic acids, α-hydroxy carboxylic
acids and mixed ligands siderophores (Figure 1.3). Catechol siderophores are produced in both
cyclic and linear variants, such as enterobactin, protochelin and vanchrobactin. This class of
siderophores has a high iron affinity, as two negatively charged oxygen atoms that can delocalize
electron density throughout the aromatic ring. Enterobactin is a well-studied cyclic trimer and one
of the strongest known iron chelators, with an extremely high iron affinity of up to 10 -52.

17

Hydroxamate bidentate chelating groups can exist in keto or iminol forms. When there in an
increased electron density on the carbonyl carbon, in the iminol form, there tends to be a larger
iron affinity, this form is stabilized with addition of electron donating groups on the nitrogen. 4
Siderophores comprising this class include Desferrioxamine E, Desferrioxamine B and
Cepabactin. While α-hydroxycarboxylic acid groups are normally found in our mixed ligand
siderophore class, there are a few siderophores, such as achromobactin and staphyloferrin, which
bind iron solely utilizing α-hydroxycarboxylic acid groups. Interestingly, these groups can be
photoreactive upon coordination to iron (III).19,20,21 The vast majority of siderophores comprise
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the fourth class of mixed-ligand siderophores which possess numerous different variations of the
three aforementioned binding moieties. This class includes acinetobactin and amychelin, as well
as many others.
Siderophores are biosynthesized via either a multimodular enzyme assembly line call
nonribosomal peptide synthetase (NRPSs) or independent of the multimodular NRPS system
deemed NRPS-independent siderophore (NIS) synthesis. NRPSs synthesize siderophores in a
modular fashion, as each domain facilitates the step for the growing peptide chain with addition of
proteinogenic and non-proteinogenic amino acids. These domains include, but are not limited to,
activation, adenylation, thioesterase, aceyl carrier proteins, condensation, cyclization, dehydration.
Examples of NRPS synthesized siderophores include enterobactin and vibriobactin. NRPSs are
also responsible for the synthesis of other small molecules, such as peptide-based antibiotics like
penicillin and vancomycin.21 Alternatively, NIS enzymes catalyze the synthesis of nonpeptidic
siderophores through the addition of alcohols, carboxylic acids and amines via the formation of
ester and amine bonds; this process allow for vast versatility. 22 Most α-hydroxycarboxylic acid
siderophores are synthesized in a NIS manner, including staphyloferrin and aerobactin. Further,
there are hybrid siderophores, such as petrobactin, which are synthesized using both NRPS and
NIS assembly. Later in this chapter, we will discuss in depth the biosynthesis of the siderophores
of interest for this dissertation.
While the exact mechanism of siderophore transport and iron acquisition is siderophore
dependent and not fully elucidated, here we will provide a generalized overview of this process.
Once the siderophore is biosynthesized, it is then effluxed outside of the bacteria to the
extracellular space where it may then bind iron. In Gram-negative pathogens, the siderophore-iron
complex is then transported across the outer membrane into the periplasm via a TonB-dependent
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protein. Once in the periplasm, periplasmic binding proteins aid in trafficking of the siderophoreiron complex. Some siderophores, like enterobactin, may be reduced in the periplasm, releasing
the iron which can then be shuttled across the inner membrane. Other siderophores, like
acinetobactin, are shuttled from the periplasmic binding protein to the ABC transport proteins of
the inner membrane. Once in the cytoplasm, a reductase enzyme can reduce the iron, and the
siderophore may be recycled and efluxed back into the extracellular space, where the cycle can
continue. (Figure 1.4).
Many pathogenic bacteria synthesize multiple siderophores and while the exact benefit of
this structure remains unclear, it is hypothesized that a siderophore cocktail provides unique
advantages for the natural producer. A. baumannii, the pathogen of interest for this dissertation, is
one such pathogen that synthesizes multiple siderophores; these siderophores will be further
discussed in the following section.

1.4 Siderophores of A. baumannii
At least three unique structural families of siderophores (acinetobactin 23, fimsbactin24, and
baumannoferrin/acinetoferrin25,26) have been detected from clinical isolates of A. baumannii and
A. haemolyticus, Figure 1.5. In this section, the biosynthesis (Figure 1.6) and chemical synthesis
of each of these siderophore families will be presented.
Acinetobactin
Acinetobactin (Acb) is the most studied A. baumannii siderophore and is highly conserved
in all clinical isolates.27 Acinetobactins were the first A. baumannii siderophore class to be isolated
in 1994 and are the most studied class of A. baumannii siderophores.28 Acinetobactin is a
nonribosomal peptide (NRP) siderophore that is produced in a pre-acinetobactin (PreAcb) form
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featuring hydroxamate and imidazole metal binding motifs derived from L-histidine, along with a
phenolate-oxazoline metal chelating group derived from the condensation of 2,3dihydroxybenzoic acid (2,3-DHB) and L-Thr.29,30 The nonribosomal peptide synthetase (NRPS)
biosynthetic assembly of PreAcb starts with activation of 2,3-DHB and L-Thr as acyl adenylates
by adenylation domains A1 (BasE) and A2 (BasA), respectively, followed by formation of the aryl
acyl carrier protein ArCP (BasF) and peptidyl carrier protein PCP (BasB) thioesters, respectively
(Figure 1.7). Acylation of the α-amino group of the L-Thr-PCP thioester by the 2,3-DHB-ArCPthioester carbonyl is mediated by the condensation C domain (BasB), followed by dehydrative
cyclization to the phenolate oxazoline-PCP thioester catalyzed by the cyclization domain Cy
(BasD). Nucleophilic attack of N-hydroxyhistamine on the phenolate oxazoline-PCP thioester
carbonyl releases the mature PreAcb scaffold from the NRPS assembly line. PreAcb spontaneously
isomerizes to the isoxazolidinone Acb via nucleophilic attack of the hydroxamate oxygen on the
oxazoline-C5’ to undergo 5-exo-tet cyclization with clean stereochemical inversion.31 Formation
of the isoxazolidinone heterocycle masks the hydroxamate metal chelating motif leaving the dicatechol of the 2,3-DHB fragment and the imidazole as the free metal binding groups. 32 Both
PreAcb and Acb form stable 2:1 ferric complexes, PreAcb2Fe and Acb2Fe, respectively, and
stimulate A. baumannii growth under iron limiting conditions.33 Isomerization of PreAcb is slow
under acidic conditions and chelation of iron(III) prevents isomerization, which has led to
speculation that both PreAcb and Acb have a natural role in iron scavenging under acidic infection
conditions.31
The first total synthesis of acinetobactin was completed in 2010 by Takeuchi and
coworkers.34 The 9 total step synthesis is shown in Figure 1.8. Briefly, histamine dihydrochloride
is treated with sodium nitrate, followed by substitution with thionyl chloride, to provide the
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cholorethyl imidazole hydrochloride salt. S N2 reaction with N-boc-O-benzyloxyamine affords the
corresponding N-boc-O-benzyloxy imidazole, which upon treatment with TFA yields the free
amine. At the same time, 2,3 dihydroxybenzaldehyde was converted to the corresponding nitrile
through treatment with ammonium hydroxide, sodium formate and formic acid. To the nitrile,
acetyl chloride in methanol is added, followed by addition of sodium bicarbonate, to provide the
imidate. The imidate is then cyclized with L-threonine benzyl ester to afford the desired oxazoline
benzyl ester which yields the free acid upon hydrogenolysis. With the free acid and amine in hand,
EDC/HOBt mediated coupling in the presence of facilitating base provides the title compound
benzyl protected. Final hydrogenolysis yields pre-acinetobactin, which can then spontaneously
isomerize to acinetobactin.
Fimsbactin
The fimsbactin siderophores, fimsbactin A–F (Figure 1.9) were discovered in 2013 and
are also derived from an NRPS assembly line resembling the acinetobactin NRPS system, with
double heterocyclization domains and a nonmodular gradient organization of condensation
domains lacking a type I thioesterase terminating domain.34, 35 Fimsbactin A (Fim) was the primary
siderophore in the mixture isolated from A. baylyi ADP1, accounting for >85% of the total mass.
Fimsbactins B and C are derived from the incorporation of L-Thr instead of L-Ser into the
siderophore backbone while fimsbactin D–F are shunt biosynthetic products lacking the
cadaverine N-hydroxy group, the entire N-acetyl-N-hydroxy-cadaverine moiety, or seryl-O-2,3DHB ester, respectively. The NRPS phase of Fim biosynthesis is proposed to start with activation
of 2,3-DHB and L-Ser as acyl adenylates by adenylation domains A1 (FbsH) and A3 (FbsF),
respectively, followed by formation of the ArCP (FbsE) and PCP 1 (FbsE) thioesters, respectively
(Figure 1.7).24 Acylation of the α-amino group of the L-Ser-PCP1 thioester by the 2,3-DHB-ArCP10

thioester carbonyl is presumably mediated by the condensation C domain (FbsF), followed by
dehydrative cyclization to the phenolate oxazoline-PCP 1 thioester catalyzed by the Cy domain
(FbsE). A second equivalent of L-Ser is activated by the A3 domain (FbsF) and loaded to PCP2
(FbsF) as a phosphopantetheinyl thioester. Nucleophilic attack of the α-amino group of the L-SerPCP2 thioester on the phenolate oxazoline-PCP1 thioester carbonyl provides the intermediate Nacyl-Ser-PCP2 thioester intermediate. Trans-thioesterification from PCP 2 (FbsF) to PCP3 (FbsG)
and acylation of the Ser free hydroxyl by 2,3-DHB, presumably with catalysis by the C 2 domain
(FbsG) provides the penultimate PCP3-thioester. The C3 domain is predicted to mediate cleavage
of mature Fim from the NRPS via nucleophilic attack of the PCP 3-thioester carbonyl by the
primary amine of N-acetyl-N-hydroxy cadaverine. Premature cleavage from the FbsG NRPS
module prior to Ser acylation by 2,3-DHB or post-NRPS hydrolysis of fimsbactin A would result
in production of fimsbactin F. The remaining fimsbactin analogs can be accounted for by
incorporation of L-Thr instead of L-Ser (fimsbactin B and C, respectively), lack of cadaverine
oxidation (fimsbactin D), and competing hydrolysis of the penultimate PCP 3 thioester (fimsbactin
E).
In 2015, the Kim group successfully synthesized Fimsbactin B, D and F. 36 While they
proposed and executed a complete total synthesis of Fimsbactin A (the predicted >90% metabolite
of the Fimsbactins)25, they failed to isolated pure Fimsbactin A due to epimerization at the final
step. Their complete synthesis is depicted in Figure 1.10. Briefly, the synthesis of part A
commences with an SN2 substitution reaction of N-Boc-O-benzylamine and 4-chlorobutyronitrile.
Removal of the Boc-protecting group with TFA followed by N-acetylation installs the
hydroxamate moiety-benzyl ester protected. Reduction of the terminal nitrile group with
hydrogenation using Raney-Ni provides the free amine. EDC/HOBt-mediated coupling in the
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presence of facilitating base of the free amine with N-Boc-O-TBS-L-serine, followed by removal
of the Boc-protecting group by TFA yields part A. The synthetic route to part B begins with acid
catalyzed esterification of 2,3-dihydroxybenzoic acid followed by reflux with 1,2bis(bromomethyl)benzene and treatment with acid to provide the o-xylyl-protected 2,3
dihydroxybenzoic acid. EDC/HOBt-mediated coupling in the presence of facilitating base of the
free carboxylic acid and L-serine-methyl ester, followed by dehydrative oxazoline formation by
catalytic MoO2(TMHD)2, yields part B methyl ester. Final hydrolysis with potassium
trimethylsilanolate affords compound part B. With both precursors in hand, free amine part A is
coupled with free acid part B using EDC. Removal of TBS-protecting group by HF-pyridine,
followed by carbodiimide-promoted esterification with an additional equivalent of part B, affords
o-benzyl-o-xylyl-protected Fimsbactin A. Global deprotection hydrogenolysis provides the title
compound.
Baumannoferrin
Baumannoferrin is the most recently characterized A. baumannii siderophore, with its’
discovery reported in 2015.25 While there is currently no synthetic route to synthesizing
baumannoferrin, it is derived from an NRPS-independent siderophore synthetase (NIS)
biosynthetic process.25 A related NIS siderophore, acinetoferrin, has been reported from
environmental strains and the opportunistic human pathogen Acinetobacter haemolyticus.26, 37
Baumannoferrin is composed of citrate, 1,3-diaminopropane, 2,4-diaminobutyrate, decenoic acid,
and α-ketoglutarate.25 The lipophilic nature of the baumannoferrin decenoic acid side chain has
led to the proposal that the siderophore might be membrane associated. 38 Baumannoferrin is
structurally distinct from the NRPS siderophores PreAcb, Acb, and Fim. The structure contains
one hydroxamate and two α-hydroxy carboxylate metal binding motifs similar to chelating groups
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found in other NIS-derived, citrate-based siderophores, such as aerobactin produced by human
pathogens including Klebsiella pneumonia and uropathogenic E. coli (UPEC).39, 40 PreAcb/Acb
and Fim are structurally related by the hydroxamate, catecholate, and phenolate oxazoline metal
binding motifs found in common siderophores such as enterobactin 41 and vibriobactin42,
respectively. Biosynthetic operons for baumannoferrin and PreAcb/Acb are present in all genomesequenced clinical isolates of A. baumannii deposited in the NCBI database (taxid: 470).27 On the
contrary, only 4 unique strains (<10% of sequenced A. baumannii strains) contain genes associated
with fimsbactin biosynthesis and utilization (Figure 1.11). It appears as though human pathogenic
strains of A. baumannii always retain the capacity for producing at least two siderophores,
PreAcb/Acb and baumannoferrin, or occasionally three siderophores, if the Fim biosynthetic
operon is present and functional. Since Fim production is optional for pathogenicity, this raises the
question as to whether the structural similarity of PreAcb/Acb and Fim is functionally redundant
or if the siderophore pathways contribute cooperatively to iron and other metal ion acquisition,
leading to increased pathogen virulence.
It is common for pathogenic and environmental microbes to produce multiple siderophores
via the presence of multiple biosynthetic gene clusters (as for PreAcb/Acb, Fim, and
baumannoferrin in A. baumannii), production of shunt/fragment biosynthetic products (as for
fimsbactin A–F), precursor-directed biosynthesis (as for fimsbactin incorporation of Thr or Ser),
and/or biosynthetic tailoring reactions (as for acyl-enterobactins43).44 Additionally, pathogens
often produce siderophore transport proteins for siderophores produced by neighboring bacteria,
so called xenosiderophores.45 Pathogenic A. baumannii express the protein FhuD to enable the
utilization of hydroxamate-based xenosiderophores including desferrioxamine B, an FDA
approved treatment for human iron overload diseases.46 Potential advantages of utilizing multiple

13

siderophores44, 47 include synergistic effects of siderophore combinations on iron acquisition 31,
evasion of immune proteins such as siderocalin48, suppression of competing microbial growth49,
50

, stimulation of cooperative and synergistic microbial growth51, 52, expansion of metal uptake

beyond iron53, 54, quorum sensing and cell signaling55, nutritional passivation of necessary but
potentially toxic metals56, 57, quenching of reactive oxygen species58, 59, and induction of metaldependent cellular responses in the host.60, 61

1.5 Trojan Horse Strategies and Medicinal Applications of
Siderophores
The rise of infections caused by multi-drug resistant (MDR) Gram-negative pathogens,
including MDR Acinetobacter baumannii, is driving the exploration of nontraditional therapeutic
strategies including antivirulence therapies.62, 63 Blocking virulence pathways such as cellular
adhesion, protein secretion, biofilm formation, motility, and nutrient acquisition are presumed to
apply less selective pressure for resistance and might work synergistically with traditional
antibiotics.64 Targeting nutrient acquisition pathways is an attractive option since a
disproportionate percentage of the pathogen’s conditionally essential genome is comprised of
genes associated with nutrient scavenging.65,

66

Fundamental research of siderophores has

illuminated a few potential antivirulence therapies that nature itself uses to provide a competitive
advantage. Taking a page from nature, researchers aim to implement these techniques into the
development of novel potential therapeutics. Herein, we will discuss the use of the Trojan horse
antibiotic delivery strategy, as well as the synthesis of structural mimics of known siderophores.
In nature, some pathogenic bacteria synthesize siderophore antibiotic conjugates called
sideromycins, such as albomycin and salmycins, which are exported into the extracellular space. 7
Sideromycins then function in a Trojan horse manner, as they can then be imported by competing
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bacteria via innate siderophore uptake pathways used to acquire iron. Once transported into the
cell, the antibiotic may then be cleaved from the siderophore mimic and can inhibit and kill the
competing bacteria. This Trojan horse strategy of synthesizing siderophore-antibiotic conjugates
has been of interest to many research groups, including the Miller group which recently reported
a synthetic siderophore daptomycin conjugate with potent inhibition (MIC values as low as 0.2 µ)
against MDR A. baumannii

strains.67 While this strategy has been historically limited

therapeutically, recently lead compound Cefiderocol of Shionogi, a siderophore cephalosporin
conjugate, was reported to have proceeded to phase III clinical trials for the treatment of a range
of MDR Gram-negative pathogens.68
Another lesson from Nature was discovered by the Henderson group via the isolation of
small molecule, escherichelin.50 The structure of escherichelin is structurally similar to that of
known siderophores pyochelin and yersiniabactin, with the largest structural difference being the
oxidization of the thiozoline ring to a thiozole (Figure 1.12). Interestingly, patients that had a
higher concentration of escherichelin in their urine were less likely to contract a UTI. 50 While the
exact mechanism of action remains unknown, this phenomenon is hypothesized to be the result of
asymptomatic bacteria synthesizing small molecules, like escherichelin, as a protective precaution
to aid in out-competing of detrimental pathogens. Escherichelin highlights that a subtle structural
change may result in role reversal of a compound, taking a molecule from being a siderophore and
growth promoter to an inhibitor.
Trojan horse strategies and inducing subtle structure changes to afford inhibitory
properties, while still mimicking the natural system, are just two examples of potential
antivirulence approaches to combat the rise in antimicrobial resistance. Chapters 2-4 will focus on
expanding the current knowledge base of two of the siderophore families of A. baumannii,
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acinetobactin and the Fimsbactin (A and F). Then, this knowledge will be applied towards potential
therapeutic applications, in Chapters 5-7, as we explore the synthesis of a structural analog of preacinetobactin that functions as an inhibitor and the synthesis of a siderophore-linker system of
interest to Trojan horse antibiotic delivery.

1.6 Figures

Figure 1.1: Iron acquisition from Heme. HasA: Heme acquisition system. SBP: Substrate binding
protein. HasR: HasA outer membrane receptor. OM: Outer membrane. IM: Inner membrane. CP:
cytoplasm.
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Figure 1.2: Iron Acquisition from Transferrin and Lactoferrin. Tf: transferrin. Lf: lactoferrin.
TbpA/LbpA: outer membrane receptor protein. TbpB/LbpB: surface-bound lipoprotein. FbpA:
periplasmic ferric-binding protein. OM: Outer membrane. IM: Inner membrane. CP: cytoplasm.
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Figure 1.5: Structures of A. baumannii siderophores.
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Figure 1.6. Biosynthetic gene clusters for acinetobactin23, fimsbactin24, and baumannoferrin25
from A. baumannii ATCC 17978 along with annotated genes.

Figure 1.7: Siderophore biosynthesis in A. baumannii. (a) NRPS assembly lines for acinetobactin
(top) and fimsbactin A (bottom) share a common precursor, 2,3-DHB, and a common phenolate
oxazoline motif. (b) DAD at 263 nm (black), EIC at m/z 347 (blue), and EIC at m/z 576 (red)
chromatograms from LCMS analysis of crude A. baumannii ATCC 17978 supernatant after
acidification, treatment with XAD-7HP resin, and methanol elution.
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Figure 1.8: Synthetic route to PreAcb34

Figure 1.9. Structures and m/z values for [M+H]+ molecular ions of fimsbactin A–F.24, 36 Structural
differences are highlighted in red.
21

BocNHOBn
NaH, NaI
DMF, 85°C
Cl

N

NBoc
OBn

N

1. TFA, DCM, rt
2. Ac2O, pyr, rt

H2, Raney-Ni, NH3
MeOH, H2O, rt

H2N

N
O
OBn

N

N
O
OBn

OTBS
OTBS
H
N

H2N

TFA

Boc

N
O
OBn

O

Boc

OTBS
H
N

N
H

O
EDC, HOBt
Hunig base
DMF, rt

N
O
OBn

O

OH

N
H

Part A
Br
Br
OH O
HO

OH O
OH

MeOH,H2SO4 HO

O

O

OK

KOTMS
Et2O, rt

N

O
O

DMF
120°C

OMe

O
O

O

N

1) Acetone/Methanol
NaOH, 0°C
2) 50C
3) HCl, 0°C

O

O
O

OMe

OMe
MoO2(TMHD)2
-78°C

O

O
O

O

OMe

O

O
OH

L-Ser-OCH3

H

N
H

O
O

EDC, HOBt
Hunig base
DMF, rt

OH

Part B

Part A
EDC
DCM, rt

Part B

O

O

O
N

N
H

O

OTBS
H
N

HF-pyr
THF, rt

O
N
OBn

O

O

O

O

H2, Pd/C
MeOH, rt

O

O
N
H

N
H

O

O

O

N

N

OH
H
N

O

OH

OH

O

O

HO

HO

O

H
N
O

O
N
OH

O

O

N
O

Fimsbactin A

Figure 1.10: Total synthesis of Fimsbactin A36

22

Part B

O

O
N
H

H
N
O

O
N
OBn

EDC, DMAP
DMF, rt

O
N
OBn

Fimsbactin Biosynthetic Gene Clusters
AbPK1 (GenBank: GCA_002753915.1)

AB042 (GenBank: GCA_001941765.1)

D36 (GenBank: GCA_001399655.1)

Strain ATCC 17978 (GenBank: GCA_001593425)

ATCC 17978-mmf (GenBank: GCA_001077675.1)

23

Acinetobactin Biosynthetic Gene Clusters
AbPK1 (GenBank: GCA_002753915.1)
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D36 (GenBank: GCA_001399655.1)
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Acinetoferrin/Baumannoferrin Biosynthetic Gene Clusters
AbPK1 (GenBank: GCA_002753915.1)

AB042 (GenBank: GCA_001941765.1)

D36 (GenBank: GCA_001399655.1)

Strain ATCC 17978 (GenBank: GCA_001593425)

ATCC 17978-mmf (GenBank: GCA_001077675.1)

Figure 1.11. AntiSMASH69 analysis of putative fimsbactin A. baumannii producers identified
from BLASTp analysis of A. baumannii genomes reveals conservation of acinetobactin and
baumannoferrin biosynthetic gene clusters (BGCs). The acinetoferrin BGC is the reference in the
antiSMASH database. Acinetoferrin and baumannoferrin BGCs share homology, so comparison
for all strains was made to the acinetoferrin BGC.70
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Figure 1.12: Structures of natural siderophores, pyochelin and yersiniabactin, and natural
siderophore uptake inhibitor, escherichelin 50
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Chapter 2: Crystal Structure of the
Siderophore Binding Protein BauB Bound to
an Unusual 2:1 Complex Between
Acinetobactin and Ferric Iron
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2.1 Preface
This chapter was adapted in part with permission from [Bailey, D. C., Bohac, T. J., Shapiro,
J. A., Giblin, D. E., Wencewicz, T. A. & Gulick, A. M. ACS Biochemistry 47, 6653-6661 (2018)]
Copyright ©2018 American Chemical Society. DCB obtained crystal structure and processed
diffraction data with structure determination and refinement. TJB synthesized pre-acinetobactin
and acinetobactin analogs and performed BauB fluorescent quenching binding studies. JAS
expressed and purified BauB and provided initial natural acinetobactin. DEG performed all DFT
calculations. TAW and AMG served as principal investigators and oversaw experimental design.

2.2 Abstract
The critical role that iron plays in many biochemical processes has led to an elaborate battle
between bacterial pathogens and their hosts to acquire and withhold this critical nutrient.
Exploitation of iron nutritional immunity is being increasingly appreciated as a potential
antivirulence therapeutic strategy, especially against problematic multidrug resistant Gramnegative pathogens such as Acinetobacter baumannii. To facilitate iron uptake and promote
growth, A. baumannii produces a nonribosomally synthesized peptide siderophore called
acinetobactin. Acinetobactin is unusual in that it is first biosynthesized in an oxazoline form called
preacinetobactin that spontaneously isomerizes to the final isoxazolidinone acinetobactin.
Interestingly, both isomers can bind iron and both support growth of A. baumannii. To address
how the two isomers chelate their ferric cargo and how the complexes are used by A. baumannii,
structural studies were carried out with the ferric acinetobactin complex and its periplasmic
siderophore binding protein BauB. Herein, we present the crystal structure of BauB bound to a
bis-tridentate (Fe3+L2) siderophore complex. Additionally, we present binding studies that show
multiple variants of acinetobactin bind BauB with no apparent change in affinity. These results are
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consistent with the structural model that depicts few direct polar interactions between BauB and
the acinetobactin backbone. This structural and functional characterization of acinetobactin and its
requisite binding protein BauB provides insight that could be exploited to target this critical iron
acquisition system and provide a novel approach to treat infections caused by this important
multidrug resistant pathogen.

2.3 Introduction
In Chapter 1 siderophore biosynthesis and transport was discussed. After export of the
siderophore from the cell and subsequent extracellular iron binding, the ferric siderophore must
then transported back into the cell to facilitate nutrient acquisition. In Gram-negative bacteria,
siderophore uptake is initiated by a siderophore-selective TonB outer membrane receptor. 1 Once
transported into the periplasm, the siderophore is bound by a siderophore binding protein (SBP)
that mediates the transfer of the siderophore to an ATP-binding cassette (ABC) transporter for
delivery across the inner membrane and into the cytoplasm.2-4 ABC transporters are
transmembrane proteins that are involved in the import and export of a wide variety of molecules.
Their cytoplasmic nucleotide binding domains catalyze ATP hydrolysis to drive conformational
changes of the transmembrane domain that enable translocation of the ligand. ABC transporters
involved in ligand import interact with a variety of substrate binding proteins that capture the
ligand in the periplasm. These transfer partners can be soluble periplasmic proteins tethered either
to the inner membrane through post-translational lipidation or directly to the ABC transporter. 2,5
SBPs belong to a larger family of binding proteins that play many roles in transport and
uptake of metals, amino acids, and peptides.6,7 These proteins contain two small α/β domains, each
with a central β-sheet that is surrounded by α-helices. The ligand binding pocket is located between
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the two globular domains forming a cradle-like structure. In many members of the family, the
relative orientation of the two domains is flexible, resulting from a hinge motion that accompanies
substrate binding. A recently updated analysis identifies seven clusters of substrate binding
proteins, with the structural motif that spans the two α/β domains forming a distinguishing feature
between different groups. SBPs belong to Cluster A, in which a central αhelix forms the bridge
between the two smaller domains.7 This relatively rigid helix limits the hinge motion between the
α/β domains and ligand-free and ligand-bound structures adopt very similar conformations
regardless of ligand content.2
The human pathogen Acinetobacter baumannii produces three siderophores. Two
siderophores, acinetobactin8,9 and fimsbactin,10 are produced through NRPSs, while a third is the
NIS-produced baumannoferrin.11 Of 15 representative A. baumannii strains present in the
Virulence Factors in Pathogenic Bacteria database, 12 fimsbactin is present in only a single genome
(strain ATCC17978). Both acinetobactin 1 and baumanoferrin are present in the other strains. A.
baumannii SDF, a strain that was isolated from a body lice and which shows many unusual
features,13 lacks all three siderophore clusters. Acinetobactin production has been identified as
being an important virulence factor in studies involving both insect and murine infection models. 14
Interestingly, acinetobactin is produced in an oxazoline form known as preacinetobactin 2 that can
spontaneously isomerize into the mature isoxazolidinone (Figure 2.1). The two forms were found
to be favored at acidic and basic pH, respectively, which suggests the single siderophore has
evolved for use in multiple environments.15
Inhibitors of BasE, an NRPS adenylation domain required for acinetobactin biosynthesis,
have been identified by rational design and empiric screening; crystal structures of the most potent
inhibitors bound to BasE have been determined.16,17 While showing promising biochemical
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activity, the compounds failed to function with whole cells, likely due to poor cell permeability.
An alternative approach to inhibition of siderophore biosynthesis includes targeting ferricsiderophore uptake and transport. A variety of acinetobactin analogues have been synthesized that
illustrate that the functional groups required for iron binding are similarly important in the ability
to support A. baumannii growth in low iron conditions.18 Additionally, oxidation of the oxazoline
ring of preacinetobactin to the oxazole results in an analogue that is able to compete in a dosedependent manner with the ability of acinetobactin to support of A. baumannii growth in low iron
conditions.19 To extend these ongoing studies, we describe herein the liganded structure of the
siderophore binding protein BauB from the acinetobactin uptake system. The binding pocket of
BauB is populated by a bis-tridentate ferric acinetobactin complex [(Acb) 2Fe]− that is stabilized
by iron(III)-coordinating bonds with catechol oxygen and imidazole nitrogen atoms from
acinetobactin. This structural model is further supported by functional characterization of
BauB/acinetobactin binding, including dissociation constants for BauB with apo- and holoacinetobactin, as well as a panel of acinetobactin structural analogues that probe the key
recognition elements required for binding.

2.4 Results and Discussion
Structure Determination of BauB.
The structure of BauB was determined by molecular replacement using YclQ, the
siderophore binding protein from petrobactin binding in Bacillus subtilis.20 The model contains
two chains in the asymmetric unit, each of which contains residues 39−322, with a single
disordered loop. The two chains do not appear to form a dimeric structure, consistent with the
monomeric gel filtration results. In chain A, residues 236−238 are disordered, while in chain B,
residues 236−240 are disordered. Additionally, beyond the C-terminal Gln322 residues, each chain
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contains density for three residues, Leu323-Glu324-His325, derived from the Histag used for
purification. In both chains, the N-terminal 17 residues are also disordered, with Glu39 being the
first observed residue. The two chains superimpose with an RMS displacement of 0.15 Å over 279
residues (Figure 2.2).
BauB adopts the classic two domain conformation seen previously with SBPs of the Cluster
A family of substrate binding proteins.7 The two globular α/β domains are bridged by a central
helix formed by residues Glu171-Thr192 (Figure 2.3). Use of the DALI structural similarity server
identified multiple homologues within the substrate binding protein family. 21 The closest
homologues, with sequence identities above 25%, all show RMS displacements of 1.9−3.0 Å over
Cα positions (Table 2.1, Figure 2.4).
Active Site Contents and Structure of Acinetobactin 2Fe3+ Complex.
The siderophore binding pocket of BauB shows clear density for the binding of a complex
between two molecules of acinetobactin and a single ferric ion. Each acinetobactin molecule
donates both catechol oxygen atoms and one nitrogen atom of the imidazole moiety to form an
octahedral arrangement around the central ferric ion. The electron density unambiguously
correlates with the molecular structure of the acinetobactin isomer (provided in the crystallization
cocktail) and not preacinetobactin (which was not provided). This is consistent with the
irreversible nature of the preacinetobactin to acinetobactin isomerization (Figure 2.5).
One molecule of acinetobactin is more deeply buried in the substrate binding pocket, while
the second is more surface exposed (Figure 2.6). Specifically, for the buried molecule, only the
2,3-dihydroxybenzoate (DHB) moiety is solvent accessible while the histamine and
isoxazolidinone groups are positioned below the ferric ion against the surface of BauB. In contrast,
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the second acinetobactin molecule lies on the surface of the protein, with its peptide backbone
exposed to solvent. We note that while the density for both molecules is unequivocal in both
chains, the density is marginally more robust for the buried molecule – suggesting that there is
perhaps minor flexibility in the binding position of the exposed acinetobactin molecule.
There are no direct polar interactions between the more buried acinetobactin molecule and
BauB. The DHB carbonyl oxygen interacts via water molecules with the side chain of Asp83 and
the main chain amides of Ile104 and Val105. The methyl group from the heterocycle projects into
a hydrophobic pocket formed byTyr84, Val264, and Tyr301. In contrast, the more exposed
acinetobactin molecule makes two polar interactions with the protein. The isoxazolidinone
carbonyl oxygen interacts with the side chain of Arg217 through a water molecule, and a hydrogen
bond is formed between one catechol oxygen and the side chain of Tyr301. The bound holosiderophore is presumed to exist as the monoanion [(Acb)2Fe]−, possibly charge stabilized by a
cationic Arg217, with four catecholate oxygens balanced by iron(III) and neutral donation of two
imidazole nitrogens to complete the octahedral metal coordination sphere. Interestingly, in both
chains, the side chain of Arg282 from a symmetry-related molecule is directed into the binding
pocket and interacts with one of the catechol oxygens of the buried acinetobactin molecule to
further stabilize the [(Acb)2Fe]− monoanion. It is also noteworthy that the contribution of the Nterminal globular domain is largely hydrophobic, while the residues from the C-terminal domain
are much more polar in nature. In particular, Arg217, Arg261, Tyr301, and potentially His239 all
reside on the C-terminal domain.
Conformational flexibility and electrostatics are both important factors contributing to the
high-affinity association of siderophore binding proteins with substrate metal complexes, as well
as interfacing with membrane-embedded permeases that gate and drive the influx of substrates to
43

the cytoplasm. Based on the ability of A. baumannii to utilize both isomeric forms of acinetobactin,
1 and 2, a high degree of substrate plasticity for BauB is anticipated.15 In the homologous SBP
CeuE from Campylobacter jejuni, the side chains of His227 and Tyr288, the homologue of BauB
His239 and Tyr301, form direct interactions with the ferric ion in complexes with catecholbased
tetradentate ligands derived from enterobactin fragments that do not complete the octahedral
coordination (Figure 2.7).22,23 The conservation of His239 and Tyr301 suggests that BauB is
poised to capture ferric complexes with alternate siderophore ligands that do not completely
coordinate the central ion, perhaps endowing A. baumannii with the ability to interact with other
siderophores that it encounters in the environment. Of note, His239 in BauB is positioned on a
poorly ordered loop, suggesting an ability to adopt distinct conformations in the presence of
different ligands (Figure 2.7).
Siderophore binding proteins with strongly anionic or cationic binding pockets are often
found to counterbalance the net charge of cognate siderophore-iron complexes (anionic
staphyloferrin A-Fe, cationic HtsA; anionic staphyloferrin B−Fe, cationic SirA). 24,25 The base of
the Bacillus subtilis FeuA SBP, which has been structurally characterized bound to ferric
enterobactin, shows a strikingly basic binding pocket with two lysine and two arginine side chains
directed into the binding pocket.26 The 1:1 tricatecholate enterobactin-Fe complex presumably
binds as the trianion [EntFe]3−, charge stabilized by protonated Lys and Arg residues lining the
FeuA siderophore binding pocket. These residues are not conserved in BauB, as has also been
observed with other catechol binding SBPs.26 In contrast, the base of the pocket in BauB is mostly
hydrophobic. In particular, Tyr84 and Pro124 in BauB are replaced by lysine residues in FeuA,
while Leu203 is replaced by an arginine.
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Like BauB, the siderophore binding pocket of FhuD2 does not exhibit the basic nature of
FeuA.27,28 However, the pockets of BauB and FhuD2 are quite different in composition with BauB
being much more hydrophobic. The pocket of FhuD2 is polar, with multiple tyrosine, threonine,
and tryptophan residues donating hydrogen bonding capabilities to interact with polar
hydroxamate ligands such as ferrioxamine B. These polar residues are distributed across the
binding pocket from both the N- and C-terminal globular domains.
DFT Calculations of the Acinetobactin 2Fe3+ Complex.
We next explored the ligand complexes using density functional theory (DFT) calculations
to assess the stability of the observed 2:1 complex with other potential isomers. The metal
coordination mode and ligand/metal stoichiometry observed in the BauB-bound Acb 2Fe complex
is consistent with reported solution-phase fluorescence and optical absorbance spectroscopic
titrations.15,18,19 The presence of stable metal coordinate bonds through two bidentate catecholates
is consistent with the broad metal−ligand charge transfer bands at ∼570 nm in the optical
absorbance spectrum.15,18,19 The cis-[Acb2Fe]− isomeric form present in the BauB substrate
binding site represents one of many possible geometric and optical isomeric forms of the metal
complex invoking metal coordinate bonds with the catecholate and imidazole moieties. The
distorted octahedron formed at the iron(III) coordination sphere is isomeric with ML a4Lb2
octahedral complexes, where La represents the catecholate oxygens and Lb represents the
imidazole nitrogens. For MLa4Lb2 complexes, two isomers, cis and trans, are possible. The cis[FeO4N2] − orientation is accommodated by the BauB substrate binding pocket; thus, we will refer
to the holo-siderophore as cis- [Acb2Fe]− as the apparent BauB substrate.
The siderophore, anguibactin, produced by the fish pathogen Vibrio anguillarum is
structurally similar the preacinetobactin (2) isomeric form with the methyloxazoline replaced by a
45

thiazoline heterocycle. Anguibactin has been crystallized as the gallium(III) chelate in a
Ga2Anguibactin2 stoichimetry.29 The Ga2Anguibactin2 structure is bioctahedral with bridging
methanols in the Ga coordination sphere. There are many potential stoichiometric, geometric, and
optical isomers for the acinetobactin-Fe complex, including structures related to the
Ga2Anguibactin2 structure that may be present in solution. It is likely that BauB selectively
recognizes the cis-[Acb2Fe]− isomeric form. We modeled this isomeric form and others using DFT
calculations and found that structures closely related to the cis-[Acb2Fe]− are predicted to be stable
in the gas phase (Figures 2.8, 2.9). Even if cis-[Acb2Fe]− is not prevalent in solution, it is possible
that upon BauB binding the coordination mode is shifted to the experimentally observed cis[Acb2Fe]−. Such protein-induced shifting of metal coordination mode has been observed for the
binding of holo-vibrobactin by human siderocalin, where the phenolate-oxazoline bidentate ligand
coordination mode predominates in solution, while the bidentate catecholate mode is favored in
the siderocalin substrate binding pocket.30 Binding of apo-siderophores by periplasmic
siderophore binding proteins and siderocalins has also been observed. In the case of human
siderocalin, the substrate binding pocket can serve as a template for small dietary catechols to
preorganize the ligands for iron sequestration as a strategy for nutritional immunity and possibly
iron acquisition.31
Binding Studies of Acinetobactin2Fe3+ to BauB.
To investigate the substrate binding specificity of BauB in solution, we performed intrinsic
Trp fluorescence quenching studies in the presence of apo- and holo-acinetobactin. Both forms of
the siderophore were bound by BauB with nanomolar affinity, with a slight preference for the holosiderophore (apparent Kd = 160 ± 80 nM) over the apo-siderophore (apparent Kd = 300 ± 100 nM)
(Table 2.2). We probed key structural features of acinetobactin required for molecular recognition
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by BauB, including the site and degree of hydroxylation on the phenyl ring and the presence of the
imidazole heterocycle.18
BauB Binds Both the apo and holo Forms of Acinetobactin.
We therefore chose to use only apo-siderophore variants for comparison since some
structural modifications result in loss of iron chelation. We also note that we have obtained
diffraction quality crystals of BauB from crystals that were grown in the presence of apoacinetobactin. We were able to fully resolve the structure, but electron density of the substrate
binding pocket did not show full occupancy of an acinetobactin molecule. A peak of ambiguous
electron density was observed in the binding pocket that could fit the central isoxazolidinone ring
with no density for the flanking DHB and histamine groups. Whether this represents limited
occupancy or movement of the aromatic groups in the absence of iron is unclear but it is intriguing
to consider the possibility that the apo-acinetobactin core is bound flexibly with iron binding
subsequently ordering the histamine and DHB rings.
All of the siderophores caused dose-dependent fluorescence quenching and curve fitting
provided apparent Kd values ranging from 160−520 nM, with no statistical significance between
analogues (Table 2.2, Figure 2.10). It appears that BauB can bind promiscuously to the
acinetobactin scaffold, which is consistent with related periplasmic siderophore binding proteins. 14

Presumably, the outer membrane receptor BauA imparts selectivity for acinetobactin import,

mitigating the need for a second level of high specificity filtering in the periplasm (Figure 2.11).
Although compounds 1, 1-Fe, and 3−9 all appear to bind BauB, it is less clear if they share the
same binding mode or if all binding modes will lead to influx across the cytoplasmic membrane.
The only strong correlation observed for the acinetobactin analogues is that the ability to form a
stable complex with iron(III) is required for A. baumannii utilization (Table 2.2).18
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2.5 Outlook and Conclusions
We report here the structural and functional analysis of BauB, the SBP from the
acinetobactin uptake pathway in A. baumannii. Our studies show that BauB adopts the typical
Class A substrate binding fold, with a central α-helix spanning the smaller N- and C-terminal
domains. The ligand is bound in a central pocket between the two domains that is contributed by
mostly hydrophobic residues. The structure of BauB illustrates an unusual [Acb 2Fe]− complex, in
which two acinetobactin molecules each provide two catechol oxygens and an imidazole nitrogen
to coordinate the central iron. To our knowledge, this is the first observation of a 2:1 complex of
a natural ligand and iron that has been observed in a crystal structure of a siderophore binding
protein. These studies continue our ongoing effort to functionally characterize the iron acquisition
pathways of A. baumannii. The residues of BauB that interact with the ligand include hydrophobic
residues that are distributed in sequence across the length of the protein and include few direct
interactions with the ligand. The lack of direct interactions enables multiple analogues of
acinetobactin to bind BauB with roughly similar affinities and may relate to the ability of bacteria
to tune their iron acquisition systems to enable utilization of siderophores produced by other
species. The broad substrate binding capability of BauB presents the opportunity for exploiting the
acinetobactin transport pathway to develop siderophore-based therapeutics, including
antivirulence agents that inhibit the acinetobactin pathway and acinetobactin conjugates including
imaging probes for infection diagnostics and antibiotic conjugates for targeted anti-A. baumannii
therapeutic agents. As noted, we have collected data on the structure of BauB that was crystallized
in the presence of acinetobactin in the absence of iron that shows either binding to core of the
siderophore or incomplete occupancy. Because of the comparable affinities of BauB for the apoand holo- forms, we favor the former scenario, in which the apo-ligand binds to the hydrophobic

48

base of the BauB pocket and the chelating groups adopt a dynamic configuration in the absence of
iron. This is further supported by the similar affinity of BauB toward the acinetobactin analogues
that we tested. We have additionally attempted to crystallize BauB with the oxazoline pre-Acb but
have not yet been able to grow diffraction quality crystals. Continued efforts to crystallize BauB
with preAcb or additional acinetobactin variants may provide further clues to the features that
enable binding to BauB. While the histamine and isoxazolidinone are buried in one of the two
acinetobactin molecules, the DHB moieties are exposed in both molecules within the [Acb 2Fe]−
complex and may provide a locus for attachment of relevant functional groups to achieve these
alternate purposes.

2.6 Materials and Methods
Cloning, Expression, and Purification.
Multiple protein constructs were designed for use in the structural and functional studies.
The 969-bp bauB gene from Acinetobacter baumannii (Genbank Accession no. AAT52185) was
first subcloned into a pET24b expression vector using restriction enzyme-based cloning.
Expression of the full-length protein resulted in most of the protein purifying as soluble aggregate,
with a small proportion isolated as a folded protein. The soluble protein migrated on analytical gel
filtration with an elution volume consistent with a monomer (Figure 2.12). Analysis of the
fulllength protein construct (1−322) revealed a putative signal peptide (1−22) at the N-terminus
directing trafficking to the periplasm.32,33
A second expression construct was designed without the putative signal peptide that
encoded the mature protein. Following the starting Met residue, the final expression construct
contained BauB residues 23−322 and a C-terminal 6 × His tag (···LEHHHHHH). Of note, Cys23
was predicted to be a N-terminal lipidation site34,35 and the presence of Asp at position 24 suggests
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that, upon cleavage of the signal peptide in the periplasm, the protein is natively retained at the
periplasmic surface of the cytoplasmic membrane according to the “D+2 Rule”. 36,37
E. coli BL21(DE3) was transformed with the expression plasmid for protein production.
Cells were grown to an OD600 of 0.6−0.8 at 37 °C (250 rpm) and induced to express BauB with
the addition of 500 μM IPTG. Following induction, the cells were incubated at 16 °C overnight
(≈18 h) before being harvested by centrifugation at 6 × 103 g at 4 °C for 15 min. The cell pellet
was flash frozen in liquid N2 and stored at −80 °C.
The frozen cell pellet (≈10 g) was resuspended in 100 mL of lysis buffer (50 mM Tris, 300
mM NaCl, 0.2 mM TCEP, 5% glycerol, 20 mM imidazole, pH 8.0) containing protease inhibitor
cocktail, DNase (10 μg/mL), and lysozyme (1 mg/ mL) and incubated at 4 °C for 30 min. Cell
lysis was further ensured by sonication (5 × 30 s cycles). The cell slurry was separated by
ultracentrifugation at 185 × 103 g for 40 min at 4 °C. The supernatant was further clarified via
filtration over a 0.45 μm polysulfone membrane. The clarified supernatant was subjected to
immobilized metal affinity chromatography (IMAC) by passing it over two 5 mL Ni 2+-NTA
columns in series. Bound proteins were eluted by passing lysis buffer plus 300 mM imidazole over
the columns. To remove imidazole, the protein was dialyzed (12 kDa MWCO) overnight at 4 °C
in 50 mM Tris, 300 mM NaCl, 0.2 mM TCEP, 0.5 mM EDTA, 5% glycerol, pH 8.0. The dialyzed
protein sample was concentrated using a centrifugal filter (10 kDa MWCO) before carrying out
preparative size exclusion chromatography (SEC). Protein was eluted over the SEC column
(HiLoad 16/60 Superdex 200, GE Healthcare) using a buffer of 50 mM Tris, 150 mM NaCl, 0.2
mM TCEP, pH 8.0 at 1 mL/min (Figure 2.12). The desired fractions containing pure BauB as
indicated by SDS-PAGE were combined, concentrated to ≈60 mg/mL using a 10 kDa MWCO
centrifugal filter, flash frozen in liquid N2, and stored at −80 °C.
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An N-terminally tagged protein, lacking the signal sequence, was also produced and used
in binding studies. N-His6-BauB was expressed from a pET28bTEV plasmid in E. coli BL21
(DE3). Briefly, E. coli BL21 (DE3) transformed with the BauB expression plasmid were grown in
Terrific Broth at 37 °C in a 3 L baffled flask, in the presence of 50 μM kanamycin to an OD 600 of
∼0.5. The culture flask was cooled to 20 °C, and BauB expression was induced by the addition of
0.5 mM IPTG (final concentration). Cells were grown overnight (∼12 h) at 20 °C. Cells were
harvested via centrifugation at 4 °C for 30 min (all remaining steps were carried out at 4 °C). Cells
were washed with lysis buffer (50 mM potassium phosphate pH 8.0, 500 mM NaCl, 5 mM BME,
20 mM imidazole, 10% glycerol) and flash frozen in liquid N2 (40 mL total volume). The frozen
cell pellet was thawed and lysed by two passes through an Emulsiflex C5 (Avestin). The lysate
was clarified by ultracentrifugation at 50000g for 35 min. The supernatant was passed through
NiNTA resin and eluted with 300 mM imidazole in lysis buffer. Elution fractions were analyzed
by SDS-PAGE with visualization by Coomassie blue staining. Fractions containing pure N-His6BauB were combined, dialyzed (50 mM potassium phosphate pH 8.0, 150 mM NaCl, 1 mM DTT,
5% glycerol), and concentrated via centrifugal filtration. Protein purity was analyzed by SDSPAGE with visualization by Coomassie blue staining. Protein identities were confirmed by ESIMS. Purified protein was flash frozen in liquid N2 at 180 μM and stored at −80 °C. The final
protein used in the binding studies contained the His6 tag and TEV cleavage site upstream of C23
from the BauB sequence.
Crystallization and X-ray Diffraction Data Collection.
Two protein crystals were used to collect a complete data set for structure determination.
Crystallization and X-ray data collection parameters for both data sets are summarized in Table
2.3. Briefly, BauB was exchanged into a minimal crystallization buffer, and ferric acinetobactin
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(Acb2Fe) in DMSO was added and incubated on ice for 1 h. Acb was isolated from A. baumannii
ATCC 17978 and purified by RP-C18 prep HPLC as described previously. 15 Acb2Fe was prepared
by treating Acb with Fe(acac)3 as described previously.15 The sample was briefly centrifuged to
pellet any precipitate before being crystallized by hanging-drop vapor diffusion. Initial
crystallization conditions were identified using an in-house 120-condition screen, in which BauB
formed thin needle/platelike crystals in cocktail conditions containing medium to high molecular
weight polyethylene glycol (PEG 4K, 8K, or PEG MME 5K) over a relatively wide pH (6.0−9.0)
range. Crystals were flash frozen in liquid N2 and shipped to synchrotron beamlines for remote
diffraction data collection.
Diffraction Data Processing, Structure Determination, and Refinement.
BauB crystallized in a monoclinic space group P21 with β = 90°. Careful analysis showed
that each data set was not twinned nor could higher symmetry be imposed on the data. Scaling the
data in the orthorhombic space group P222 resulted in Rmerge values of 0.25, compared to 0.09
determined with the monoclinic space group. The structure of ferric Acb bound BauB was initially
solved by molecular replacement to 1.9 Å resolution employing Data Set 1 (Table 2.3) using the
protein atoms of YclQ35 (PDB 3GFV, 33% sequence identical) as the search model. Due to the
thin needle/plate-like morphology of the crystals, it was difficult to achieve a high completeness
from a single crystal despite collecting images over an oscillation range of 360°. We therefore
merged the data from the initial crystal with data from a second crystal. To do this, the two
integrated reflection files from MOSFLM were scaled together with AIMLESS of the CCP4
software suite. Although this second data set was weaker in overall intensity, the increase in
completeness was viewed as a reasonable compromise with the resulting poorer merging statistics
from combining the two data sets. Processing statistics for the individual (Table 2.3) and combined
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(Table 2.4) data sets are provided. The merged data set was then used to refine the structure of
BauB complexed with Acb2Fe. All data processing and merging was carried out using iMosflm, 38
molecular

replacement

employing

Phaser,39

automated

model

building

using

PHENIX.Autobuild,40 manual model building and refinement utilizing Coot, 41 and automated
refinement employing PHENIX.Refine.42 Structure-based alignments were performed with
PROMALS 3d.43 The atomic coordinates and structure factors for BauB complexed with ferric
Acb have been deposited in the PDB (6MFL).
BauB Binding Studies.
Acinetobactin (1) and analogues (3−9) were prepared as described previously.18 A stock
solution of N-His6-BauB, thawed on ice, was prepared at 400 nM in assay buffer (25 mM TrisHCl, 8 g/L NaCl, 0.2 g/L KCl, pH 7.4). For each experiment, 300 μL of the BauB stock solution
was transferred to a fluorescence cuvette (HellmaAnalytics High Precision Cell cuvette made of
Quartz SUPRASIL; light path 10 × 2 mm) in the presence of substrate (compounds 1, 1-Fe, and
3−9) at variable concentrations ranging from 100−1200 nM. An emission spectrum was taken
using a PerkinElmer LS 55 Luminescence Spectrometer (slit width 10 nm; scan speed 400 nm/min)
at 300−400 nm using an excitation wavelength of 280 nm. Fluorescence intensity at 320 nm versus
substrate concentration (nM) was plotted. The apparent Kd was calculated by nonlinear regression
using a one binding site model in GraphPad Prism v7.0b (Figure 2.10). All experiments were
performed in duplicate as independent trials.
DFT Calculations.
For starting geometry of the bimetallic complexes, we chose the crystal structure of the
acinetobactin2FeIII(S = 5/2) complex bound to BauB. Conformer spaces for complexes were
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explored by Monte Carlo/ MMFF molecular mechanics/dynamics, and first step of optimization
was performed by using the PM3d semiempirical algorithm (Spartan Linux v10, WaveFunction,
Inc.). Using either as an input, we employed DFT (density functional theory, Gaussian 09,
Gaussian Inc.) for calculations by using the PBE0 hybrid functional (PBE1PBE in Gaussian
parlance) with basis sets Def2-SVP and Def2-TZVP. Minima were optimized at the level
PBE0/Def2-SVP, and single-point energies were calculated at level PBE0/Def2-TZVP, with
scaled thermal-energy corrections from scaling factors for B3LYP/6-31G(d,p).44 Solvent-based
single-point energies were calculated at the same level by using the CPCM polarizable conductor
calculation model for water and using the Universal Force Field for atomic radii. 45 DFT was
selected for computational efficiency and integrity. 46,47 Functional and basis sets were chosen for
use with the ferric complexes.48-50
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2.7 Figures and Tables

Figure 2.1. Chemical structures of acinetobactin (1) and pre-acinetobactin (2) from A.
baumannii.

Figure 2.2. Overlay of two BauB chains (chain A, pink; chain B, green) superimposed with
RMS displacement of 0.15 Å over 279 residues.
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Figure 2.3. Ribbon representation of BauB bound to the Acb2•Fe complex. (N-domain, yellow;
C-domain pink; α helix green). Two views are shown, approximately 90° apart rotated around
the horizontal axis. The single gap in the protein between residues 235 and 239 is indicated with
the dashed line.
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PDB
3GFV
3TEF
5AD1
4JCC
4MX8
3MWF
3TNY
2WHY
4FNA

% ID
36
32
29
29
26
26
26
21
21

RMS Disp.
2.0
2.1
2.2
1.9
2.3
3.1
3.2
3.2
3.2

Residues Aligned
276/286
274/279
272/290
270/284
272/302
258/292
263/280
266/283
252/278

Name
B. subtilis YclQ
V. cholerae VctP V. cholera
C. jejuni CeuE
S. pneumoniae PiuA
X. cellulosilytica Periplasmic BP
S. aureus SirA
B. cereus YfiY
B. subtilis FeuA
S. aureus FhuD2

The top hits the search for structural homologs were filtered to remove PDB coordinates for
identical proteins with multiple ligands. FeuA and FhuD2 were not among the most highly
homologous but are included for comparison with the discussion in the main text.
Table 2.1. Structural homologs of BauB
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Abaum_BauB

MNWKKKYGGVALIIAAAVTLQACDQKVADTTQASQKLAEPITVKHAL------------G

48

3MWF SaSirA

MNKVIKMLVVTLAFLLVLAGCSGNSNKQSSDRKDKETTSIKHAM------------G

45

3TEF VcVctF

MVLIIVRTLLMRISIKMIPLAYLNHLWKEHMKSRIHCAALGLLAAFAAQAETVTIEHRL------------G

60

3GFV BsYclQ

MRSMKKFALLFIALVTAVVISACGNQSTSSKGSDTKKEQITVKHQL------------D

47

4MX8 XcPBP

MSRTRPIARASMLAVLALTLAACAPSSAGTADDSAETTPATASYTWDRNTATEEGADPVYE

61

4JCC SpPiuA

MKTSLKLYFTALVASFLLLLGACSTNSSTSQTETSSSAPTEVTIKSSL------------D

49

5AD1 CjCeuE

MKKSLVFAFFAFFLSLILTACNSNSNENNASSTTKTNTATVKVLPISMSDEGDSFLVKDSL------------G

62

2WHY BsFeuA

MKKISLTLLILLLALTAAACGSKNESTASKASGTASEKKKKIEYLD------------K

46

MKKLLLPLIIMLLVLAACGNQGKKNNKAETKSYKMDD------------G

38

Abaum_BauB

--TTVIDHLPQR-VAVLDM-NE-ADFLDQLNVP--IMGM-PKDY----VP-HFLEKYKKDAQI-QDLGA-IVQ-

106

3MWF SaSirA

--TTEIKGKPKRVVVTLYQ-GA-TDVAVSLGVKK-PVGA-VESWTQKPKFEEYIKNDL--KDT-KIVGQQEPA-

105

3TEF VcVctF

--KTTLEQKPQR-VVVIGV-GA-LDAIDSFGIE--PVAV-SKFDG---TP-DYLAKYK-SDKY-PSAGS-LFE-

118

3GFV BsYclQ

KNGTKVPKNPKK-VVVFDF-GS-LDTLDKLGLDDIVAGL-PKQV----LP-KYLSKFK-DDKY-ADVGS-LKE-

108

4MX8 XcPBP

ETTVEVPVDPQR-IVVFDM-AA-LDTIGALGGE--IAGA-PLDS----VP-DYLEEYL-ADDA-FNAGT-LFE-

120

4JCC SpPiuA

-EVVKLSKVPEEKIVTFDL-GA-ADTIRALGFAKNIVGMMPTKTT---VP-TYLKDLV-GTVKKKNVGSMMKEP

108

5AD1 CjCeuE

-ENKKIPKNPSK-VVILDLLGI-LDTFDALKLNDKVVGV-PAKN----LPKYYLQQQF--KNK-PSVGG-VQQ-

119

2WHY BsFeuA

--TYEVTVPTDK-IAITGSVESMMEDAKLLDVH--PQGA-ISFSGK--FP-DMFKDIT--DKA-EPTGE-KME-

105

4FNA SaFhuD2

-KTVDIPKDPKR-IAVVAP-TY-AGGLKKLGAN--IVAV-NQQV---DQS-KVLKDKFKGV---TKIGD-----

93

Abaum_BauB

PNMERIYALKPD-LILMTP-LHVNQYQE-LSKIAPTIHYDINFNNSESNHIGLVKDHM-MTLG-KIFN--KED-

172

3MWF SaSirA

PNLEEISKLKPD-LIVASKVRNEKVYDQQLSKIAPTVSSTDTV--------FKFKDTT-KLMG-KALG--KEK-

163

3TEF VcVctF

PDFETIYTQKPD-LIVIGP-RASKSYDE-LSKIAPTIVFAAEA---DQGYWESTQQQW-RNLG-KVFA--IEP-

181

3GFV BsYclQ

PDFDKVAELDPD-LIIISA-RQSESYKE-FSKIAPTIYLGVDTA----KYMESFKSDA-ETIG-KIFD--KED-

170

4MX8 XcPBP

ADLIAIEAQQPD-LIVVGG-RSSGLWAD-LNEIAPTIDLSLRG-----SYLDTLEQNT-TFLG-KVLG--AEA-

183

4JCC SpPiuA

PDLEAIAALEPDDLIIASP-RTQKFVDKFKKEIAPTVLFQASKD----DYWTSTKANIEESLA-SAFGETGTQK

171

5AD1 CjCeuE

VDFEAINALKPD-LIIISG-RQSKFYDK-LKEIAPTLFVGLDNA----NFLSSFENNV-LSVAKKLYG--LEK-

186

2WHY BsFeuA

PNIEKILEMKPD-VILASTKFPEKTLQK-ISTAGTTIPVSHISS--------NWKENMMMLLA-QLTG--KEK-

163

4FNA SaFhuD2

GDVEKVAKEKPD-LIIVYS--TDKDIKK-YQKVAPTVVVDYNKH--------KYLEQQ-EMLG-KIVG--KED-

150

Abaum_BauB

LARQKVSELDE-QVK-QVQAVTA-----NRPERALVVL--HNN-GAFSNFGIQ------S-RYGF-IFNNAFGV

227

3MWF SaSirA

EAEDLLKKYDD-KVA-AFQKDAKAKYKDAWPLKASVVN--FRA-DHTRIYAG-------G-YAGE-IL-NDLGF

222

3TEF VcVctF

AVEAKIEQVDA-QFK-SIMQYNQ-----QHKSDAMLVM--SSG-GNLTTFGAN------S-RFSS-VY-KDFGF

236

3GFV BsYclQ

KVKDELANIDHHSIADDVKKTAE-----KLNKNGLVIM--AND-GKISAFGPK------S-RYGL-IH-DVFGV

225

4MX8 XcPBP

EAESVLAELEA-GIA-EAKAAVT-----EASGTGLGIM--VSG-GQLSALSPNTGNDPRGARGGL-IY-DVFGV

243

4JCC SpPiuA

KAKEELAKLDE-SIQ-EVATKNE-----SSDKKALAIL--LNE-GKMAAFGAK------SRFFSF-LY-QTLKF

226

5AD1 CjCeuE

EALEKISDIKN-EIE-KAKSIV-----DEDKKKALIILLTNSSNNKISAFGPQ------S-RFGI-IH-DVLGI

235

4FNA SaFhuD2

58

2WHY BsFeuA

KAKKIIADYEQ-DLK-ETKTKIN---DKAKDSKALVIR--IRQ-GNIYIYPEQ------V-YFNSTLY-GDLGL

222

4FNA SaFhuD2

KVKAWKKDWEE-TTA-KDGKEIKKAI--GQDATVSLFD--EFD-KKLYTYGDN------WGRGGEVLY-QAFGL

210

Abaum_BauB

KPASG-----VVDTSLHGQPISSE-FIIKKADPDILYIVDRTAVMEH-RPNINAASVE-NPL--LRQTKAWKNG

290

3MWF SaSirA

KRNKDLQKQVDNGKD-IIQLTSKE-SIPLMN-ADHIFVVKSDPNAKD-AALVKKTESEWTSSKEWKNLDAVKNN

292

3TEF VcVctF

SETVPV----SKESS-HGDLISFE-YIREHN-PKTLLVVDRDKVVTK-GETNIRQTFE-NDL--VKATTAYKNG

299

3GFV BsYclQ

APADQN----IKASTHHGQSVSYE-YISKTN-PDYLFVIDRGTAIGE--TSSTKQVVE-NDY--VKNVNAVKNG

287

4MX8 XcPBP

QPVLED----IKAA-THGEPISFE-FLLEHD-PQWLWVVDRDAATGAEGAQAAKVVLD-NEI--VNRTTAATED

307

4JCC SpPiuA

KPTDTK-----FEDSRHGQEVSFESSVKEIN-PDILFVINRTLAIGGDNSSSNDGVLE-NAL--IAETPAAKNG

289

5AD1 CjCeuE

NAVDEN----IKVGT-HGKSINSE-FILEKNNPDYIFVVDRNVILGN-KERAQQGILD-NAL--VAKTKAAQNK

297

2WHY BsFeuA

KAPNEVKA---AKAQ-ELLISLLEKLLSEMN-PDHIFVQFSD-DENADKPDALKDLEK-NPI--WKSLKAVKED

284

4FNA SaFhuD2

KMQPEQQK--LTAKA-GWAEVKQE-EIEKYA-GDYIVSTSEGK--------PTPGYES-TNM--WKNLKATKEG

268

Abaum_BauB

RVI-FVDADAWYTT-AASPTSL--KIVMED-VKKGYQ

322

3MWF SaSirA

QVSDDLDEITWNLA-GGYKSSS--LKLIDDDLYEKLNNIEKQSK

330

3TEF VcVctF

HIA-YLDVNAWYIA-ISGVKAT--EQMVAD-MKASVGMQ

333

3GFV BsYclQ

HVI-YLDSATWYLS-GGGLESMT-QQMIKE-VKDGLEK

320

4MX8 XcPBP

HVL-YLNPTAWYIVFFGGVEETT-RIMIDD-VLQ-VAAR

340

4JCC SpPiuA

KKIIQLTPDLWYLS-GGGLESTKKLMMIED-IQKALK

321

5AD1 CjCeuE

KII-YLDPEYWYLASGNGLESL--KTMILE-IKNAVK

330

2WHY BsFeuA

HVY-VNSVDPLAQ--GGTAWSKV-VRFLKA-AAEKLTQNKLTQN

317

4FNA SaFhuD2

HIV-KVDAGTYW---YNDPYTL--DFMRKD-LKEKLIKAAK

302

Figure 2.4. PROMALS3d structure-based alignment of BauB with homologous siderophore
binding proteins. Sequences are identified by PDB code as described in Table 2.1. Conserved
sequences are identified in red, while homologous residues are identified in blue. His239 and
Tyr301 of BauB are highlighted in green. BauB residues in Figure 2.6B are highlighted in
yellow. Disordered residues are shown in orange.
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Figure 2.5. Modeling of acinetobactin2Fe structure into the electron density in the BauB
substrate binding pocket. Stereorepresentation of the final model of ligands bound to BauB. Omit
map electron density, contoured at 2.5 σ, was calculated with coefficients of the form Fo-Fc
using the final model from which the ligands were removed and subjected to a round of
simulated annealing refinement.
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Figure 2.6. Siderophore binding pocket in BauB. (A) The Acb2Fe ligand is shown with buried
(green) and exposed (yellow) acinetobactin molecules with a surface representation of BauB. (B)
Stereorepresentation of the residues that form the binding pocket.
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Figure 2.7. Overlay of BauB and CeuE. A. Ribbon diagram showing BauB (6MFL, cyan) and
CeuE (5ADW, pink). B. Stereorepresentation of the siderophore binding pocket of BauB bound
to [Acb2:Fe]-1 anion superimposed with CeuE bound to bis-(2,3-dihydroxybenzoyl-L-Ser).
His227 and Tyr288 from CeuE directly coordinate the ferric ion. Tyr301 of BauB interacts with
a catechol oxygen of the more exposed acinetobactin molecule. The side chain of His239 in
BauB is adjacent to a disordered loop and no density is present for the side chain.
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A.

B.

C.

Figure 2.8. Structures of (Acb)2Fe from (A) experimental fitting into the electron density of the
BauB substrate binding pocket and (B) DFT calculated lowest energy structure for the
monoanionic [(Acb)2Fe]- metal complex (PBE0/Def2-SVP; PBE0/Def2-TZVP; PBE1PBE =
PBE0 in Gaussian). (C) Overlay of (Acb)2Fe structures from experimental (grey) and DFT
(salmon) modeling.
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Figure 2.9. Structural representations of the experimentally observed cis-[Acb2Fe]- geometric
and optical isomer. The cis-[Acb2Fe]- structure is isomeric with ML4aL2b octahedral metal
complexes where La is oxygen and Lb is nitrogen represented as [FeO4N2]-.
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BauB

CAS (+/-)1

A. baumannii Growth
Promotion (+/-)1

Apparent Kd (nM)2

+

++

300 ± 100

1-Fe, R1 = 2,3-OH; R2 = Im

NA

+++

160 ± 80

3, R1 = 2,3-OH; R2 =CH2Im

+

+

320 ± 130

4, R1 = 2-OH; R2 = Im

–

–

520 ± 270

5, R1 = 3-OH; R2 = Im

–

–

250 ± 70

6, R1 = 4-OH; R2 = Im

–

–

250 ± 70

7, R1 = 2,3-OMe; R2 = Im

–

–

270 ± 70

8, R1 = H; R2 = Im

–

–

520 ± 220

9, R1 = 2,3-OH; R2 = Me

+

+

320 ± 130

1, R1 = 2,3-OH; R2 = Im

1

Results from CAS assay and A. baumannii growth promotion were reported previously.27 For the
CAS assay, + indicates a positive result correlating to Fe binding and a – indicates no apparent Fe
binding. For the growth promotion of A. baumannii, a +/++/+++ indicates positive promotion of
growth with more ‘+’ symbols correlating to more relative growth. 2Experiments were performed in
duplicate as independent trials. Error represents standard deviation from the mean. 3NA = not
applicable.

Table 2.2. Structure of acinetobactin analogs and associated properties.
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Compound 1-Fe (acinetobactin 2Fe)
Normalized Abs (320 nm)
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Figure 2.10. Siderophore-dependent fluorescence quenching of C-His6-BauB. Graphs depict
intrinsic tryptophan fluorescence quenching (y-axis; excitation = 280 nm; emission = 340 nm) of CHis6-BauB in the presence of variable siderophore concentrations (x-axis). Apparent Kd values
were calculated using a single-binding mode curve fitting model in GraphPad Prism version
7.0b.
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Figure 2.11. Overview of the acinetobactin pathway in A. baumannii. BarAB is a putative efflux
pump for cytoplasmic apo-Acb. Once formed, the holo-Acb ferric complex is imported to the
periplasm by the TonB-dependent outer membrane protein BauA. Presumably, BauA is selective
for importing various forms of Acb. Periplasmic holo-Acb is delivered to the inner membrane
permease BauCDE by the SBP BauB (the focus of this work). Once imported to the cytoplasm,
the holo-Acb ferric complex is likely reduced giving ferrous iron and apo-Acb, which is
recycled.
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A

B

C

Figure 2.12. BauB purification. (A) Analytical gel filtration of full length BauB showing
monomeric status in solution. Retention times for β-Amylase (200 kD), Alcohol Dehydrogenase
(150 kD), Albumin (66 kD), Carbonic Anhydrase (29 kD) and Cytochrome C (12.4 kD)
standards are indicated. (B) SDS-PAGE gel recombinant C-His 6-BauB purified from E. coli
BL21. Molecular weight markers and mass of protein loaded are labeled. (C) SDS-PAGE
analysis of Ni-NTA purified N-His6-BauB (~36.1 kDa).
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Data Set Entry

1

2

Crystal Identifier

BB_41

BB_5

Protein

CHis_BauB-SS (50 mg/mL) + ferric Acb (3 mM)

Protein Buffer

10 mM Tris, 30 mM
NaCl, 0.04 mM TCEP,
pH 8.0

50 mM Tris, 150 mM NaCl, 0.2
mM TCEP, pH 8.0

Crystallization
Cocktail

25% PEG MME 5k, 50
mM MES pH 6.0 (14 °C)

34% PEG 4k, 100 mM EPPS
pH 8.0 (14 °C)

Cryoprotection

Serial transfer through 8,16,20% ethylene glycol in cocktail

Beamline

SSRL 12-2

APS GM/CA 23ID-D

Detector Distance
(mm)

375

325

Oscillation Range (°)

360

180

Oscillation Angle (°)

0.25

0.20

No. of Images

1,440

900

Exposure Time (s)

0.5

0.2

Beam size (w × h, µm)

100 × 100

200 × 100

Wavelength (Å)

0.9795

1.0332

Resolution range (Å)

68.6 – 1.9 (2.0 – 1.9)

45.6 – 2.0 (2.04 – 2.0)

Space group

P 21

P 21

Unit cell a, b, c (Å)
𝜶, 𝜷, 𝜸 (°)

37.6, 137.3, 56.3
90.0, 90.0, 90.0

37.9, 136.8, 56.3
90.0, 90.1, 90.0

Total Observations

260338

123410

Unique reflections

39102

38149

Multiplicity

6.7

3.2

Completeness (%)

87.3 (90.5)

97.7 (91.1)

Mean I/sigma(I)

11.8 (6.7)

3.2 (3.0)

RMERGE

0.09 (0.17)

0.19 (0.58)

RMEAS

0.11 (0.20)

0.26 (0.80)

CC1/2

0.99 (0.97)

0.94 (0.42)

Data Collection

Table 2.3. Summary of BauB crystallization and data collection.
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PDB ID
Data Collection
Resolution range (Å)
Space group
Unit cell a, b, c (Å) 𝛼, 𝛽, 𝛾 (°)
Number Crystals
Total Observations
Unique reflections
Multiplicity
Completeness (%)
Mean I/sigma(I)
RMERGE
RMEAS
CC1/2
Structure Refinement
Reflections used in refinement
Reflections used for RFREE
RWORK
RFREE
Number of non-hydrogen atoms
macromolecules
Ligands
Solvent
Wilson B-factor (Å2)
Average B-factor (Å2)
Chain A (main, side)
Chain B (main, side)
Acb2Fe
Water
Ethylene glycol
RMSD bond lengths (Å)
RMSD bond angles (°)
Ramachandran analysis
favored (%)
allowed (%)
outliers (%)
Rotamer outliers (%)
MolProbity Clashscore

BauB-Acb2-Fe3+
6MFL
68 – 1.9 (1.94-1.90)
P 21
37.8, 137.1, 56.2, 90, 90.0, 90
2
347119 (22375)
44580 (2908)
7.8
99.2 (99.6)
11.6 (5.6)
0.178 (0.570)
0.204 (0.662)
0.970 (0.679)
44255
2140
16.9
21.4
4928
102
372
13.8
14.8, 20.5
13.9, 20.4
18.0
23.3
34.7
0.01
1.12
97.0
3.0
0.0
0.8
2.9

Table 2.4. Data collection and refinement statistics
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Chapter 3: Fimsbactin and Acinetobactin
Compete for the Periplasmic Siderophore
Binding Protein BauB in Pathogenic
Acinetobacter baumannii
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3.1 Preface
This chapter was adapted in part from [Bohac, T. J., Fang, L., Giblin, D. E. & Wencewicz,
T. A. ACS Chemical Biology, Manuscript accepted DOI: 10.1021/acschembio.8b01051]. TJB
isolated Fimsbactin A, performed characterization, BauB fluorescent quenching binding studies
and BauB displacement assays. LF performed all growth curves. DEG performed all DFT
calculations. TAW served as principal investigator and oversaw experimental design.

3.2 Abstract
Environmental and pathogenic microbes produce siderophores as small iron-binding
molecules to scavenge iron from natural environments. It is common for microbes to produce
multiple siderophores to gain a competitive edge in mixed microbial environments. Human
pathogenic Acinetobacter baumannii produces up to three siderophores: acinetobactin,
baumannoferrin, and fimsbactin. Production of acinetobactin and baumannoferrin is highly
conserved amongst clinical isolates, while fimsbactin production appears to be less common.
Fimsbactin is structurally related to acinetobactin through the presence of catecholate and
phenolate oxazoline metal binding motifs, and both are derived from non-ribosomal peptide
assembly lines with similar catalytic domain orientations and identities. Here we report on the
chemical, biochemical, and microbiological investigation of fimsbactin and acinetobactin alone
and in combination. We show that fimsbactin forms a 1:1 complex with iron(III) that is
thermodynamically more stable than the 2:1 acinetobactin ferric complex. Alone, both
acinetobactin and fimsbactin stimulate A. baumannii growth, but in combination the two
siderophores appear to compete for uptake and collectively inhibit bacterial growth. We show that
fimsbactin directly competes with acinetobactin for binding the periplasmic siderophore binding
protein BauB, suggesting a possible biochemical mechanism for the phenomenon where
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siderophore build up in the periplasm leads to iron starvation. We propose an updated model for
siderophore utilization and cooperativity in A. baumannii that frames the molecular, biochemical,
and cellular interplay of multiple iron acquisition systems in a multi-drug resistant Gram-negative
human pathogen.

3.3 Introduction
We sought to investigate the interplay of two high-affinity A. baumannii siderophore-based
iron acquisition systems; the PreAcb/Acb and Fim pathways. Here, we show that Acb and Fim
alone stimulate A. baumannii growth under iron deficient conditions. Both siderophores promote
growth more efficiently in the holo, iron-bound forms. Surprisingly, we found that apo-Fim is
antagonistic towards holo-Acb, leading us to hypothesize that Acb and Fim have competing
transport pathways. We recently reported the x-ray crystal structure of the periplasmic siderophore
binding protein BauB bound to a stable Acb2Fe complex which provided the template for
understanding siderophore molecular recognition in A. baumannii.1 In this work, we show that
both isomers of acinetobactin, PreAcb and Acb, and Fim bind to BauB with nanomolar affinity.
Intrinsic fluorescence quenching and direct binding via an immobilized BauB-LCMS competition
experiment validated meaningful BauB binding to apo- and holo-forms of PreAcb, Acb, and Fim.
The promiscuity of BauB is explained using density functional theory (DFT) calculated structures
of the PreAcb2Fe and FimFe complexes against the BauBAcb2Fe crystal structure which reveals
how the three A. baumannii siderophores fulfill the octahedral iron(III) coordination sphere using
ligands derived from the common 2,3-DHB-Thr/Ser phenolate oxazoline, catechol, and
imidazole/hydroxamate motifs that display identical stereochemistry about the ferric metal center
and overlapping electron density in the ligand coordination sphere. Pathway competition between
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Acb and Fim might explain, in part, why it is rare to find clinical isolates of pathogenic A.
baumannii harboring biosynthetic operons for both siderophores.

3.4 Results and Discussion
Purification of Acb and Fim from A. baumannii ATCC 17978.
The fimsbactin siderophores were originally isolated from the environmental strain A.
baylyi ADP1.2 Up to this point, Fim had not been isolated from any pathogenic strains of A.
baumannii, although comparative genomics predicts the presence of the Fim operon in at least 4
unique strains of A. baumannii in the NCBI database (Figure 3.1). One of these strains is human
pathogenic A. baumannii ATCC 17978, a clinical isolate that is predicted to be a producer of Acb,
Fim, and baumannoferrrin.3 We isolated crude Acb and fimsbactin A–F from A. baumannii ATCC
17978 grown in iron deficient M9 minimal medium at 37 °C. LC-MS analysis of the crude
fermentation broths from two separate trials showed the presence of Acb and all of the fimsbactin
isomers, fimsbactin A–F, with fimsbactin A providing the largest signal in the optical absorbance
and extracted ion chromatogram (EIC) traces (Figure 3.2-3.6). This validates coproduction of Acb
and Fim by a human pathogenic strain of A. baumannii. Acb and fimsbactin A were purified via
RP-C18 prep-HPLC allowing for isolation of both siderophores from a single fermentation. Acb
was isolated in >95% purity by LCMS at a mass recovery after purification of 31 mg/L averaged
over two trials. No PreAcb was observed, which is consistent with the instability of PreAcb during
extended fermentations at physiological pH and previous failed isolation attempts. However,
PreAcb is readily available in our group through total synthesis.4 Fimsbactin A was isolated as a
mixture of fimsbactin A (>90%) and fimsbactins B, C, and F (≤10%) according to LCMS and
NMR analysis. We validated that fimsbactin A is the primary component by HRMS and
comparison of the 1D (1H,

13

C) NMR spectra against the literature reported values (Table 3.1,
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Figures 3.7-3.9).2 The mass recovery of Fim after purification was 5 mg/L averaged over two
independent trials. The greater mass production of Acb over Fim is consistent with the
observations for siderophore production in A. baylyi.2 We were unable to detect any positively
charged ions corresponding to apo- or holo- baumannoferrin in the A. baumannii ATCC 17978
supernatants, despite the predicted biosynthetic capacity for this siderophore (Figure 3.1).5 It is
possible that the baumannoferrins remain membrane associated or have a low ionization potential
in positive mode electrospray ionization (ESI) due to the anionic carboxylate/hydroxamate metal
chelating groups, thus, proving to be undetectable by the low-resolution single quadrupole mass
spectrometer employed in this study.6 We utilized synthetic PreAcb, natural Acb, and natural Fim
(>90% fimsbactin A) for all studies in this work.
Iron-Binding properties of fimsbactin A.
Fimsbactin A is a mixed ligand biscatecholate-monohydroxamate siderophore that is
structurally related to other NRPS siderophores including heterobactin A 7, JBIR-168,
vibriobactin9, vulnibactin10, fluvibactin11, agrobactin12, parabactin13,14, and protochelin15 (Figure
3.10). All of these related siderophores are hexadentate metal chelators with three bidentate ligands
(either catecholates, phenolate oxazolines, and/or hydroxamates) branching from three arms of a
tetrahedral atom, either nitrogen or carbon, creating a tripodal ferric coordination template.
Vibriobactin, vulnibactin, fluvibactin, agrobactin, and parabactin are all spermidine-based with a
tetrahedral nitrogen at the apex of the tripod, while protochelin and heterobactin are lysine-based
using the α-carbon of L-Lys as the tetrahedral branch point for the three metal chelating ligands.
Fimsbactin A is most similar to protochelin and heterobactin in that the tetrahedral branching atom
for the three metal chelating ligands is the α-carbon of L-Ser. Additionally, the 2,3-DHB catechol
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moiety is attached via ester linkage to the Ser hydroxyl group as opposed to amide linkages in the
related siderophores.
The structure of fimsbactin A is unique and resembles a cross between the metal chelating
groups found in heterobactin A7, produced by Rhodococcus erythropolis, and agrobactin12, from
plant pathogenic Agrobacterium temufaciencs (Figure 3.10). Fimsbactin A is composed of
hydroxamate, phenolate oxazoline, and catecholate metal chelating groups derived from N-acetylN-hydroxy-cadaverine, serine-2,3-DHB oxazoline, and 2,3-DHB, respectively. 2 Heterobactin A
contains hydroxamate, phenolate oxazoline, and catecholate ligands derived from cyclized Nhydroxy-ornithine, 2,5-dihydroxy-5-amino-benzoate and 2,3-DHB, respectively. 7 The phenolate
oxazoline group of heterobactin A is distinct from that found in fimsbactin in that metal
coordination between the oxazoline nitrogren and phenolate oxygen is not possible in heterobactin
A. Instead, metal chelation for this ligand arrangement probably occurs through the amide carbonyl
oxygen and either the phenolate oxygen or the oxazoline nitrogen. Agrobactin contains two
catecholates from 2,3-DHB and one phenolate oxazoline derived from cyclized L-Thr-2,3-DHB
methyl oxazolines.12 Both heterobactin A and agrobactin form stable 1:1 complexes with unique
ligand-to-metal charge transfer bands in the optical absorbance spectra appearing at 560 nm and
520 nm, respectively, for the ferric holo-siderophores.7,12,16 For comparison, the well known 1:1
enterobactin tris-catecholate ferric complex has a characteristic ligand-to-metal charge transfer
band at 498 nm.17 The unique optical absorbance bands arise from metal:ligand charge transfer
and reflect the unique metal:ligand geometry and speciation of the soluble ferric siderophore
complexes. We sought to investigate the iron binding properties of fimsbactin A in comparison to
PreAcb and Acb to better understand metal chelation dynamics of the mixed siderophore system
in A. baumannii.
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The ferric holo-siderophore complexes of PreAcb, Acb, and Fim were prepared by
treatment with Fe(acac)3 using a method reported previously by our group.4,18,19,20 Titration of Fim
with Fe(acac)3 in MeOH monitored by fluorescence quenching (λexcitation = 330 nm; λemission = 380
nm) was consistent with the formation of a stable ferric complex of Fim (Figure 3.11). At low iron
concentrations, the titration curve appears to indicate formation of 2:1 Fim 2Fe complexes that
eventually convert to the 1:1 FimFe complex with added iron. These observations are consistent
with previous studies of mixed ligand siderophores, including heterobactin A, where iron chelation
geometry and metal:ligand stoichiometry of holo-siderophores was shown to vary with
metal/ligand concentrations and pH.16 LCMS analysis of FimFe was also consistent with the
formation of a 1:1 siderophore:iron complex. Using ESI in positive ion mode, FimFe ionized as
the [M+H]+ ion with an observed m/z = 627. Both PreAcb and Acb form 2:1 siderophore:iron
complexes, PreAcb2Fe and Acb2Fe, respectively, that lose iron upon ionization by ESI in positive
ion mode to give [M+H]+ ions with m/z = 347.4 This difference in ionization modes reflects the
increased relative stability of a 1:1 siderophore:iron complex, FimFe, compared to 2:1
siderophore:iron complexes, PreAcb2Fe and Acb2Fe, towards ESI.
The optical absorbance spectrum of FimFe shows a broad ligand-to-metal charge transfer
absorbance band at 445 nm (Figure 3.12). PreAcb2Fe and Acb2Fe show ligand-to-metal charge
transfer absorbance bands at 515 and 570 nm, respectively, in the optical absorbance spectra. The
red spectral shift for FimFe (λmax = 445 nm) compared to PreAcb2Fe (λmax = 515 nm) and Acb2Fe
(λmax = 570 nm) implies that there are greater interactions between ferric iron and stronger-field
ligands in the FimFe complex. We also measured the apparent iron(III) affinity (log KFe) of FimFe
to be 27.1 ± 0.2 using an EDTA competition assay (Table 3.2; Equations 3.1). The FimFe
complex appears to be more stable than the PreAcb2Fe (apparent log KFe = 27.4 ± 0.2) and Acb2Fe
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(apparent log KFe = 26.2 ± 0.1).4 This is consistent with the relative stability of mycobactin (more
stable; phenolate oxazoline, bis-hydroxamate) and exochelin (less stable;imidazole-containing bishydroxamate) ferric siderophores from Mycobacterium tuberculosis.21 We confirmed that apparent
KFe for FimFe was greater than Acb2Fe through a competitive iron exchange assay. Treatment of
Acb2Fe with an equimolar amount of apo-Fim resulted in formation of the FimFe complex. The
exchange of iron(III) from Acb2Fe to Fim was confirmed by optical absorbance spectroscopy and
LCMS. The iron exchange was slow, but after 20 hours nearly full exchange was observed,
suggesting that the 1:1 FimFe was thermodynamically more stable than the 2:1 Acb 2Fe complex
(Figure 3.13). The relevance of iron exchange between siderophores is unknown but could play a
role in the overall iron acquisition process through a metal shuttle. 22 The potential for siderophore
cooperativity via iron exchange between Fim and PreAcb/Acb involvement is discussed further in
the following sections of this chapter. Collectively, these observations support 1:1 stoichiometry
and metal chelation through the phenolate oxazoline ligand for the soluble FimFe complex at pH
7.4.
Fimsbactin A stimulates A. baumannii growth under iron-deficient conditions.
Formation of stable ferric complexes is the first requirement for siderophore-mediated iron
acquisition.23 The second requirement is import of the holo-siderophore across the bacterial cell
envelope. To investigate the ability of A. baumannii to utilize FimFe as an iron source, we
performed kinetic growth recovery assays in M9 minimal medium supplemented with 2,2’dipyridyl (DIP). We used the model strain A. baumaunnii ATCC 17978, a natural producer of Fim
and PreAcb/Acb, and fine tuned DIP concentrations, as previously described 4,18,20, to where only
weak growth is observed unless an iron supplement is added to the medium (Figure 3.14). As a
positive control we showed that both Acb and Acb 2Fe recover the growth of A. baumaunnii ATCC
86

17978 in a dose-dependent manner (Figure 3.14a,c, 3.15, 3.16). As expected from our previous
work4, Acb2Fe stimulates growth at lower concentrations and to a higher final cell density, as
measure by optical density at 600 nm (OD600) for liquid cultures incubated at 37 °C up to 48 hours.
A similar trend was observed for Fim and FimFe, where both promote A. baumannii growth in a
time- and dose-dependent manner with FimFe, providing faster and more enhanced growth
recovery (Figure 3.14b,d, 3.15, 3.16). Clearly, pre-loading Acb and Fim with iron(III) is beneficial
for growth promotion under these growth conditions. Since Acb2Fe and FimFe were both prepared
as pure ferric complexes with removal of all residual iron, the potent growth stimulating effects
must be attributed to utilization of the siderophore ferric complexes as an iron source. These results
show for the first time that FimFe can serve as a true iron source for A. baumannii ATCC 17978
and support the role of the fimsbactins as natural siderophore substrates. 24
apo-Fim antagonizes the growth promoting effects of [Fe(Acb) 2].
After establishing the individual roles of Fim and PreAcb/Acb as siderophores, we sought
to probe the more challenging question of why A. baumannii produces multiple siderophores in
the first place. More specifically, we thought it curious why all pathogenic A. baumannii maintain
the ability to produce and utilize PreAcb/Acb while <10% produce Fim. We hypothesized that
siderophore competition, as opposed to cooperativity, might have led to evolutionary selection of
PreAcb/Acb over Fim. To test for siderophore competition between Acb and Fim, we performed
checkerboard kinetic growth recovery assays using combinations of Acb, Fim, Acb 2Fe, and FimFe
against A. baumannii ATCC 17978 under the same iron restrictive growth conditions described
previously (Figure 3.17-3.18). We were surprised to discover that combinations of aposiderophores Acb and Fim were growth inhibitory (Figure 3.17a) compared to each aposiderophore alone (Figure 3.14). Increasing the concentration of Acb from 3.9 μM to 62.5 μM in
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the presence of 3.9 μM Fim slightly recovered growth. Increasing the concentration of Fim to 62.5
μM in the presence of 62.5 μM Acb returned the antagonistic effect on Acb-promoted growth. The
addition of holo-siderophores recovered A. baumannii growth, but increasing the concentration of
apo-siderophores could still antagonize growth slightly. Figure 3.17b shows that 15.6 μM Acb2Fe
can recover A. baumannii growth in the presence of 3.9 μM or 62.5 μM Fim. However, Acb2Fe at
0.5 μM was not capable of recovering growth in the presence of Fim at 3.9 or 62.5 μM. The
addition of apo-Acb at 62.5 μM was also slighty antagonistic towards FimFe at 0.5 and 15.6 μM
in the growth recovery assay (Figure 3.17c), although to a lesser extent than the effect of apo-Fim
on Acb2Fe (Figure 3.17b).
The discovery that Fim and Acb appear to be antagonistic adds to the complexity of
understanding the delicate balance of metals and siderophores in pathogenic A. baumannii. This
phenomenon is consistent with our hypothesis that Acb and Fim competition drove natural
selection of the Acb pathway found in all A. baumannii clinical isolates. In natural environments
siderophore competition plays a critical role in microbial population dynamics. 25,26 Siderophore
producers often produce siderophore cocktails and express siderophore transport and utilization
proteins for xenosiderophores in order to gain a competitive advantage. 19 Some siderophores are
inhibitory towards competing bacteria by withholding metals from the extracellular and/or
intracellular environment.27 Some siderophores are attached to antibiotics, so called sideromycins,
to deliver a toxic payload into susceptible competitor cells. 28 Some siderophores are thought to
directly compete for uptake at the receptor level through endogenous pathways. 20.29 Thus, we
turned out attention to probing for pathway competition between Acb and Fim in A. baumannii to
gain further insight on the underlying cause of the antagonistic siderophore relationship.
Fim, PreAcb, and Acb binding to BauB.
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Bioinformatic analysis of the fimsbactin biosynthetic operon revealed some potential gaps
in the uptake pathway, including no dedicated periplasmic siderophore binding protein (SBP) and
no inner membrane permease. (A more detailed discussion of the PreAcb/Acb and Fim transport
pathways is provided in a later section.) Outer membrane receptors (OMRs) are often highly
selective for binding cognate substrates, while SBPs can be broader in terms of binding small
molecules.19,23,28,30 Thus, we hypothesized that the SBP responsible for binding PreAcb/Acb might
also bind Fim, which shares structural homology to PreAcb/Acb through the phenolate oxazoline
and catecholate moieties. We turned our focus towards BauB, the highly conserved periplasmic
SBP responsible for binding PreAcb/Acb and shuttling the corresponding holo-siderophores to the
membrane permease, BauCDE, to facilitate import to the cytoplasm. We hypothesized that Fim
might compete with PreAcb/Acb for BauB binding and inhibit the import of ferric siderophore
complexes to the cytoplasm. To test this hypothesized, we pursued in vitro reconstitution of BauB
and evaluated the ability of apo- and holo-forms of PreAcb, Acb, and Fim to compete for binding.
The gene encoding for BauB (GenBank AAT52185) contains a N-terminal signal sequence
(residues 1–22), indicating that BauB is exported from the cytoplasm and localized to the
periplasm. The full length bauB gene was codon optimized for expression in E. coli, and the
genetic region encoding for residues 23–322 of BauB was subcloned into a pET28 vector encoding
for an N-terminal hexahistdine tag and including a TEV protease cleavable site (Figure 3.19).
After expression in E. coli BL21 (DE3) and purification by Ni-NTA affinity chromatography the
N-His6-BauB was used in siderophore binding studies with the intact hexahistidine tag (Figure
3.20). We first confirmed binding of BauB to authentic PreAcb and Acb using an intrinsic
tryptophan fluorescence quenching assay.1 We observed dose-dependent fluorescence quenching
for both the apo- and holo-forms of both acinetobactin isomers. The binding of both apo- and holo-
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siderophores by outer membrane siderophore receptors and perisplasmic siderophore binding
proteins is common.19,31 The apparent Kd values for apo-PreAcb and holo-PreAcb2Fe were 380 ±
110 nM and 750 ± 160 nM, respectively (Table 3.2). While the apparent Kd for holo-PreAcb2Fe
appeared to be greater than apo-PreAcb, it is noteworthy that the degree of fluorescence quenching
was greater for the ferric complex (Figure 3.21). In fact, the degree of BauB fluorescence
quenching by holo-PreAcb2Fe was greater than all of the siderophores in the study possibly
indicating a unique binding mode. The apparent Kd values for apo-Acb and holo-Acb2Fe were 300
± 100 nM and 160 ± 80 nM, respectively (Table 3.2). The apparent trend in binding affinities of
apo-Kd < holo-Kd for Acb appear to be reversed for the measurements obtained for PreAcb where
apo-Kd > holo-Kd. Treatment of BauB with apo- and holo-forms of Fim resulted in dose dependent
fluorescence quenching with curve shapes and apparent Kd values falling within the margin of
error for those observed for Acb (Table 3.2). The apparent Kd values for apo-Fim and holo-FimFe
were 360 ± 140 nM and 240 ± 90 nM, respectively. All apparent Kd values were calculated using
a one-site binding model to fit the binding stoichiometry observed in the BauBAcb2Fe crystal
structure.1 These results are consistent with our hypothesis that PreAcb, Acb, and Fim compete for
binding to BauB. We next turned to investigating the nature of this binding competition using a
siderophore displacement assay with resin-immobilized BauB.
Fimsbactin A and acinetobactin directly compete for binding to BauB.
To validate that Fim binding to BauB is authentic we performed a competitive binding
experiment with Acb2Fe and FimFe using resin-immobilized BauB. Our group previously has
reported this type of binding assay on the study of ferrioxamine siderophore competition for
binding FhuD2, the xenosiderophore receptor displayed on the cell surface of pathogenic
Staphylococcus aureus.32 We started by preparing a resin-immobilized BauB column by saturating
90

Ni-NTA resin with N-His6-BauB. Column saturation and quantity of immobilized BauB was
determined by SDS-PAGE analysis of column flowthrough from the protein-loading step.
Treatment of the BauB resin with a solution of Acb2Fe resulted in a decrease of ion counts in the
EIC trace for m/z 347, corresponding to the [M+H]+ ion for Acb (this is the dominate ion in the
MS spectrum of Acb2Fe). Treatment of the BauBAcb2Fe resin with a solution of FimFe recovered
ion counts for Acb2Fe, indicating that the excess FimFe displaced Acb 2Fe from the resin resulting
in BauBFimFe resin and elution of Acb2Fe (Figure 3.22a). Similarly, treatment of the BauB resin
with FimFe resulted in a decrease of ion counts in the EIC trace for m/z 627, corresponding to the
[M+H]+ ion for FimFe (this is the dominate ion in the MS spectrum of FimFe) after washing the
column with buffer. Treatment of the BauBFimFe resin with a solution of Acb2Fe recovered ion
counts for FimFe in the elution, indicating that the excess Acb2Fe displaced FimFe from the resin
resulting in BauBAcb2Fe resin and elution of FimFe (Figure 3.22b). We also found that the BauB
resin could be cycled between treatment with Acb2Fe and FimFe multiple times with reversible
siderophore displacement. These competition experiments validate that BauB binds to tightly and
reversible to both Acb2Fe and FimFe. Since BauB binding is reversible, the delicate balance
between concentrations of apo-siderophores PreAcb, Acb, Fim, and corresponding holo ferric
complexes will ultimately determine which siderophore species dominates the BauB binding
equilibrium. Our results here show that Fim antagonizes A. baumannii growth promotion by
Acb2Fe, suggesting that occupancy of BauB in the periplasm by Fim might exclude import of
Acb2Fe to the cytoplasm. This suggests that concentrations of Acb are kept higher than
concentrations of Fim during growth of A. baumannii ATCC 17978 under iron deficient minimal
medium conditions to balance siderophore cooperativity and pathway competition allowing for
efficient iron scavenging.
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Structural similarity of FimFe, PreAcb2Fe, and Acb2Fe ferric complexes.
In order to bind BauB, the molecular volume, stereochemistry, and geometrical orientation
of ligands around the ferric metal center must be similar for PreAcb 2Fe, Acb2Fe, and FimFe. We
investigated these properties using density functional theory (DFT) calculations to create energy
minimized structural models of PreAcb2Fe and FimFe using the experimentally observed geometry
of the Acb2Fe complex recently reported for the BauBAcb2Fe crystal structure (Figure 3.23).1
We assumed that PreAcb2Fe, Acb2Fe, and FimFe exist as the mono anions in the ferric complexes.
BauB appears to recognize one enantiomer of the cis-[Acb2Fe]- isomeric form. The DFT-computed
energy minimized structures of [FimFe]- (Figure 3.23a) and cis-[PreAcb2]- (Figure 3.23b) were
strikingly similar to the experimentally observed cis-[Acb2Fe]- complexed to BauB (Figure 3.23c).
An overlay of the three structures revealed how the common phenolate oxazoline fragment aligns
nicely and the L-Ser stereochemistry enables [FimFe]- to map the hydroxamate and catecholate
ligands to the same ferric binding sites as the imidazole and catecholate ligands of cis-[Acb2Fe]-,
respectively. As shown in Figure 3.23e, BauB binds one half of the cis-[Acb2Fe]- complex through
hydrophobic interactions with one of the Acb ligands while the second Acb ligand remains largely
solvent exposed. The computed structures of cis-[PreAcb2Fe]- and [FimFe]- would appear to fit
this same binding mode to BauB and might explain how all three siderophores can compete for
binding to periplasmic BauB. Since FimFe is the only stable 1:1 complex, this could indicate that
BauB cannot facilitate transport of 1:1 siderophore:iron complexes across the inner membrane
through the associated membrane permease BauCDE hinting at a potential shuttling mechanism
for 2:1 PreAcb/Acb:iron complexes.22,33,34
A new model for siderophore cooperativity in A. baumannii.

92

Our findings have been largely consistent with the current understanding of PreAcb/Acb
biosynthesis and utilization in pathogenic A. baumannii (Figure 3.24). PreAcb is the kinetic
biosynthetic product of the biosynthetic enzymes BasA–J, while Acb is formed via non-enzymatic
isomerization of PreAcb as the thermodynamic biosynthetic end product. 35,36 Both PreAcb and
Acb can reach the extracellular space, presumably via efflux mediate in part by BarAB.4 The
TonB-dependent OMR BauA has been shown to be essential for PreAcb/Acb utilization,
presumably providing import of holo-siderophores to the periplasm.37,38 The periplsamic SBP
BauB, which might be membrane anchored although this has not been experimentally confirmed 1,
is then thought to shuttle holo-siderophores to the ABC-type membrane permease BauCDE2 where
import to the cytoplasm is driven by ATP hydrolysis. BauF is a putative flavin-dependent
oxidoreductase responsible for reduction of the ferric holo-siderophore complexes to release
ferrous for incorporation into protein scaffolds such as the iron-sulfur cluster generating protein
SufU.39,40,41 The apo-siderophores, PreAcb and/or Acb, can then reenter the transport cycle.
Our findings provide new insight into the role of PreAcb, Acb, and Fim in overall
siderophore-mediated iron acquisition by A. baumannii. The Fim biosynthetic operon contains
genes encoding for an efflux pump FbsOQ, a TonB-dependent OMR FbsN, and a putative
reductase FbsP. The reductase FbsP is predicted to be secreted to the perisplasm due to the
presence of an N-terminal signal sequence, similar to the siderophore-interacting periplasmic
reductases YqjH and FpvC in E. coli and P. aeruginosa, respectively.40,42 We propose that Fim is
exported in part by FbsOQ after biosynthesis in the cytoplasm. Extracellular FimFe is presumably
imported to the periplasm by FbsN where periplasmic reduction by FbsN releases Fim that reenters
the transport cycle and ferrous iron for direct import to the periplasm via the endogenous ferrous
transport system FeoABC.43,44 This transport model is analogous to the well-studied utilization
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pathway for the siderophore pyoverdine in pathogenic P. aeruginosa.45 Furthermore, P.
aeruginosa balances the use of multiple siderophores for adaptive iron acquisition during infection
where some siderophores stay in the periplasm (pyoverdine) and some enter the cytoplasm
(pyochelin).46 Analogously, A. baumannii might utilize Fim as the periplasmic siderophore and
PreAcb/Acb as the cytoplasmic siderophore. This model suggests that Fim never makes it to the
cytoplasm, which is consistent with the observation that fimsbactin analogs conjugated to
antibiotics with periplasmic targets (beta-lactams, daptomycin, vancomycin) show potent, irondependent growth inhibitory activity against A. baumannii while the same siderophores conjugated
to antibiotics with cytoplasmic targets (fluoroquinolones) show no antibacterial activity. 47 One
unique structural feature of fimsbactin A is the presence of an L-Ser-2,3-DHB ester, which
resembles a fragment of the L-Ser-2,3-DHB tri-lactone scaffold of enterobactin.48 Similar to
enterobactin, it is possible that hydrolysis of the L-Ser-2,3-DHB ester in the periplasm may play a
role in iron release.49 The product of fimsbactin A hydrolysis is fimsbactin F, which is the second
most concentrated member of the fimsbactin mixture present in A. baumannii ATCC 17978
supernatants (Figures 3.3-3.6, 3.25).
If fimsbactins accumulates in the periplasm, this would create a scenario for competition
between Fim and PreAcb/Acb to bind BauB that is consistent with our current findings. A build
up of excess Fim in the periplasm could shift the BauB equilibrium towards BauBFim and inhibit
the import of PreAcb/Acb leading to the growth inhibitory effect that we observed for the
siderophore combinations. It is also possible that Fim, PreAcb, and Acb compete for iron and form
mixed siderophore ferric complexes that act as transport inhibitors. A crystal structure of the A.
baummannii outer membrane siderophore receptor, BauA, bound to a mixed (PreAcb)(Acb)Fe
ferric complex was recently deposited in the protein data bank (PDB 6H7F). The
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BauA(PreAcb)(Acb)Fe structure shows complexation of the iron by the PreAcb ligand through
phenolate oxazoline, hydroxamate, and imidazole filling four of the size coordination sites in the
octahedral ferric center. The final two coordination sites are apparently filled by the 2,3-DHB
catecholate of the Acb ligand. The structure suggests that BauA only interacts with the PreAcb
ligand while the Acb dangles outside of the binding pocket. Our group recently reported a
competitive inhibitor of siderophore uptake based on an oxidized analog of PreAcb that induces
an iron-dependent growth inhibitory effect on A. baumannii that is similar to the effect of apoFim.20 The oxidized PreAcb features an aromatic oxazole in place of the PreAcb oxazoline that
stabilizes the PreAcb structure and prevents isomerization to Acb. The BauA(PreAcb)(Acb)Fe
structure suggests that apo- and holo- variants of the oxazole PreAcb and/or fimsbactin A might
also bind to BauA in a similar manner, although this requires experimental validation.
Our work suggests that competition for periplasmic BauB is possible, but it is not entirely
clear whether competition for BauA plays a role in the growth inhibitory effect of apo-fimsbactin
A. We tested the effect of excess apo-Fim on the growth of A. baumannii ATCC 19606T, a strain
that does not produce the fimsbactins, but does produce PreAcb/Acb and is predicted to produce
baumannoferrin (Figure 3.26).5,37 Treatment of wild type A. baumannii ATCC 19606T and mutant
variants s1 (insertional mutant in basD, deficient in PreAcb/Acb biosynthesis), t6 (insertional
mutation in bauA, deficient in PreAcb/Acb import to periplasm), and t7 (insertional mutation in
bauD, deficient in PreAcb/Acb import to cytoplasm) with apo-Fim under iron deficient minimal
medium conditions produced the same growth inhibited phenotype in the kinetic growth studies
(Figures 3.27-3.28). Addition of holo-FimFe recovered the growth of wild type and mutant A.
baumannii strains suggesting that FimFe can serve as an iron source in the absence of the dedicated
Fim utilization proteins FbsOQNP. It is possible that FimFe can be imported through BauA and/or
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some of the other ~20 TonB-dependent outer membrane receptors 50 present in pathogenic strains
of A. baumannii through direct import or siderophore shuttling with PreAcb/Acb. 22,51 These results
suggest that fimsbactin A bioactivity is independent of BauA and BauD consistent with the
hypothesis for periplasmic accumulation of toxic levels of Fim. A recent study in Mycobacterium
tuberculosis showed that a siderophore efflux mutant accumulated toxic concentrations of
mycobactin siderophores supporting the idea that maintaining the appropriate balance of
intracellular siderophores is critical to balance metal homeostasis.52 The same appears to be true
for A. baumannii. Regardless of the underlying cause of apo-fimsbactin toxicity, the growth
studies with A. baumannii ATCC 19606T confirm that pathway competition between PreAcb,
Acb, and Fim is important even for non-producers of the fimsbactins, including the majority of A.
baumannii clinical isolates.

3.5 Outlook and Conclusions
Pathogenic bacteria often produce multiple siderophores to enhance iron acquisition,
expand capacity for metal scavenging, evade the human immune system, and gain a competitive
edge in mixed microbial environments. All genome sequenced clinical isolates of the MDR Gramnegative pathogen A. baumannii produce the siderophores PreAcb, Acb, and baumannoferrin.
PreAcb and Acb both enhance iron acquisition and contribute to pathogen virulence, while the role
of baumannoferrin has not yet been investigated. A small percentage (<10%) of A. baumannii
clinical isolates produce a third family of siderophores known as the fimsbactins. We have shown
that A. baumannii ATCC 17978 produces Acb in greater quantities than Fim and both siderophores
can be purified from culture supernatants. Here, we show that fimsbactin A, the primary
component of the fimsbactin siderophore mixture, competes directly with Acb/Acb 2Fe for import
across the A. baumannii cell envelope. The two siderophores compete directly for binding to the
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periplasmic siderophore binding protein BauB and possibly to other proteins in the Acb pathway.
This competition might explain why the majority of A. baumannii clinical isolates have lost the
ability to produce the fimsbactins but have maintained genes for Acb biosynthesis and expression
in a highly conserved manner. Due to the structural similarities of Fim, PreAcb, and Acb, sharing
common NRPS-derived fragments from phenolate oxazolines and catecholates from 2,3-DHB, we
propose that the fimsbactin scaffold serves as an ideal template for designing new siderophoreantibiotic conjugates that can outcompete native siderophores for cell entry under infection
conditions; however, this antibiotic delivery strategy should be reserved for antibiotics with
periplasmic targets, since our current understanding of the fimsbactin pathway suggests import is
limited to the periplasm.47,53,54 The inherent growth inhibitory effect of apo-Fim towards A.
baumannii also presents the opportunity to design competitive inhibitors of siderophore uptake
that might serve as antivirulence agents to starve the pathogen of iron. 20,27 Our findings suggest
that if concentrations of the fimsbactin are kept low, we hypothesize that Acb and Fim can function
cooperatively to enhance iron acquisition in A. baumannii; but if the concentration of Fim exceeds
Acb, the presence of multiple siderophores becomes counter productive. Further studies on the
effects of natural siderophore combinations are needed to reveal the subtle details of cooperativity
and competition at the molecular, protein, and cellular level of bacterial iron acquisition.

3.6 Materials and Methods
Strains, Materials, and Instrumentation.
Growth studies were conducted using A. baumannii ATCC 17978 and ATCC 19606T. The
s1, t6, and t7 mutant strains of A. baumannii ATCC 19606T were obtained from Prof. Luis Actis
(Miami University).37 Pre-cultures and 96-well plate A. baumannii growth assays were performed
in filter-sterilized M9 minimal media. M9 minimal media was prepared for all experiments as
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previously described.4,18,20 Samples for LC-MS were prepared in 0.45 μM PTFE mini-UniPrep
vials from Agilent. All preparatory HPLC was performed using a Beckman Coulter SYSTEM
GOLD 127P solvent module and 168 detector with a Phenomenex Luna 10u C18(2) 100A column,
250 × 21.20 mm, 10 μm with guard column. Prep HPLC was performed with a mobile phase of 5
mM ammonium acetate in (A) water and (B) acetonitrile, and data were processed using 32 Karat
software, v7.0. LC-MS was performed on an Agilent 6130 quadrupole LC-MS with G1313
autosampler, G1315 diode array detector, and 1200 series solvent module. A Phenomenex Gemini
C18 column, 50 × 2 mm, 5 μm with guard column was used for all LC-MS separations. LC-MS
mobile phases were 0.1% formic acid in (A) water and (B) acetonitrile, and data were processed
using G2710 ChemStation software. NMR was performed on a Varian Unity Inova-600 MHz
instrument with a cold probe. Bacterial growth studies were performed using polystyrene 96-well
plates with polystyrene lids. OD600 measurements were taken on a Molecular Devices SpectraMax
Plus 384 plate reader.
Isolation and purification of Acb and Fim.
Acinetobactin (Acb) and fimsbactin A (Fim) was isolated and purified from A. baumannii
ATCC 17978 cultures using a modified literature procedure. 4,55 PreAcb was synthesized as
described previously by our group.4 Briefly, 1 L cultures of A. baumannii ATCC 17978 were
grown overnight in M9 minimal media. Cells were pelleted and the supernatant was adjusted to
pH ~6 using citric acid. XAD-7HP resin was added to the supernatant and the mixture was shaken
gently. The mixture was filtered and the resin was washed with methanol. The methanol washings
were combined and concentrated via rotary evaporation under reduced pressure. Acb (retention
time 12 min, 31 mg/L) and Fim (retention time 15 min, 5 mg/L) were purified from the crude
residue by preparatory HPLC (gradient of 0% B to 95% B over 17 min, then 95% B to 100% B
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over 8 min). Fim represents a mixture of fimsbactin A (>90%) and fimsbactins B,C,F (≤10%) as
judged by NMR and LC-MS analysis (Figures 3.3-3.9). The holo-siderophores were prepared by
mixing PreAcb, Acb, and Fim with excess Fe(acac)3 in methanol following by concentration and
trituration with Et2O to provide the pure PreAcb2Fe, Acb2Fe, and FimFe complexes.4,18
A. baumannii Growth Studies.
Stock solutions of Acb, Fim, Acb2Fe, and FimFe were prepared in M9 media at 250 μM
(up to 2.5% final DMSO v/v). Each well of a 96-well plate was filled with 50 μL of M9 media. 50
µL of the 250 µM test compound stock solutions were added to the first row of a 96 well plate.
Compounds were serially diluted down the plate to 3.9 μM. An inoculum was made by adding 100
μL of 0.5 McFarland standard (A. baumannii ATCC 17978 or ATCC 19606T-wt, s1, t6, and t7
mutants) to 4.0 mL of M9 minimal media supplemented with 350 μM 2,2’-dipyridyl (DIP).
Inoculum (50 μL) was added to each well for a final concentration of 175 μM DIP per well and a
serial dilution of test compounds at 62.5-1.95 μM. Growth promotion was determined at 37 °C by
measuring OD600 using a microplate reader (Molecular Devices SpectraMax Plus 384 plate reader).
Control growth curves were perfomed in M9 media with 175 μM DIP and no test compounds. DIP
concentrations were optimized prior to each experiment by serial dilution against A. baumannii
under the growth conditions described in this section. All experiments were performed in triplicate
as independent trials.
For the biological evaluation of combinations of Acb, Fim, and corresponding ferric
complexes, a 96-well plate was filled with 40 μL of M9 minimal media per well, 5 μL of each of
the compounds of interest, a final concentration of 175 μM DIP per well and 50 μL of the inoculum.
To explore the combination of Acb/Fim, the following concentrations were tested in duplicate in
all possible combinations: 3.9 μM, 15.6 μM, 62.5 μM. For the combination of Acb/FimFe the
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following concentrations were tested in duplicate in all possible combinations: Acb 3.9 μM, 15.6
μM, 62.5 μM; FimFe 0.5 μM, 3.9 μM, 15.6 μM. For the combination of Acb 2Fe/Fim the following
concentrations were tested in duplicate in all possible combinations: Acb 2Fe 0.5 μM, 3.9 μM, 15.6
μM; Fim 3.9 μM, 15.6 μM, 62.5 μM. Growth promotion was determined at 37 °C by measuring
OD600 using a microplate reader (Molecular Devices SpectraMax Plus 384 plate reader). Control
growth curves were perfomed in M9 media with 175 DIP and no test compounds. All experiments
were performed in duplicate as independent trials.
Determination of FimFe Complex Stoichiometry.
A solution of 570 μM Fim in methanol was prepared. A fluorescence emission spectrum
was recorded (λexcitation = 330 nm; λemission = 380 nm). To determine stoichiometry of the complex
between Fim and Fe(III), aliquots of a methanolic solution of Fe(acac) 3 were added 0.044
equivalents at a time via Hamilton syringe and emission spectra were recorded after each addition.
Peak fluorescence (Abs380nm) was plotted against Fe(III) equivalents to reveal a 1:1 FimFe
stoichiometry (Figure 3.11).
Determination of Apparent KFe for FimFe.
A stock solution of 100 µM FimFe was prepared in 10 mM HEPES buffer (10 mM HEPES,
600 mM NaCl, 100 mM KCl, pH 7.4) and an optical absorbance spectrum was obtained from λ =
300–700 nm (Figure 3.12). While continuously monitoring optical absorbance at 500 nm, EDTA
was added at a final concentration of 120 μM (1.2 equivalents relative to FimFe). The apparent
iron-binding affinity (KFe) was determined based on the change in optical absorbance at 500 nm
after 800 min for two independent trials using the equations provided in the supplementary
information.
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N-His6-BauB Expression and Purification.
The bauB gene from Acinetobacter baumannii (Genbank Accession Number AAT52185)
was codon optimized for expression in E. coli and cloned into a pET28b vector by GenScript
Biotech Corporation. The bauB gene was then subcloned into a pET28bTEV vector using
restriction enzyme-based cloning (Figure 3.19).1 BauB was expressed as the N-terminal
hexahistidine fusion, N-His6-BauB, in E. coli BL21 (DE3). Briefly, E. coli BL21 (DE3)
transformed with the BauB expression plasmid were grown in 1 L of terrific broth at 37 °C in a 3
L baffled flask, in the presence of 50 μg/mL kanamycin to an OD600 of ~0.5. The culture flask was
cooled to 20 °C and BauB expression was induced by the addition of 0.5 mM IPTG (final
concentration). Cells were grown overnight (~12 h) at 20 °C. Cells were harvested via
centrifugation at 4 °C for 30 min (all remaining steps were carried out at 4 °C). Cells were washed
with lysis buffer (50 mM potassium phosphate pH 8.0, 500 mM NaCl, 5 mM BME, 20 mM
imidazole, 10% glycerol) and flash frozen in liquid N2 (40 mL total volume). The frozen cell pellet
was thawed and lysed by two passes through an Emulsiflex C5 (Avestin). The lysate was clarified
by ultra-centfiguation at 50000g for 35 min. The supernatant was passed through Ni-NTA resin
and eluted with 300 mM imidazole in lysis buffer. Elution fractions were analyzed by SDS-PAGE
with visualization by Coomassie blue staining. Fractions containing pure N-His6-BauB were
combined, dialyzed (50 mM potassium phosphate pH 8.0, 150 mM NaCl, 1 mM DTT, 5%
glycerol), and concentrated via centrifugal filtration. Protein purity was analyzed by SDS-PAGE
with visualization by Coomassie blue staining (Figure 3.20). Protein mass were confirmed by ESIMS. Purified protein was flash frozen in liquid N2 at 180 μM and stored at –80 °C.
Determination of Apparent Kd Values for BauB.
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N-His6-BauB was recovered on ice from a –80 °C freezer stock. A 400 nM BauB stock
solution was prepared in assay buffer (25 mM Tris-HCl, 8 g/L NaCl, 0.2 g/L KCl, pH 7.4). For
each measurment, 300 μL of the BauB stock solution was transferred to a fluorescence cuvette
(HellmaAnalytics High Precision Cell cuvette made of Quartz SUPRASIL; light path 10 x 2 mm)
in the presence of substrate (PreAcb, PreAcb2Fe, Acb, Acb2Fe, Fim, FimFe) at concentrations
ranging from 100–1200 nM. Emission spectra were recorded at λ emission = 300–400 nm using a
PerkinElmer LS 55 Luminescence Spectrometer (slit width 10 nm; scan speed 400 nm/min) at
excitation = 280 nm. Fluorescence intensity at 320 nm was plotted versus substrate concentration
(nM) and apparent Kd was calculated using nonlinear regression and a one binding site model in
GraphPad Prism v7.0b (Figure 3.21).1 All experiments were performed in duplicate as
independent trials.
Siderophore Competition Studies with Immobilized BauB.
N-His6-BauB was immobilized on Ni-NTA resin following a literature protocol for
performing siderophore-affinity chromatography.32 Saturation of the Ni-NTA resin (2.3 cm x 1 cm
resin volume) with BauB was confirmed by SDS-PAGE analysis of the column flowthrough. The
Ni-NTA-BauB column was washed thoroughly with phosphate buffer (50 mM potassium
phosphate pH 8.0, 150 mM NaCl, 1 mM BME, 5% glycerol). A solution of Acb2Fe (5 mL, 0.1
mg/mL) was loaded onto the column and column was rocked gently for 30 min at 4 °C. Column
flowthrough was collected and the resin was washed with excess phosphate buffer (5 x 5 mL).
FimFe (5 mL, 0.1 mg/mL) was then loaded and the column was gently rocked for 30 min at 4 °C.
The flowthrough was collected and the resin was washed with excess phosphate buffer (5 x 5 mL).
Acb2Fe (5 mL, 0.1 mg/mL) was then added back onto the column and after rocking for 30 min the
flowthrough was collected. Aliquots of the column loading solutions and elutions were analyzed
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by LCMS for the presence of Acb2Fe and FimFe. For Acb2Fe, the extracted ion chromatogram
(EIC) for m/z = 347, corresponding to the [M+H]+ for apo-Acb, was plotted. For FimFe, the EIC
for m/z = 627 corresponding to the [M+H]+ for holo-FimFe was plotted.
DFT Calculations.
Stable holo-siderophore complexes with ferric iron were calculated using density
functional theory56,57 (DFT) in a similar manner as described previously.1 We used the crystal
structure of the Acb2FeIII(S=5/2) complex bound to BauB (PDB 6FML) as starting geometry of
the PreAcb2Fe and FimFe ferric complexes. Monte Carlo/MMFF molecular mechanics/dynamics
was used to explore conformer spaces. Initial structure optimization was performed by using the
PM3d semi-empirical algorithm (Spartan Linux v10, WaveFunction, Inc.). We employed DFT
(Density Functional Theory, Gaussian 09, Gaussian Inc.) for calculations using the PBE0 hybrid
functional (PBE1PBE in Gaussian parlance) with basis sets Def2-SVP and Def2-TZVP. Minima
were optimized at the level PBE0/Def2-SVP and single-point energies were calculated at level
PBE0/Def2-TZVP, with scaled thermal-energy corrections from B3LYP/6-31G(d,p). 58 Solventbased single-point energies were calculated at the same level using the CPCM polarizable
conductor calculation model for water and the Universal Force Field for atomic radii. 59 DFT
functionals and basis sets were chosen for efficiency and compatibility with ferric
complexes.60,61,62
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3.7 Figures and Tables
Fimsbactin Biosynthetic Gene Clusters
AbPK1 (GenBank: GCA_002753915.1)

AB042 (GenBank: GCA_001941765.1)

D36 (GenBank: GCA_001399655.1)

Strain ATCC 17978 (GenBank: GCA_001593425)

ATCC 17978-mmf (GenBank: GCA_001077675.1)
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Acinetobactin Biosynthetic Gene Clusters
AbPK1 (GenBank: GCA_002753915.1)

AB042 (GenBank: GCA_001941765.1)

D36 (GenBank: GCA_001399655.1)

Strain ATCC 17978 (GenBank: GCA_001593425)

ATCC 17978-mmf (GenBank: GCA_001077675.1)
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Acinetoferrin/Baumannoferrin Biosynthetic Gene Clusters
AbPK1 (GenBank: GCA_002753915.1)

AB042 (GenBank: GCA_001941765.1)

D36 (GenBank: GCA_001399655.1)

Strain ATCC 17978 (GenBank: GCA_001593425)

ATCC 17978-mmf (GenBank: GCA_001077675.1)

Figure 3.1. AntiSMASH63 analysis of putative fimsbactin A. baumannii producers identified from
BLASTp analysis of A. baumannii genomes reveals conservation of acinetobactin and
baumannoferrin biosynthetic gene clusters (BGCs). The acinetoferrin BGC is the reference in the
antiSMASH database. Acinetoferrin and baumannoferrin BGCs share homology, so comparison
for all strains was made to the acinetoferrin BGC.64
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Figure 3.2: Siderophore biosynthesis in A. baumannii. (a) NRPS assembly lines for acinetobactin
(top) and fimsbactin A (bottom) share a common precursor, 2,3-DHB, and a common phenolate
oxazoline motif. (b) DAD at 263 nm (black), EIC at m/z 347 (blue), and EIC at m/z 576 (red)
chromatograms from LCMS analysis of crude A. baumannii ATCC 17978 supernatant after
acidification, treatment with XAD-7HP resin, and methanol elution. Same as Figure 1.7.
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Figure 3.3. Diode array optical absorbance detection (DAD) and extracted ion chromatograms
(EICs) for fimsbactin A–F [M+H]+ ions from LCMS analysis of A. baumannii ATCC 17978
culture supernatant extractions (Trial #1) using ESI ionization in positive ion mode. The x-axis
represents retention time (min) for all chromatograms.
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Figure 3.4. Diode array optical absorbance detection (DAD) and extracted ion chromatograms
(EICs) for fimsbactin A–F [M+H]+ ions from LCMS analysis of HPLC-purified fimsbactin A from
A. baumannii ATCC 17978 (Trial #1) using ESI ionization in positive ion mode. The x-axis
represents retention time (min) for all chromatograms.
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Figure 3.5. Diode array optical absorbance detection (DAD) and extracted ion chromatograms
(EICs) for fimsbactin A–F [M+H]+ ions from LCMS analysis of A. baumannii ATCC 17978
culture supernatant extractions (Trial #2) using ESI ionization in positive ion mode. The x-axis
represents retention time (min) for all chromatograms.
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Figure 3.6. Diode array optical absorbance detection (DAD) and extracted ion chromatograms
(EICs) for fimsbactin A–F [M+H]+ ions from LCMS analysis of HPLC-purified fimsbactin A from
A. baumannii ATCC 17978 (Trial #2) using ESI ionization in positive ion mode. The x-axis
represents retention time (min) for all chromatograms.
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Table 3.1. NMR characterization data for purified fimsbactin A from this work compared with
previously reported data from the original isolation and characterization of fimsbactin A. 2
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Figure 3.7. High-resolution ESI MS (positive ion mode) of fimsbactin A purified by prep-HPLC
from A. baumannii ATCC 17978 culture supernatant (Trial #1). Expected [M+H]+ for
C26H31N4O11 575.1984, found 575.2056.
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Figure 3.8. 1H-NMR (600 MHz, DMSO-d6) spectrum of purified fimsbactin A purified by prepHPLC from A. baumannii ATCC 17978. The x-axis is chemical shift given in parts per million
(ppm). The y-axis is arbitrary peak intensity.
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Figure 3.9. 13C-NMR (151 MHz, DMSO-d6) spectrum of purified fimsbactin A purified by prepHPLC from A. baumannii ATCC 17978. The x-axis is chemical shift given in parts per million
(ppm). The y-axis is arbitrary peak intensity.
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Figure 3.10. Structures and microbial producers of amino acid-based siderophores fimsbactin A 2,
heterobactin A7, and JBIR-168 and spermidine-based siderophores vibriobactin9, vulnibactin10,
fluvibactin11, agrobactin12, parabactin13,14, and protochelin15. Iron chelating groups are shown in
blue. The tetrehdral branch point for metal chelating ligands is highlighted by a yellow circle.
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Figure 3.11. Fimsbactin A forms a 1:1 complex with Fe(III). Graph depicts fluorescence (λ excitation
= 330 nm; λemission = 380 nm) vs equivalents of FeCl3 showing a titration end point correlating with
1:1 stoichiometry. Was performed as two independent trials. Error bars represent standard
deviation from the mean.
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Figure 3.12. Optical absorbance spectrum of the holo-FimFe complex at 100 μM in phosphate
buffer (50 mM potassium phosphate pH 8.0, 150 mM NaCl, 1 mM DTT, 5% glycerol). Molar
exctinction coefficient (ε) of holo-[Fe(Fim)] was determined to be 4255 M-1 cm-1 at 445 nm. The
inset shows the visible color of the [Fe(Fim)] solution at 100 μM.
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Siderophore:Fe(III)
Stoichiometrya

Metal:Ligand Charge
Transfer Band (λabs)

Apparent
log KFeb

Apparent
BauB Kd (nM)c

PreAcb

2:1

515 nm

27.4 ± 0.2

380 ± 110 (750 ± 160)

Acb

2:1

570 nm

26.2 ± 0.1

300 ± 100 (160 ± 80)

Fim

1:1

445 nm

27.1 ± 0.2

360 ± 140 (240 ± 90)

Siderophore

a

Siderophore:Fe stoichiometry was measured by titration of siderophores with Fe(acac) 3 monitored by

quenching of intrinsic siderophore fluorescence. bApparent log KFe values for PreAcb2Fe and Acb2Fe are
literature values.4 cValues in parentheses are for the ferric holo-siderophore complexes. The apparent Kd
for Acb and Acb2Fe are literature values.1 Data is reported as mean ± standard deviation from the mean
for at least two independent trials.

Table 3.2. Siderophore iron binding properties and apparent BauB dissociation constants (Kd).
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Equations 3.1
As described in the experimental methods section of the main text, an EDTA competition experiment was
used to measure the apparent KFe for FimFe at pH 7.4. The following equations were used to calculate
apparent KFe based on the change in optical absorbance observed at 500 nm for FimFe in the presence of
1.2 equivalents of EDTA. A KFe value of 1025.1 was used for EDTA at pH 7.4 in final calculations.64
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[EDTA]T = total EDTA added

0 mM Fim

(Acb)2Fe + Variable Fim

30 mM Fim

0.30

60 mM Fim
Abs (au)

0.25

90 mM Fim
120 mM Fim

0.20

150 mM Fim
180 mM Fim

0.15
0.10
400

210 mM Fim
210 mM Fim - 20 hrs
500

600

700

Wavelength (nm)

Figure 3.13. Titration of holo-Acb2Fe with apo-Fim reveals slow exchange of iron leading to
apparent complete formation of holo-FimFe. Optical absorbance spectra were collected for each
concentration after 20 min in phosphate buffer (50 mM potassium phosphate pH 8.0, 150 mM
NaCl, 1 mM DTT, 5% glycerol). The final optical absorbance spectrum with 210 μM apo-Fim
added was measured after 20 hours.
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Figure 3.14. Influence of apo- and holo-siderophores on A. baumannii growth. Line graphs
depict the growth of A. baumannii ATCC 17978 determined by measuring the optical density at
600 nm (OD600) as a function of time in the presence of (a) Acb or Acb2Fe and (b) Fim or
FimFe. Bar graphs depict the comparison of OD600 values after 30 hours in the presence of
variable concentrations of (c) Acb or Acb2Fe and (d) Fim or FimFe. Error bars represent
standard deviations from the mean for three independent trials. ****p < 0.0001

122

Figure 3.15. Dose dependent growth promotion of A. baumannii ATCC 17978 by (A) apoacinetobactin (Acb), (B) holo-acinetobactin (Acb_Fe), (C) apo-fimsbactin (Fim), and (D) holofimsbactin (Fim_Fe). Line graphs depict the growth of A. baumannii ATCC 17978 in M9 minimal
medium supplemented with 175 μM 2,2′-dipyridyl (DIP) determined by measuring the optical
density at 600 nm (OD600) as a function of time in the presence of variable siderophore
concentrations. All experiments were performed in triplicate. Error bars are shown in Figure 3.16.
Data from these plots were used to create the line and bar graphs shown in Figure 3.14
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Figure 3.16. Dose dependent growth promotion of A. baumannii ATCC 17978 by (A) apoacinetobactin (Acb), (B) holo-acinetobactin (Acb_Fe), (C) apo-fimsbactin (Fim), and (D) holofimsbactin (Fim_Fe). Line graphs depict the growth of A. baumannii ATCC 17978 in M9 minimal
medium supplemented with 175 μM 2,2′-dipyridyl (DIP) determined by measuring the optical
density at 600 nm (OD600) as a function of time in the presence of variable siderophore
concentrations. Error bars represent standard deviations from the mean for three independent trials.
Line graphs are shown without error bars for clarity in Figure 3.15. Data from these plots were
used to create the line and bar graphs shown in Figure 3.14.
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Figure 3.17. Influence of apo- and holo-siderophore combinations on A. baumannii growth. Bar
graphs depict the comparison of A. baumannii ATCC 17978 growth measured by optical density
at 600 nm (OD600) values after 30 hours in the presence of variable concentrations of (a) Fim and
Acb, (b) Fim and Acb2Fe, and (c) FimFe and Acb. Error bars represent standard deviations from
the mean for two independent trials. **** p < 0.0001; ns = not significant
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Figure 3.18. Influence of apo- and holo-siderophore combinations on the growth of A. baumannii
ATCC 17978. Line graphs depict the growth of A. baumannii ATCC 17978 in M9 minimal
medium supplemented with 175 μM 2,2′-dipyridyl (DIP) determined by measuring the optical
density at 600 nm (OD600) as a function of time in the presence of variable concentrations of
siderophore mixtures. For all graphs, siderophore concentration gradients are provide on the xaxis and y-axis of the checkerboard. The black line graph represents bacterial growth without
addition of siderophores. The red line graph represents bacterial growth in the presence of variable
concentrations of (A) apo-Fim and apo-Acb, (B) holo-FimFe and apo-Acb, (C) apo-Fim and holoAcb2Fe or (D) apo-Fim and holo-FimFe. Error bars represent standard deviations from the mean
for two independent trials. Data from these plots were used to create bar graphs shown in Figure
3.17
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N-His6-BauB in pET28bTEV (cleavable N-term His-tag):

Nucleotide:
AAGGAGATATACCATGGGCAGCAGCCATCATCATCATCATCACAGCAGCGGCGAAAACCTGTATTTTCAG⇣GGCC
ATATGTGCGACCAAAAAGTTGCGGATACCACCCAGGCGAGCCAAAAACTGGCGGAGCCGATTACCGTTAAGCAC
GCGCTGGGCACCACCGTGATCGACCACCTGCCGCAGCGTGTGGCGGTTCTGGATATGAACGAAGCGGACTTCCTG
GATCAACTGAACGTTCCGATTATGGGCATGCCGAAAGACTACGTGCCGCACTTTCTGGAGAAGTATAAAAAGGAC
GCGCAGATTCAAGATCTGGGTGCGATCGTTCAGCCGAACATGGAACGTATTTATGCGCTGAAACCGGATCTGATC
CTGATGACCCCGCTGCACGTGAACCAGTACCAAGAGCTGAGCAAGATCGCGCCGACCATTCACTATGACATCAACT
TCAACAACAGCGAAAGCAACCACATTGGCCTGGTTAAAGATCACATGATGACCCTGGGTAAAATCTTTAACAAAG
AGGACCTGGCGCGTCAGAAAGTGAGCGAGCTGGATGAACAAGTGAAGCAGGTTCAAGCGGTGACCGCGAACCG
TCCGGAACGTGCGCTGGTTGTGCTGCACAACAACGGTGCGTTCAGCAACTTTGGCATTCAGAGCCGTTACGGTTTC
ATCTTTAACGCGTTCGGCGTTAAGCCGGCGAGCGGTGTGGTTGACACCAGCCTGCACGGTCAACCGATTAGCAGC
GAGTTTATCAAAAAGGCGGACCCGGATATCCTGTATATTGTTGATCGTACCGCGGTGATGGAGCACCGTCCGAAC
ATCAACGCGGCGAGCGTGGAAAACCCGCTGCTGCGTCAGACCAAAGCGTGGAAGAACGGCCGTGTTATTTTCGTT
GATGCGGATGCGTGGTACACCACCGCGGCGAGCCCGACCAGCCTGAAGATCGTTATGGAAGACGTGAAAAAGGG
TTATCAATAAAAGCTT

Amino Acid:
GSSHHHHHHSSGENLYFQ⇣GHMCDQKVADTTQASQKLAEPITVKHALGTTVIDHLPQRVA
VLDMNEADFLDQLNVPIMGMPKDYVPHFLEKYKKDAQIQDLGAIVQPNMERIYALKPDLI
LMTPLHVNQYQELSKIAPTIHYDINFNNSESNHIGLVKDHMMTLGKIFNKEDLARQKVSE
LDEQVKQVQAVTANRPERALVVLHNNGAFSNFGIQSRYGFIFNAFGVKPASGVVDTSLHG
QPISSEFIKKADPDILYIVDRTAVMEHRPNINAASVENPLLRQTKAWKNGRVIFVDADAW
YTTAASPTSLKIVMEDVKKGYQ

Figure 3.19. Nucleotide and amino acid sequence of N-His6-BauB in pET28bTEV (TEVcleavable N-term hexahistidine-tag). Start and stop codons are underlined. The TEV cleavage site
is indicated by an arrow. The 969-bp bauB gene from Acinetobacter baumannii (Genbank
Accession Number AAT52185) was used as the sequence template for subcloning.
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Figure 3.20. SDS-PAGE analysis of Ni-NTA purified N-His6-BauB (~36.1 kDa). Gel was stained
using Coomassie blue dye. This image was also used in the supplementary information for our
manuscript describing the x-ray crystal structure of BauB.1
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Figure 3.21. Siderophore-dependent fluorescence quenching of N-His6-BauB. Graphs depict
intrinsic tryptophan fluorescence quenching (y-axis; excitation = 280 nm; emission = 340 nm) of 400
nM N-His6-BauB in the presence of variable siderophore concentrations (x-axis). Apparent Kd
values were calculated using a single-binding mode curve-fitting model in GraphPad Prism version
7.0b. Error bars represent standard deviations for two independent trials.
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Figure 3.22. Acb2Fe and FimFe compete for BauB binding. N-His6-BauB was immobilized on
Ni-NTA resin and loaded with (a) Acb2Fe or (b) FimFe, washed with phosphate buffer, and
eluted with a competing holo-siderophore. Column elutions were analyzed by LCMS for Acb2Fe
(m/z = 347) and FimFe (m/z = 627) after each step. Extracted ion chromatograms (EIC) are
shown for the initially bound holo-siderophore. EICs are representative for two independent
trials.
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Figure 3.23. Structural comparison of PreAcb2Fe, Acb2Fe, and FimFe complexes. DFT calculated
structures of the monoanionic (a) 1:1 [FimFe] - and (b) 2:1 cis-[PreAcb2Fe]- complexes (see
experimental methods for DFT parameters). (c) Experimentally observed structure of the
monoanionic cis-[Acb2Fe]- complex bound to the siderophore binding protein BauB (PDB 6MFL).
(d) Overlay of all three structures highlighting similarity of geometry and placement of ligands
(ox, oxazoline; cat, catecholate; hx, hydroxamate; im, imidazole) around the ferric iron center. (e)
Surface view of the siderophore binding pocket of BauB occupied by cis-[Acb2Fe]- (PDB 6MFL).
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Figure 3.24. Schematic overview of the PreAcb/Acb and Fim iron acquisition pathways in A.
baumannii. The Fim pathway has not been experimentally characterized and is hypothesized based
on homology to related pathways in Gram-negative bacteria. Periplasmic BauB is highlighted to
show interactions with both PreAcb/Acb and Fim connecting the two pathways through
competition for the periplasmic siderophore-binding protein.
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Figure 3.25. Structures and m/z values for [M+H]+ molecular ions of fimsbactin A–F.2 Structural
differences are highlighted in red.
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Acinetobactin BGCs
ATCC 19606 (GenBank: GCA_000162295.1)
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ATCC 19606 (GenBank: GCA_000162295.1)

ATCC 19606 (GenBank: GCA_002811175.1)

Figure 3.26. Antismash analysis of two deposited genomes of A. baumannii ATCC 19606 turned
up acinetobactin and acinetoferrin/baumannoferrin as the only siderophore BGCs present in the
genome. No fimsbactin BGCs were detected.
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Figure 3.27. Dose dependent influence of apo-Fim and holo-FimFe on A. baumannii ATCC 19606
growth. Line graphs depict the growth of wild-type A. baumannii ATCC 19606 in M9 minimal
medium supplemented with 175 μM 2,2′-dipyridyl (DIP) determined by measuring the optical
density at 600 nm (OD600) as a function of time in the presence of variable siderophore
concentrations. Error bars represent standard deviations from the mean for three independent trials.
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Figure 3.28. Dose dependent growth promotion of A. baumannii ATCC 19606 strains by holoFimFe. Line graphs depict the growth of wild-type (wt), s1-mutant (insertional mutant in basD,
deficient in PreAcb/Acb biosynthesis), t6-mutant (insertional mutation in bauA, deficient in
PreAcb/Acb import to periplasm), and t7-mutant (insertional mutation in bauD, deficient in
PreAcb/Acb import to cytoplasm) strains of A. baumannii ATCC 19606 in M9 minimal medium
supplemented with 175 μM 2,2′-dipyridyl (DIP) determined by measuring the optical density at
600 nm (OD600) as a function of time in the presence of variable siderophore concentration. Error
bars represent standard deviations from the mean for three independent trials.
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Chapter 4: Exploring Apparent Redundancy
in Siderophore Systems of
Acinetobacter baumannii
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4.1 Preface
This chapter was written by TJB. TJB, LF, DEG and TAW contributed to the work in this
chapter. TJB isolated Fimsbactin F, performed characterization, BauB fluorescent quenching
binding studies and metal titration assays. LF performed all growth curves and protein expression
and purification. DEG performed all DFT calculations. TAW served as principal investigator and
oversaw experimental design.

4.2 Abstract
Exploring the concept of siderophore redundancy in pathogenic bacteria has been one of
interest in recent decades. Understanding the inter-workings of the relationship of the production
of siderophores in a “siderophore cocktail”, is an area we sought to help elucidate. Herein, we
report the production, isolation, characterization and protein interactions of a previously
underexplored Fimsbactin isomer, Fimsbactin F. We investigate the relationship between
Fimsbactin F and other two other A. baumannii siderophores, acinetobactin and Fimsbactin A,
through competition assays. Furthermore, we sought to understand the metal preference and
selectivity of these siderophores. This was achieved through the titrations of four known A.
baumannii siderophores (Acb, PreAcb, FimA and FimF) and one synthetic siderophore mimic
(OxPreAcb) with six metal chloride solutions (iron, copper, nickel, cobalt, zinc and magnesium).
We observed the ability of these small molecules to bind a wide range of metals and set the stage
for further explore of the role of PreAcb in zinc homeostasis particularly.

4.3 Introduction
In Chapter 1, and then again in Chapter 3, we introduced the concept of apparent
siderophore redundancy as a potential evolutionary advantage for bacterial virulence. In this
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chapter, we sought to further investigate the need or purpose for pathogenic bacteria to synthesize
and utilize multiple siderophore scaffolds to acquire essential nutrients. Though there is often
uneven production of each individual siderophore in most siderophore cocktails, many pathogenic
bacteria produce multiple sideorphores of their own—including E. coli, M. tuberculosis and the
focus of this dissertation, A. baumannii.1,2,3 Additionally, pathogens like S. aureus can utilize
xenosiderophores, or siderophores produced by other bacteria, as a means to a gain competitive
over neighboring colonies.
As highlighted numerous times throughout this dissertation, A. baumannii synthesizes a
siderophore cocktail comprised of three classes of siderophores—acinetobactin, the fimbactins,
and the baumannoferrins Figure 4.1. In chapter 3, we explored Fimsbactin A and the relationship
between acinetobactin (Acb) and Fimsbactin A (FimA). We highlighted the importance of balance
in the relative concentrations of siderophores in the ability to provide a competitive advantage.
Herein, we aim to explore the apparent siderophore redundancy of the Fimsbactin siderophore
class. This class is comprised of Fimsbactin isomers A-F, Figure 4.2, which contain multiple iron
chelating groups including hydroxamates and catechols.4 In particular, we were interested in the
relationship between FimA and Fim F— a shunt biosynthetic product lacking the seryl-O-2,3DHB ester, and we hypothesized that an enzymatic interconversion between FimA and FimF might
result in a single biologically relevant siderophore entity. The following chapter outlines a series
of studies aimed at elucidating the apparent siderophore reduncies in pathogenic A. baumannii,
particularly as it relates to the complete Fimsbactin-iron acquisition pathway.

4.4 Results and Discussion
Purification of Acb, FimA and FimF from A. baumannii ATCC 17978.
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In Chapter 3, the isolation, purification and evaluation of Fimsbactin A was discussed in
depth. Herein, we highlight the isolation and evaluation of isomer Fimsbactin F. In this regard, we
isolated crude Acb and Fimsbactins A and F from A. baumannnii ATCC 17978 grown in M9
minimal media supplement with 2,2’-dipyridyl (DIP). LC-MS analysis of crude supernatant broth,
seen in Figures 4.3 and 4.4, identified Acb as the most produced siderophore, followed by
Fimsbactin A and Fimsbactin F, respectively. Preparatory HPLC of the crude mixtures allowed
for separation, isolation and purification of these three siderophores (Acb: 31 mg/L, FimA: 5 mg/L
and FimF: 2 mg/L), and the full characterization of Fimsbactin F is highlighted in Figures 4.5-4.9.
Iron-Binding properties of FimF
Similarly to that previously described for acinetobactin and fimsbactin A, we determined
the iron binding affinity of FimF using a competitive binding assay carried out in the presence of
EDTA. The iron-binding affinity of FimF was consistent with those previously reported for Acb
and FimA (LogKFe = 25.9 for FimF compared to 27.4, 26.2 and 27.1 for PreAcb, Acb and FimA,
respectively), suggesting no significant iron-binding advantage for the production of any one
siderophore (Table 4.1). In addition to iron binding, we sought to investigate the dose-dependent
influence of FimF on the whole cell growth of A. baumannii. We observed dose-dependent growth
promotion of whole cell A. baumannii cultured in the presence of Fimsbactin F, with an enhanced
effect observed for the holo-variant (Figure 4.10 and 4.11). These findings are consistent with
previous sideorphores growth studies, which demonstrate increased growth promotion of
siderophores doped in the metal-bound form.
Siderophore competition assays
Our previous work highlighted the necessity for balance in siderophore combinations, as
we saw an inhibitory effect on whole cell growth of A. baumannii at high concentrations of FimA,
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in the presence of both low and high concentrations of Acb. Thus, to explore possible new
relationships, we conducted checkerboard-combination growth studies with purified FimF in
combination with Acb or FimA. We first examined the effect that combinations of FimA and FimF
in both apo- and holo-forms had on the whole cell growth of A. baumannii. Interestingly, we
observed an inhibitory effect at high concentrations of FimA that was strikingly similar to the
observations gathered in our prior work on FimA and Acb cooperativity. Notably, this inhibition
can be mitigated by the addition of holo-siderophore to the apo-FimA populated environment
(Figures 4.12 and 4.13). However, in combinations of Acb and FimF, no inhibitory effect was
observed; instead, higher concentrations of siderophore led to increased growth promotion across
the board, suggesting a cooperative, as oppose to competitive, relationship between Acb and FimF
(Figure 4.14 and 4.15).
Siderophore binding to BauB
In addition to metal binding, siderophore competition cocktails, and effects on whole cell
growth, we were particularly interested in the ability of FimF to bind to periplasmic protein
BauB—since we previously demonstrated a direct competition between Acb and FimA for BauB
through fluorescence quenching assays.5 Thus, through intrinsic tryptophan fluorescence
quenching assays, we identified siderophore-dependent quenching and were able to calculate
apparent Kd values for BauB binding of both the apo- as well as the holo- siderophores to be 297.4
nM and 360.3 nM, respectively, using a single-binding mode curve-fitting model in GraphPad
Prism (Figure 4.16, Table 4.1). These values indicate BauB binding of both FimF and FimF-Fe—
with a higher affinity observed for the iron-bound form. These dissociation constants are consistent
with the BauB binding affinities observed for other A. baumannii siderophores, suggesting
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potential competition for the siderophore transport pathway involved in the acquisition of iron
required for bacterial virulence.
Fimsbactin A potential cleavage by esterase enzymes
Through studies of Trojan horse siderophore-antibiotic conjugates, work by Wencewicz et
al. suggests Fimsbactin A fails to transverse the inner membrane to reach the cytoplasm of the
cell.6 In must be noted, however, that the fimsbactin mimic utilized in the studies by Wencewicz
et al are not able to be hydrolyzed; this ability to be hydrolyzed might be required to enter into the
cytoplasm. Our studies in this chapter draw a parallel between A. baumannii siderophores Acb and
FimF—as both siderophores possess similar iron affinities, bind in 2:1 siderophore-iron
complexes, and behave similarly in combination growth studies. However, in order to help
elucidate apparent siderophore redundancies, we sought to investigate if FimA can be cleaved by
an esterase to afford FimF—a molecule that might be able to cross the inner membrane. To test
this hypothesis, we are currently expressing and purifying FbsM—a thioesterase enzyme encoded
for in the Fimsbactin gene cluster.4 Additionally, our lab is expressing and purifying BesA—a
common ferri-bacillibactin esterase which could also potentially hydrolyze the FimA ester to
afford FimF.7 With these enzymes in hand, future efforts will explore possible cleavage of the
FimA ester in an in vitro assay coupled to LCMS detection. However, based upon our current
understanding of the siderophore cocktail cooperativity, our updated working model of the
transport uptake pathways of the siderophore cocktail of A. baumannii is shown in Figure 4.20.
According to this working model, Fimsbactin A is biosynthesized in the cytoplasm and
effluxed out of the cell, where the siderophore can then bind what would otherwise be biounavailable iron. The holo-siderophore is then imported into the periplasm via outer-membrane
transport protein FbsN. Once in the periplasm, an esterase enzyme may facilitate the conversion
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of FimA to FimF, at which time the iron may be reduced by FbsP from Fe(III) to Fe(II) and pass
into the cytoplasm through inner membrane FeoAB transporters. The now apo-FimF might then
bind with BauB (as shown to be possible by our fluorescence quenching assays), potentially
forming a 2:1 complex with PreAcb or Acb and iron, and be transported through inner-membrane
transport protein BauCDE. Once in the cytoplasm, FimF might then be recycled into FimA through
FimA biosynthesis, and the cycle would repeat.
Siderophore metal binding assays
While the vast majority of the work with and studies of siderophores have centered on iron
binding, metal binding specificity and metal affinities may distinguish these seemly redundant
siderophores as multifunctional collections of multipurpose small molecule metal chelators with
important implications in metal homeostasis beyond iron. In this light, aiming to explore metal
chelation selectivity, we conducted fluorescence titration assays of four siderophores of A.
baumannii (PreAcb, Acb, FimA and FimF), along with one synthetic analog and growth inhibitor
(OxPreAcb—discussed at length in Chapters 5 and 6), with a panel of six metals (iron, copper,
nickel, cobalt, zinc and magnesium). Across the board, iron promoted quenching was most
pronounced, indicating a distinct preference for iron binding (or iron is just a better quencher),
with FimA possessing the highest preference (Figures 4.21-4.27). In addition, we were able to
observe siderophore-metal binding with copper, nickel and cobalt, as well, which supports the
potential role of siderophores in maintaining metal homeostasis in pathogenic bacteria.
Interestingly, we observed a small fluorescence enhancement with addition of magnesium to
siderophores in solution and a large enhancement upon the addition of zinc; notably, PreAcb-zinc
binding produced a large fluorescence response, reaching maximum detection limits upon the
addition of less than 0.2 equivalents of zinc. While we are still working to better understand this
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result, we hypothesize unique interactions between zinc and the metal chelating functional groups
present in the siderophores of A. baumannii are responsible for the unusual increase in fluorescence
upon metal binding—as other small molecule siderophores, such as pyoverdin, containing
hydroxmate and catecholate metal binding motifs are known to be of vital importance for optimal
growth in the presence of zinc in Pseudomonas aerginosa.8 It must be noted, however, that
fluorescence quenching was observed in the case of zinc titration with siderophore analog
OxPreAcb. We hypothesize that this structurally rigidified synthetic molecule may allow for
unique metal binding modes which differs from the natural PreAcb/Acb siderophore systems.
Current efforts with our collaborator Dr. Daryl Giblin are ongoing to investigate metal preference
via DFT calculations of these metal complexes.

4.5 Outlook and Conclusions
In conclusion, we isolated, purified and characterized a previously under-studied A.
baumannii siderophore, Fimsbactin F. We demonstrated the ability of FimF to promote growth, as
well as bind iron, and we determined both siderophore-iron binding stoichiometry and BauB
binding affinity for the truncated FimA analog (FimF). Current efforts in our laboratory are aimed
at investigating the relationship between FimA and FimF through purification of esterase and
thioesterase enzymes to probe the apparent redundancy of fimsbactin production in A. baumannii.
In addition, in this chapter, we sought to explore the metal preference of A. baumannii siderophores
(PreAcb, Acb, FimA and FimF) and synthetic inhibitor (OxPreAcb) in an effort to better
understand the role of siderophore cocktails in bacterial metal homeostasis. We discovered a
distinct preference for siderophore iron-binding but identified the ability of the screened
siderophores and siderophore analog to bind other metals such as copper and cobalt. Most notably,
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there appears to be a unique relationship between PreAcb and zinc which we believe warrants
further study. .

4.6 Materials and Methods
Strains, Materials, and Instrumentation.
Growth studies were conducted using A. baumannii ATCC 17978 and ATCC 19606T. Precultures and 96-well plate A. baumannii growth assays were performed in filter-sterilized M9
minimal media. M9 minimal media was prepared for all experiments as previously described. 9,10,11
Samples for LC-MS were prepared in 0.45 μM PTFE mini-UniPrep vials from Agilent. All
preparatory HPLC was performed using a Beckman Coulter SYSTEM GOLD 127P solvent
module and 168 detector with a Phenomenex Luna 10u C18(2) 100A column, 250 × 21.20 mm,
10 μm with guard column. Prep HPLC was performed with a mobile phase of 5 mM ammonium
acetate in (A) water and (B) acetonitrile, and data were processed using 32 Karat software, v7.0.
LC-MS was performed on an Agilent 6130 quadrupole LC-MS with G1313 autosampler, G1315
diode array detector, and 1200 series solvent module. A Phenomenex Gemini C18 column, 50 × 2
mm, 5 μm with guard column was used for all LC-MS separations. LC-MS mobile phases were
0.1% formic acid in (A) water and (B) acetonitrile, and data were processed using G2710
ChemStation software. NMR was performed on a Varian Unity Inova-600 MHz instrument with
a cold probe. Bacterial growth studies were performed using polystyrene 96-well plates with
polystyrene lids. OD600 measurements were taken on a Molecular Devices SpectraMax Plus 384
plate reader.
Isolation and purification of Acb, FimA and FimF.
Acinetobactin (Acb), Fimsbactin A (FimA) and Fimsbactin F were isolated and purified
from A. baumannii ATCC 17978 cultures using a modified literature procedure. 9,12 PreAcb and
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OxPreAcb were synthesized as described previously by our group.5,9 Briefly, 1 L cultures of A.
baumannii ATCC 17978 were grown overnight in M9 minimal media. Cells were pelleted and the
supernatant was adjusted to pH ~6 using citric acid. XAD-7HP resin was added to the supernatant
and the mixture was shaken gently. The mixture was filtered and the resin was washed with
methanol. The methanol washings were combined and concentrated via rotary evaporation under
reduced pressure. Acb (retention time 12 min, 31 mg/L), FimA (retention time 15 min, 5 mg/L)
and FimF (retention time 13 min, 2 mg/L) were purified from the crude residue by preparatory
HPLC (gradient of 0% B to 95% B over 17 min, then 95% B to 100% B over 8 min). The holosiderophores were prepared by mixing PreAcb, Acb, FimA and FimF with excess Fe(acac) 3 in
methanol following by concentration and trituration with Et 2O to provide the pure PreAcb2Fe,
Acb2Fe, FimAFe and FimF2Fe complexes.9,10
A. baumannii Growth Studies.
Stock solutions of FimF and FimFFe were prepared in M9 media at 250 μM (up to 2.5%
final DMSO v/v). Each well of a 96-well plate was filled with 50 μL of M9 media. 50 µL of the
250 µM test compound stock solutions were added to the first row of a 96 well plate. Compounds
were serially diluted down the plate to 3.9 μM. An inoculum was made by adding 100 μL of 0.5
McFarland standard (A. baumannii ATCC 17978) to 4.0 mL of M9 minimal media supplemented
with 350 μM 2,2’-dipyridyl (DIP). Inoculum (50 μL) was added to each well for a final
concentration of 175 μM DIP per well and a serial dilution of test compounds at 62.5-1.95 μM.
Growth promotion was determined at 37 °C by measuring OD 600 using a microplate reader
(Molecular Devices SpectraMax Plus 384 plate reader). Control growth curves were performed in
M9 media with 175 μM DIP and no test compounds. DIP concentrations were optimized prior to
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each experiment by serial dilution against A. baumannii under the growth conditions described in
this section. All experiments were performed in triplicate as independent trials.
For the biological evaluation of combinations of FimA, FimF, and corresponding ferric
complexes, a 96-well plate was filled with 40 μL of M9 minimal media per well, 5 μL of each of
the compounds of interest, a final concentration of 175 μM DIP per well and 50 μL of the inoculum.
To explore the combination of FimA/FimF, the following concentrations were tested in duplicate
in all possible combinations: 3.9 μM, 15.6 μM, 62.5 μM. For the combination of FimAFe/FimF
the following concentrations were tested in duplicate in all possible combinations: FimAFe 0.5
μM, 3.9 μM, 15.6 μM; FimF 3.9 μM, 15.6 μM, 62.5 μM. For the combination of FimA/FimFFe
the following concentrations were tested in duplicate in all possible combinations: FimA 3.9 μM,
15.6 μM, 62.5 μM; FimFFe 0.5 μM, 3.9 μM, 15.6 μM. Growth promotion was determined at 37
°C by measuring OD600 using a microplate reader (Molecular Devices SpectraMax Plus 384 plate
reader). Control growth curves were performed in M9 media with 175 μM DIP and no test
compounds. All experiments were performed in duplicate as independent trials.
For the biological evaluation of combinations of FimF, Acb, and corresponding ferric
complexes, a 96-well plate was filled with 40 μL of M9 minimal media per well, 5 μL of each of
the compounds of interest, a final concentration of 175 μM DIP per well and 50 μL of the inoculum.
To explore the combination of FimF/Acb, the following concentrations were tested in duplicate in
all possible combinations: 3.9 μM, 15.6 μM, 62.5 μM. For the combination of FimFFe/Acb the
following concentrations were tested in duplicate in all possible combinations: FimFFe 0.5 μM,
3.9 μM, 15.6 μM; Acb 3.9 μM, 15.6 μM, 62.5 μM. For the combination of FimF/Acb 2Fe the
following concentrations were tested in duplicate in all possible combinations: FimF 3.9 μM, 15.6
μM, 62.5 μM; Acb2Fe 0.5 μM, 3.9 μM, 15.6 μM. Growth promotion was determined at 37 °C by
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measuring OD600 using a microplate reader (Molecular Devices SpectraMax Plus 384 plate reader).
Control growth curves were performed in M9 media with 175 μM DIP and no test compounds. All
experiments were performed in duplicate as independent trials.
Determination of FimFFe Complex Stoichiometry.
A solution of 570 μM FimF in methanol was prepared. A fluorescence emission spectrum
was recorded (λexcitation = 330 nm; λemission = 380 nm). To determine stoichiometry of the complex
between Fim and Fe(III), aliquots of a methanolic solution of Fe(acac) 3 were added 0.044
equivalents at a time via Hamilton syringe and emission spectra were recorded after each addition.
Peak fluorescence (Abs380nm) was plotted against Fe(III) equivalents to reveal a 2:1 FimFFe
stoichiometry (Figure 4.18).
Determination of Apparent KFe for FimFFe.
A stock solution of 100 µM FimFFe was prepared in 10 mM HEPES buffer (10 mM
HEPES, 600 mM NaCl, 100 mM KCl, pH 7.4) and an optical absorbance spectrum was obtained
from λ = 300–700 nm (Figure 4.17). While continuously monitoring optical absorbance at 500
nm, EDTA was added at a final concentration of 120 μM (1.2 equivalents relative to FimFFe). The
apparent iron-binding affinity (KFe) was determined based on the change in optical absorbance at
500 nm after 800 min for two independent trials using the equations provided in the supplementary
information.
N-His6-BauB Expression and Purification.
The bauB gene from Acinetobacter baumannii (Genbank Accession Number AAT52185)
was codon optimized for expression in E. coli and cloned into a pET28b vector by GenScript
Biotech Corporation. The bauB gene was then subcloned into a pET28bTEV vector using
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restriction enzyme-based cloning.14 BauB was expressed as the N-terminal hexahistidine fusion,
N-His6-BauB, in E. coli BL21 (DE3) as described in Chapter 3. Protein purity was analyzed by
SDS-PAGE with visualization by Coomassie blue staining. Protein mass were confirmed by ESIMS. Purified protein was flash frozen in liquid N2 at 180 μM and stored at –80 °C.
Determination of Apparent Kd Values for BauB.
N-His6-BauB was recovered on ice from a –80 °C freezer stock. A 400 nM BauB stock
solution was prepared in assay buffer (25 mM Tris-HCl, 8 g/L NaCl, 0.2 g/L KCl, pH 7.4). For
each measurment, 300 μL of the BauB stock solution was transferred to a fluorescence cuvette
(HellmaAnalytics High Precision Cell cuvette made of Quartz SUPRASIL; light path 10 x 2 mm)
in the presence of apo- and holo-FimsbactinF at concentrations ranging from 100–1200 nM.
Emission spectra were recorded at λemission = 300–400 nm using a PerkinElmer LS 55
Luminescence Spectrometer (slit width 10 nm; scan speed 400 nm/min) at excitation = 280 nm.
Fluorescence intensity at 320 nm was plotted versus substrate concentration (nM) and apparent Kd
was calculated using nonlinear regression and a one binding site model in GraphPad Prism v7.0b
(Figure 4.16, Table 4.1).14 All experiments were performed in duplicate as independent trials.
Metal Titration Studies.
A 500 μM stock solution of apo-small molecule (PreAcb, Acb, FimA, FimF or OxPreAcb)
was prepared in methanol. 300 μL of the small molecule stock solution was transferred to a
fluorescence cuvette (HellmaAnalytics High Precision Cell cuvette made of Quartz SUPRASIL;
light path 10 x 2 mm). An emission spectra was recorded at λ emission = 300–400 nm using a
PerkinElmer LS 55 Luminescence Spectrometer (slit width 10 nm; scan speed 400 nm/min) at
excitation = 280 nm. 10 mM metal chloride stock solutions were prepared (Fe 3+, Ni2+, Zn2+, Cu2+,
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Co2+ and Mg2+). 1 µL portions of the 10 mM metal chloride stock solutions were added to the 300
μL 500 μM small molecule solution. Following each addition, the solution was gently mixed and
an emission spectra was recorded. In the case of PreAcb and Zinc, absorption maxed out the
detector limits following less than 0.2 equivalents added. To obtain a more accurate view of the
absorption from the addition of Zinc, experiment was re-ran using 0.0066 equivalent additions of
zinc chloride. Fluorescence intensity at 460 nm was plotted versus equivalents of metal ion in
GraphPad Prism v7.0b (Figures 4.21-4.27, Table 4.1). All experiments were performed in
duplicate as independent trials.
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4.7 Figures and Tables

Figure 4.1: Siderophores of Acinetobacter baumannii.
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Figure 4.2: Fimsbactin siderophores A-F.
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Figure 4.3: DAD at 263 nm (black), EIC at m/z 347 (blue), EIC at m/z 576 (red) ), and EIC at m/z
439 (green) chromatograms from LCMS analysis of crude A. baumannii ATCC 17978 supernatant
after acidification, treatment with XAD-7HP resin, and methanol elution.
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Figure 4.4: Diode array optical absorbance detection (DAD) and extracted ion chromatograms
(EICs) for fimsbactin A–F [M+H]+ ions from LCMS analysis of culture supernatant extraction
from A. baumannii ATCC 17978 using ESI ionization in positive ion mode. The x-axis represents
retention time (min) for all chromatograms.
165

Figure 4.5: Diode array optical absorbance detection (DAD) and extracted ion chromatograms
(EICs) for Fimsbactin F [M+H]+ ions from LCMS analysis using positive ion mode of A.
baumannii ATCC 17978 culture supernatant HPLC-Prep purified. The x-axis represents retention
time (min) for all chromatograms
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Figure 4.6: Diode array optical absorbance detection (DAD) and extracted ion chromatograms
(EICs) for Fimsbactin-F [M+H]+ ions from LCMS analysis using positive ion mode of A.
baumannii ATCC 17978 culture supernatant HPLC-Prep purified. Fimsbactin F-Fe ionizes as
Fimsbactin-F ion [M+H]+ The x-axis represents retention time (min) for all chromatograms
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Figure 4.7: High-resolution ESI MS (positive ion mode) of Fimsbactin F purified by prep-HPLC
from A. baumannii ATCC 17978 culture supernatant. Expected [M+H] + for C19H27N4O8 439.1823,
found 439.1817.
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Figure 4.8: 1H-NMR (600 MHz, CD3OD) spectrum of purified Fimsbactin F purified by prepHPLC from A. baumannii ATCC 17978. The x-axis is chemical shift given in parts per million
(ppm). The y-axis is arbitrary peak intensity.
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Figure 4.9A: 13C-NMR (151 MHz, CD3OD) spectrum of purified Fimsbactin F purified by prepHPLC from A. baumannii ATCC 17978. The x-axis is chemical shift in parts per million (ppm).
The y-axis is arbitrary peak intensity.
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Figure 4.9B: COSY-NMR (CD3OD) spectrum of purified Fimsbactin F purified by prep-HPLC
from A. baumannii ATCC 17978.
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Figure 4.9C: HMBC-NMR (CD3OD) spectrum of purified Fimsbactin F purified by prep-HPLC
from A. baumannii ATCC 17978.
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Figure 4.9D: HSQC-NMR (CD3OD) spectrum of purified Fimsbactin F purified by prep-HPLC
from A. baumannii ATCC 17978.
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OD600

Figure 4.10: Dose dependent growth promotion of A. baumannii ATCC 17978 by apo-Fimsbactin
F and holo-Fimsbactin F. Line graphs depict the growth of A. baumannii ATCC 17978 in M9
minimal media supplemented with 175 µM 2,2’-dipyridyl (DIP) determined by measuring the
optical density at 600 nm (OD600) as a function of time in the presence of variable siderophore
concentrations. All experiments were performed in triplicate. Data from these plots were used to
crease the bar graphs in Figure 4.11.
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Figure 4.11: Influence of apo- and holo-siderophore on A. baumannii growth depicting the
comparison of OD600 values after 30 hours in the presence of variable concentrations of FimF and
FimF2Fe. Error bars represent standard deviations from the mean for three independent trials.
****p<0.0001, ***p<0.001.
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Figure 4.12: Influence of apo- and holo-siderophore combinations on A. baumannii growth. Bar
graphs depict the comparison of A. baumannii ATCC 17978 growth measured by optical density
at 600 nm (OD600) values after 30 hours in the presence of variable concentrations of (a) FimA
and FimF, (b) FimAFe and FimF, and (c) FimA and FimF2Fe. Error bars represent standard
deviations from the mean for two independent trials. ****p<0.0001; **p<0.01; *p<0.1; ns = not
significant. Figure 4.13 shows full growth curve data.
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Figure 4.13: Influence of apo- and holo-siderophore combinations on the growth of A. baumannii
ATCC 17978. Line graphs depict the growth of A. baumannii ATCC 17978 in M9 minimal media
supplemented with 175 µM 2,2’-dipyridyl (DIP) determined by measuring the optical density at
600 nm (OD600) as a function of time in the presence of variable concentrations of siderophore
mixtures. For all graphs, siderophore concentration gradients are provide on the x-axis and y-axis
of the checkerboard. The black line graph represents bacterial growth without addition of
siderophores. The red line graph represents bacterial growth in the presence of variable
concentrations of (A) apo-FimA and apo-FimF, (B) holo-FimAFe and apo-FimF, or (C) apo-FimA
and holo-FimF2Fe. Error bars represent standard deviations from the mean for two independent
trials. Data from these plots were used to create bar graphs shown in Figure 4.12
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Figure 4.14: Influence of apo- and holo-siderophore combinations on A. baumannii growth. Bar
graphs depict the comparison of A. baumannii ATCC 17978 growth measured by optical density
at 600 nm (OD600) values after 30 hours in the presence of variable concentrations of (a) Acb and
FimF, (b) Acb2Fe and FimF, and (c) Acb and FimF2Fe. Error bars represent standard deviations
from the mean for two independent trials. **p<0.01; *p<0.1; ns = not significant. Figure 4.15
shows full growth curve data.
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Figure 4.15: Influence of apo- and holo-siderophore combinations on the growth of A. baumannii
ATCC 17978. Line graphs depict the growth of A. baumannii ATCC 17978 in M9 minimal media
supplemented with 175 µM 2,2’-dipyridyl (DIP) determined by measuring the optical density at
600 nm (OD600) as a function of time in the presence of variable concentrations of siderophore
mixtures. For all graphs, siderophore concentration gradients are provide on the x-axis and y-axis
of the checkerboard. The black line graph represents bacterial growth without addition of
siderophores. The red line graph represents bacterial growth in the presence of variable
concentrations of (A) apo-Acb and apo-FimF, (B) holo-Acb2Fe and apo-FimF, or (C) apo-Acb
and holo-FimF2Fe. Error bars represent standard deviations from the mean for two independent
trials. Data from these plots were used to create bar graphs shown in Figure 4.14
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Figure 4.16: Siderophore-dependent fluorescence quenching of N-His6-BauB. Graphs depict
intrinsic tryptophan fluorescence quenching (y-axis: λexcitation = 280 nm; λemission = 340 nm) of 400
nm N-His6-BauB in the presence of variable siderophore concentrations (x-axis). Apparent K d
values were calculated using a single-binding mode curve-fitting model in GraphPad Prism version
7.0b. Error bars represent standard deviations for two independent trials.
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Compound

BauB Binding

LogKFe

Affinity (apo/holo)
FimA5

Fe Binding
Ratio

354.8 ± 139.3/

27.1 ± 0.2

1:1

27.4 ± 0.2

2:1

26.2 ± 0.1

2:1

25.9 ± 0.1

2:1

244.4 ± 93.3
PreAcb9,10,14

382.8 ± 106.1/
754.4 ± 155.4

Acb9,10,14

302.5 ± 105.1/
162.3 ± 81.4

FimF

297.4 ± 67.3/
360.3 ± 86.1

Table 4.1. Comparison of A. baumannii siderophore periplasmic siderophore binding protein,
BauB, iron affinity and iron stoichiometry.
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Figure 4.17: Optical absorbance spectrum of the holo-FimF2Fe complex at 100 µM in phosphate
buffer (50 mM potassium phosphate at pH 8.0, 150 mM NaCl, 1 mM DTT, 5% glycerol).

Figure 4.18: Fimsbactin F forms a 2:1 complex with Fe(III). Graph depicts fluorescence (λ excitation
= 330 nm; λemission = 380 nm) vs equivalents of Fe(acac)3 showing a titration end point correlating
with 2:1 stoichiometry.
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Absorbance (au)
Figure 4.19: Absorbance over time of FimF in 10 mM HEPES following addition of EDTA. Data
from this figure was used to calculate the apparent KFe of FimsF
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Figure 4.20: Hypothesized potential relationship between FimA and FimF. We hypothesize
Fimsbactin can compete with some acinetobactin transport proteins, as we already demonstrated a
competition for siderophore binding protein, BauB.
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O
N
OH

Figure 4.21: Metal titration studies with Copper, iron, nickel, cobalt and zinc chloride with Acb,
PreAcb, FimA, FimF and OxPreAcb. Top graph x-axis: 1/[(min abs at 460 nm /starting abs at
460 nm) x 100]. Bottom graph x-axis: log(1/[(min abs at 460 nm /starting abs at 460 nm) x
100]).
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Figure 4.22: Metal titration curves for FimA
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Figure 4.23: Metal titration curves for FimF
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Figure 4.24: Metal titration curves for Acb
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Figure 4.25: Metal titration curves for PreAcb

193

Norm Abs (425 nm)

Norm Abs (425 nm)

Abs (425nm)

Norm Abs (425 nm)

Norm Abs (425 nm)

Norm Abs (425 nm)

Figure 4.26: Metal titration curve for PreAcb titrated with Zn, maxed out the detector at less
than 0.2 equivalents.
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Figure 4.27: Metal titration curves for OxPreAcb

195

Equations 4.1
As described in the experimental methods section of the main text, an EDTA competition experiment was
used to measure the apparent KFe for FimF2Fe at pH 7.4. The following equations were used to calculate
apparent KFe based on the change in optical absorbance observed at 500 nm for FimF2Fe in the presence of
1.2 equivalents of EDTA. A KFe value of 1025.1 was used for EDTA at pH 7.4 in final calculations.15
[

]
][ ]

(1)

𝐾 =

(2)

𝐾

(3)

𝐾

=

(4)

𝐾
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(5)
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KFe = apparent KL
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[
[

]
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[
[

for the following equilibrium;

[Fe3+] + [EDTA] ⇌ [FeEDTA]

for the following equilibrium;

[FeEDTA] + [2L] ⇌ [FeL2] + [EDTA]

]
]

][

×

[Fe3+] + [2L] ⇌ [FeL2]

][
][

]
]

where
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[EDTA]T = total EDTA added
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Chapter 5: Rigid Oxazole Acinetobactin
Analog Blocks Siderophore Cycling in
Acinetobacter baumannii
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5.1 Preface
This chapter was adapted in part with permission from [Bohac, T. J., Shapiro, J. A. &
Wencewicz, T. A. ACS Infect. Dis.3, 802-806 (2017)] Copyright ©2017 American Chemical
Society. All authors contributed to writing of the manuscript. TJB synthesized all compounds and
performed Spartan computational work. JAS performed biological evaluation of compounds.
TAW served as principal investigator and oversaw experimental design.

5.2 Abstract
The emergence of multi-drug resistant (MDR) Gram-negative bacterial pathogens has
raised global concern. Non-traditional therapeutic strategies, including antivirulence approaches,
are gaining traction as a means of applying less selective pressure for resistance in vivo. Here, we
show that rigidifying the structure of the siderophore pre-acinetobactin from MDR Acinetobacter
baumannii via oxidation of the phenolate-oxazoline moiety to a phenolate-oxazole results in a
potent inhibitor of siderophore transport and imparts a bacteriostatic effect at low micromolar
concentrations under infection-like conditions.

5.3 Introduction
As discussed in prior chapters, our laboratory seeks to understand the PreAcb pathway in
great molecular detail.1 The PreAcb pathway starts when the siderophore scaffold is assembled on
an NRPS biosynthetic template.2 After formation of the phenolate oxazoline moiety, the
penultimate thioester is cleaved from the NRPS peptidylcarrier domain by N-hydroxyhistamine
releasing PreAcb (1) (Figure 5.1). Upon release from the NRPS, PreAcb is effluxed to the
extracellular space where it isomerizes to the isooxazolidinone acinetobactin (Acb, 2) (Figure
5.1).2 The 5-exo-tet cyclization proceeds with clean stereochemical inversion at C5’ and shows a
distinct pH-rate-dependent profile.1 The isomzerization is slow at acidic pH and fast at neutral and
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basic pH. Both forms of the siderophore, 1 and 2, promote the growth of A. baumannii ATCC
17978 under iron-restrictive conditions and use the same transport proteins. Given that most sites
of A. baumannii infection are acidic, we hypothesize that both PreAcb and Acb will be present and
functional as iron-sequestering virulence factors, providing a growth advantage under an expanded
pH range. Consistent with this hypothesis, PreAcb accumulates in A. baummannii supernatants in
acidic media, while only Acb is detectable in neutral media. Both PreAcb and Acb form stable,
2:1 complexes with iron(III). Structure-function studies of PreAcb and Acb analogs showed that
iron(III) chelation is required for growth promotion of A. baumannii in iron-restrictive media.3
Structural analogs incapable of promoting growth might competitively inhibit the Acb pathway.
Subtle structural changes in a siderophore scaffold can dramatically influence function. A
single carbon epimer of mycobactin was shown to block siderophore cycling in M. tuberculosis
leading to high intracellular accumlulation of siderophores that induced a lethal phenotype. 4
Mutasynthesis of pyochelin analogs by feeding substituted salicylate precursors to P. aeruginosa
decreases the efficiency of iron uptake.5 The modified pyochelin analogs are potential competitive
inhibitors that block pyochelin uptake. Furthermore, oxidation of the thiazoline in pyochelin to the
corresponding aromatic thiazole was shown to block transport of ferric pyochelin in P.
aeruginosa.6 Oxidized des-methyl pyochelin binds tightly to the pyochelin outer membrane
transporter FptA and blocks uptake, but not binding, of ferric pyochelin. Computational docking
and molecular dynamics simulations showed that oxidized pyochelin is more rigid than pyochelin,
which might limit its ability to form stable metal complexes and increase stability of the FptA
complex. The des-methyl phenolate-bis-thiazoline precursor to pyochelin is also a known
intermediate in yersiniabactin biosynthesis.7 Recently, Henderson and coworkers showed that
yersiniabactin-producing Enterobacteriaceae also excrete oxidized des-methyl pyochelin, a
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compound now identified as escherichelin, to block virulence of opportunistic P. aeruginosa
during clinical bacteriuria.8 Escherichelin-producing Enterobacteriaceae have potential as
probiotic treatments for urinary tract infections and purified escherichelin might also be useful as
an antivirulence agent. Similar to escherichelin blocking siderophore transport in pyochelinutilizing pathogens, we hypothesize that oxidation of the PreAcb oxazoline to the corresponding
aromatic oxazole (3) might rigidify the siderophore backbone, block isomerization to Acb, and
result in inhibition of PreAcb/Acb uptake (Figure 5.1).

5.4 Results and Discussion
The synthesis of oxidized pre-acinetobactin (OxPreAcb, 3) commenced with two
precursors, N-Boc-O-benzylhydroxy-histamine 6 and oxazole benzyl ester 8 (Scheme 5.1).
Hydroxyhistamine 6 was synthesized starting from histamine, as previously reported. 1,9
Diazotization/halogenation of histamine dihydrochloride 4 with sulfuric acid and potassium
bromide, followed by addition of sodium nitrite, provided the corresponding bromo- and chloroethylimidazoles 5 in 52% yield, as a ~3:1 bromo-/chloro-mixture. SN2 displacement of halomixture 5 with the sodium salt of N-boc-O-benzylhydroxamine afforded N-Boc-Obenzylhydroxyhistame 6 in good yield. Oxazole 8 was synthesized in a one-pot, two- step synthesis
adapted from Graham,10 via the condensation of 2,3-dihydroxybenzyaldehyde with Bn-protected
L-Thr and subsequent oxidation of the intermediate aminal with BrCCl 3. Hydrogenolytic
debenzylation of 8 and TFA-mediated Boc-removal of 6 generated the free acid 9 and amine 10,
respectively (Scheme 5.2). EDC/HOBt coupling of 9 and 10 provided O-benzyl protected Nhydroxyamide 11. Hydrogenolysis of 11 yielded OxPreAcb 3 to complete the synthesis in 5 longest
linear steps (LLS) and 7 total steps.
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OxPreAcb is stable and does not spontaneously isomerize in aqueous buffer as observed
for the oxazoline to isooxazolidinone isomerization from PreAcb and Acb. 1 Thus, OxPreAcb is
structurally “locked” in the PreAcb-like form via aromatization to the phenolate-oxazole
heterocycle. We investigated the effect of Acb and OxPreAcb on the growth of A. baumannii
ATCC 19606T in M9 minimal medium under iron-restrictive (125 μM 2,2’-dipyridyl) conditions.
We chose Acb over PreAcb because we have shown in previous work that both isomers have
equivalent growth promoting effects at pH 7, and Acb is easier to isolate from A. baumannii
cultures.1 As expected, Acb promoted the growth of A. baumannii ATCC 19606T in a dosedependent manner (Figure 5.2A). In striking contrast, OxPreAcb strongly inhibited growth at all
concentrations tested (0.78-50 μM) (Figure 5.2B). Furthermore, growth inhibition by OxPreA was
competitive and dose-dependent in the presence of 10 μM Acb (Figure 5.2C). Antagonism of
OxPreAcb growth inhibitory activity by Acb supports competition for the same biological target
or transport pathway. OxPreAcb activity was confirmed on two separate synthetic lots to confirm
the observed biological activity (Figure 5.3). In medium supplemented with 100 μM 2,2’dipyridyl, OxPreAcb inhibited A. baumannii ATCC 19606T growth with an MIC of 1.56 μM.
To probe the iron-dependence of OxPreAcb activity, wild-type A. baumannii ATCC
19606T and a biosynthesis deficient ATCC 19606T s1 mutant were grown in M9 media in the
presence of variable OxPreAcb with and without supplemented 10 μM Fe(acac) 3 (Figure 5.4).
Ciprofloxacin was included as a control antibiotic with activity that is not strongly affected by iron
concentration.11 As expected, ciprofloxacin activity against A. baumannii ATCC 19606T and the
s1 mutant was not affected by iron concentration. However, the growth inhibitory activity of
OxPreAcb was strongly antagonized by iron supplementation. The amount of OxPreAcb required
to fully inhibit growth of wild-type ATCC 19606T and ATCC 19606T s1 was 50 µM (Figure
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5.4AC). Upon supplementation with 10 μM Fe(acac)3, the concentration of Ox-PreAcb required
to fully inhibit growth increased to 200 µM (Figure 5.4BD). PreAcb biosynthesis is under the
transcriptional control of ferric uptake repressors (FURs).2 FUR proteins repress transcription
when bound to Fe(II) and allow transcription when no metal is bound. This level of transcriptional
control ensures that expression of proteins in costly siderophore pathways remain reserved for
times of iron restriction when the metal is needed most. Iron-dependence is commonly observed
for SACs and other antibiotics that rely on siderophore-binding proteins for cell entry. 12 Thus,
OxPreAcb might be entering cells via the Acb pathway.
To investigate the role of Acb transport proteins on the growth inhibiting activity of
OxPreAcb we performed growth studies in M9 medium using gene insertion mutants of A.
baumannii ATCC 19606T t6 and t7, which are deficient in the outer membrane receptor protein
BauA and inner-membrane transport protein BauD, respectively (Figure 5.5).1 Wild type ATCC
19606T and the t7 mutant showed similar levels of growth, while the s1 and t6 mutants showed
reduced growth across multiple concentrations of OxPreAcb (Figure 5.5A). Interestingly, when
OxPreAcb was pre-complexed with Fe(III) prior to growth studies, the growth of wild type A.
baumannii ATCC 19606T and the s1, t6, and t7 mutants was promoted suggesting that the
OxPreAcb-Fe(III) complex can be used as a source of iron and only the metal-free form of
OxPreAcb has growth inhibitory activity (Figure 5.5B). Disrupting Acb biosynthesis and transport
systems does not strongly affect the growth inhibitory activity of OxPreAcb. The activity of
OxPreAcb is antagonized by supplementing growth medium with Fe(III). Thus, it remains unclear
whether complexation of OxPreAcb truly abolishes the growth inhibitory effect or if that added
Fe(III) is simply having the same antagonistic effect as supplementation with Fe(acac) 3. During
human infections, iron is a limiting nutrient so OxPreAcb would be presumably be metal free and
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growth inhibitory towards A. baumannii pathogens.13 The overall growth inhibitory effect of
OxPreAcb on A. baumannii appears to be bacteriostatic (Figure 5.6).
We tested the antibiotic activity of OxPreAcb against two additional clinical isolates of A.
baumannii (ATCC 17978 and ATCC 19961), the non-pathogenic strain Acinetobacter baylyi
ATCC 33305, and pathogenic E. coli ATCC 29522 (Figure 5.7). The iron-restrictive M9 medium
supplemented with DIP was optimized specifically for A. baumannii ATCC 19606T. To ensure
growth of all the strains the M9 media was not supplemented with DIP, which reduces the potency
of OxPreAcb for inhibiting bacterial growth (similar to supplementing Fe(acac) 3). OxPreAcb
inhibited the growth of all the Gram-negative bacteria at 100–200 µM. This could indicate that a
more general mechanism than siderophore disruption, such as metal withholding or
metalloenzyme targeting, is at play. All of the Acinetobacter strains produce Acb, and E. coli is
known to transport catecholate siderophores, so a siderophore-based inhibition mechanism is still
possible.
The conversion of OxPreAcb from a growth inhibitor to a growth promoter upon iron(III)
chelation inspired us to study the iron(III) binding properties. We used a fluorescence quenching
assay to titrate OxPreAcb with iron(III) showing that a stable 2:1 (OxPreAcb) 2Fe(III) complex
forms (Figure 5.8). PreAcb and Acb also form stable 2:1 complexes with iron(III). 3 We used an
EDTA competition assay to measure the apparent stability constants (K Fe) of the (PreAcb)2Fe(III),
(Acb)2Fe(III), and (OxPreAcb)2Fe(III) complexes (Figure 5.9). Apparent KFe values were 27.4 ±
0.2, 26.2 ± 0.1, and 26.5 ± 0.3 for (PreAcb)2Fe(III), (Acb)2Fe(III), and (OxPreAcb)2Fe(III),
respectively. Based on similarity of the apparent KFe values we predict that OxPreAcb will be
competitive with PreAcb and Acb for iron(III) in a biological setting.
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5.5 Outlook and Conclusions
The mechanistic basis for the growth inhibitory activity of OxPreAcb against Gramnegative bacteria remains unknown. Simple oxidation of the PreAcb oxazoline to the OxPreAcb
oxazole is predicted to increase rigidity of the siderophore backbone. Energy minimization of the
metal-free PreAcb and OxPreAcb structures revealed significant differences in 3D-orientations of
the phenolate-oxazoline and phenolate-oxazole moieties, respectively (Figure 5.10). Both the
phenolate-oxazoline and phenolate-oxazole systems are relatively flat, with the trans-oxazoline of
PreAcb slightly puckered and the oxazole of OxPreAcb appearing in plane with the phenyl ring.
In the gas phase, a stable H-bond was predicted between the 2-hydroxyl group of the phenyl ring
with the oxazoline nitrogen of PreAcb, which presumably stabilizes the planar structure and
restricts rotation around the oxazoline C1 to phenyl C1’ bond. The same type of H-bonding
interaction was found in the OxPreAcb energy minimized structure except the H-bond was formed
between the oxazole nitrogen and the hydroxyl group of the hydroxamic acid. PreAcb is capable
of this same H-bonding interaction, but it was not found during energy minimization. The origin
for this difference in H-bonding modes might be the relative rotational barriers about the
oxazoline/oxazole C4 to hydroxamate carbonyl carbon bond. The trans-orientation of the
oxazoline methyl and hydroxamate substituents decreases steric clash in rotational isomers. The
cis-planar orientation of the oxazole methyl and hydroxamate substituents introduces A1.3-strain.
Computational analysis of the energy landscape for rotational isomers about the oxazoline/oxazole
C4 to hydroxamate carbonyl carbon bond of PreAcb and OxPreAcb supported this model (Figure
5.11, 5.12). The sterically smaller carbonyl group of the hydroxamate prefers to eclipse the oxazole
methyl group to minimize the A1,3-strain, which puts the bulky N-alkyl-N-hydroxy group closer to
the oxazole nitrogen. Restricted rotation in the rigid phenolate-oxazole ligand set of OxPreAcb is
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predicted to limit the accessible number of theoretical modes for iron(III) chelation compared to
the more flexible PreAcb and Acb structures. In medicinal chemistry, rigidity is often used to
increase the affinity of a ligand for a protein target. 14 Escherichelin, a rigid pyochelin analog, was
shown to tightly bind the outer membrane receptor FptA and block transport of ferric pyochelin. 6
A similar phenomenon might be taking place in A. baumannii for OxPreAcb in the presence of
Acb. Like escherichelin8, OxPreAcb might be effective at blocking virulence of A. baumannii by
disrupting siderophore utilization, which is required for growth during infection (Figure 5.13).14
Here, the importance of molecular recognition is revealed by subtle structural changes (Figure
5.14). A more detailed understanding of siderophore receptor binding and membrane transport
paradigms in A. baumannii are required to fully appreciate how OxPreAcb competes with Acb for
cellular uptake.15 It also remains unclear whether the net growth inhibitory effect of OxPreAcb is
due exclusively to blocking siderophore cycling or if inhibition of metalloenzymes or disruption
of metal homeostasiss are contributing factors.16 Phenolate-oxazolines and phenolate-thiazolines
are common motifs in many siderophore scaffolds, including siderophores associated with
virulence in bacterial pathogens.17 Simple oxidation of the oxazolines/thiazolines found in
bacterial siderophores might be a general strategy for preparing rigid siderophore analogs as
antivirulence agents that competitively block siderophore utilizaton in producing pathogens.

5.6 Materials and Methods
Strains, Materials, and Instrumentation
Growth studies were conducted using A. baumannii ATCC 19606TT and derivatives t6
(bauA::EZ::TN<R6Kcori/KAN-2>), t7 (bauD::EZ::TN<R6Kcori/KAN-2>), and s1 (basD::aph)
provided by Dr. Luis Actis. Precultures and 96-well plate A. baumannii growth assays were
performed in filter-sterilized M9 minimal media. Samples for LC-MS were prepared in 0.45 μM
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PTFE mini-UniPrep vials from Agilent. All preparatory HPLC was performed using a Beckman
Coulter SYSTEM GOLD 127P solvent module and 168 detector with a Phenomenex Luna 10u
C18(2) 100A column, 250 × 21.20 mm, 10 μm with guard column. Prep HPLC was performed
with a mobile phase of 5 mM ammonium acetate in (A) water and (B) acetonitrile, and data were
processed using 32 Karat software, version 7.0. All LC-MS was performed on an Agilent 6130
quadrupole LC-MS with G1313 autosampler, G1315 diode array detector, and 1200 series solvent
module. A Phenomenex Gemini C18 column, 50 × 2 mm, 5 μm with guard column was used for
all LC-MS separations. LC-MS mobile phases were 0.1% formic acid in (A) water and (B)
acetonitrile, and data were processed using G2710 ChemStation software. NMR was performed
on a Varian Unity Inova-600 MHz instrument with a cold probe. Bacterial growth studies were
performed using polystyrene 96-well plates with polystyrene lids. OD600 measurements were
taken on a Molecular Devices SpectraMax Plus 384 plate reader.
Acinetobactin Isolation
Natural acintobactin was isolated and purified from A. baumannii cultures as previously reported.1
Briefly, liter cultures of A. baumannii ATCC 17978 were grown overnight in M9 minimal media.
The cultures were centrifuged down and the supernatant was adjusted to pH 6. XAD-7HP resin
was added and the supernatant was shaken. The resin was washed with methanol. The methanol
extract was concentrated and preparatory HPLC purified to yield pure acinetobactin.
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Compound Synthesis

Benzyl 2-(2,3-dihydroxyphenyl)-5-methyloxazole-4-carboxylate (8). The synthesis of 8 was
adapted from a previously reported, one-pot synthesis of oxazoles. 10 To a clean, dry round bottom
flask equipped with a stirbar and argon inlet was added L-throenine benzyl ester oxalate (1.0 g,
3.34 mmol), potassium carbonate (0.92 g, 6.68 mmol), and N,N’-dimethylacetamide (8.3 mL)
(Note: a white, cloudy solution was formed). To the resultant mixture was added 2,3dihydroxybenzaldehyde (0.46 g, 3.34 mmol) [solid, in one portion], which resulted in the
formation of a bright yellow solution which stirred at room temperature, under argon, for 12 hrs.
After 12 hrs, the reaction was cooled to 0°C, and bromotrichloromethane (0.99 mL, 10.02 mmol)
and 1,8-diazabicyclo[5.4.0]undec-7-ene (1.50 mL, 10.02 mmol) were added. The resulting deep
orange solution was stirred at 0°C for 2 hrs, at which point the reaction was removed from the ice
bath and warmed to rt. The mixture stirred at rt for an additional 10 hrs [monitored by LC-MS].
The reaction was diluted with DD-H2O (3x original volume) and extracted with MTBE (3 x 15
mL) and EtOAc (3 x 15 mL). The organic layers were combined, washed with brine, and dried
over Na2SO4. The product was concentrated by rotary evaporation to yield a dark orange sticky
solid (0.92 g, 85% crude yield). The crude product was then purified as needed by prep HPLC
(gradient of 0% B to 95% B for 17 min then hold at 100% B for 8 minutes) to provide the title
compound as a pale yellow oil (5 mg per injection, yielded 3.5 mg of pure compound). 1H NMR
(600 MHz, Chloroform-d) δ 7.46 (d, J = 7.1 Hz, 2H), 7.43 – 7.33 (m, 4H), 7.31 (d, J = 8.0 Hz,
1H), 7.03 (d, J = 7.9 Hz, 1H), 6.86 (t, J = 7.9 Hz, 1H), 5.38 (s, 2H), 2.70 (s, 3H). 13C NMR (151
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MHz, Chloroform-d) δ 161.5, 159.5, 155.4, 145.3, 144.7, 135.7, 128.8, 128.6, 128.4, 127.0, 120.0,
117.6, 116.9, 110.2, 66.8, 12.3. LC-MS cald for C 18H16NO5 (M + H)+ 326.1028; found 326.1.

2-(2,3-dihydroxyphenyl)-5-methyloxazole-4-carboxylic acid (9). To a solution of oxazole 8 (20
mg, 0.06 mmol) in MeOH (2 mL) was added 10% P/C (2 mg) at rt. The vial was purged with H 2
and allowed to stir under H2 atm (1 atm) for 1 hr [monitored by LC-MS]. Once complete, as judged
by LC-MS, the solid catalyst was removed via syringe filtration, and the solution was concentrated
under reduced pressure to provide pure carboxylic acid 9 as a clear colorless oil (99% yield). 1H
NMR (600 MHz, Methanol-d4) δ 7.33 (d, J = 7.9 Hz, 1H), 6.94 (d, J = 7.9 Hz, 1H), 6.83 (t, J = 7.9
Hz, 1H), 2.72 (s, 3H). 13C NMR (151 MHz, Methanol-d4) δ 164.8, 160.8, 156.7, 147.2, 146.8,
128.5, 120.8, 119.4, 117.6, 111.7, 12.0. LC-MS cald for C 11H10NO5 (M + H)+ 236.0559; found
236.1.

N-(2-(1H-imidazol-4-yl)ethyl)-N-(benzyloxy)-2-(2,3-dihydroxyphenyl)-5-methyloxazole-4carboxamide (11). To a clean, dry round bottom flask equipped with a stirbar and argon inlet was
added carboxylic acid 9 (60 mg, 0.25 mmol), DMF (8 mL), and hydroxyhistamine 7 (82 mg, 0.38
mmol). To the stirring solution was added EDC (198 mg, 1.28 mmol) and HOBt (172 mg, 1.28
mmol), and Et3N was added to the reaction dropwise until a pH of ~9 was obtained. The reaction
stirred under argon for 12 hrs (monitored by LC-MS), at which point the reaction mixture was
concentrated by rotary evaporation and purified by prep HPLC (gradient of 0% B to 95% B in 17
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minutes, 95% B to 100% B in 2 minutes, hold 100% B for 8 minutes) to yield title compound 11
as a pale yellow oil (64 mg, 58% yield). 1H NMR (600 MHz, DMSO-d6) δ 7.49 (s, 1H), 7.38 –
7.26 (m, 5H), 7.20 (dd, J = 7.9, 1.6 Hz, 1H), 6.92 (d, J = 7.8 Hz, 1H), 6.79 (s, 1H), 6.75 (t, J = 7.8
Hz, 1H), 4.95 (s, 2H), 4.06 (t, J = 7.2 Hz, 2H), 2.87 (t, J = 7.2 Hz, 2H), 2.42 (s, 3H). 13C NMR
(151 MHz, DMSO-d6) δ 172.0, 161.4, 157.9, 146.1, 145.1, 134.8, 129.3, 129.1, 128.6, 128.3,
119.6, 118.2, 116.5, 111.1, 75.6, 25.0, 21.1, 11.4. HRMS cald for C23H23N4O5 (M + H)+ 435.1663;
found 435.1669

N-(2-(1H-imidazol-4-yl)ethyl)-2-(2,3-dihydroxyphenyl)-N-hydroxy-5-methyloxazole-4carboxamide (3). O-benzyl-oxidized-pre-acinetobactin 11 (12 mg, 0.05 mmol) was stirred in
MeOH with ~1/10 mass equivalent of 10% Pd/C under H 2 atmosphere (1 atm). Upon
confirmation of reaction completion by LC-MS (~1 hr), the solid catalyst was removed through
syringe filtration and the solution was concentrated by rotary evaporation to provide oxidized
preacinetobactin 3 as a colorless oil. 1H NMR (600 MHz, DMSO-d6) δ 7.54 (s, 1H), 7.23 (dd, J =
7.9, 1.6 Hz, 1H), 6.95 – 6.92 (m, 1H), 6.86 (s, 1H), 6.80 (t, J = 7.9 Hz, 1H), 3.93 (s, br, 2H), 2.88
(t, J = 7.3 Hz, 2H), 2.50 (s, 3H, under DMSO residual solvent peak). 13C NMR (151 MHz,
DMSO-d6) δ 157.8, 151.4, 146.2, 145.3, 134.8, 128.0, 119.5, 118.2, 116.1, 110.7, 48.6,
11.4.HRMS cald for C16H17N4O5 (M + H)+ 345.1199; found 345.1193.
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Biological Studies
M9 minimal media was prepared for all experiments as previously described. 1
For biological assessment of acinetobactin 2 and oxidized pre-acinetobactin 3 under ironrestrictive conditions, stock solutions of 800 μM 2 and 3 were prepared in M9 minimal media and
filter sterilized. A 96-well plate was filled with 50 μL of M9 minimal media per well. Into the first
column, 50 μL of either acinetobactin stock or oxidized pre-acinetobactin stock was added, and
columns were serially diluted down to 1.56 μM. An inoculum was made by adding 200 μL of 0.5
McFarland standard (A. baumannii ATCC 19606TT s1) to 29.8 mL of M9 minimal media
supplemented with 250 μM 2,2’-dipyridyl. Inoculum (50 μL) was added to each well for a final
concentration of 125 μM 2,2’-dipyridyl and a serial dilution of 200-0.78 μM acinetobactin and
oxidized pre-acinetobactin. Growth promotion or inhibition was determined as compared to a
control with 125 μM 2,2’-dipyridyl, 0 μM acinetobactin and 0 μM oxidized pre-acinetobactin. All
experiments were performed in triplicate. For confirmation of biological activity of re-purified
compound, procedure was reproduced but with 200 μM 2,2’-dipyridyl inoculum for a final
concentration of 100 μM 2,2’-dipyridyl.
For biological assessment of competition between acinetobactin 2 and oxidized preacinetobactin 3, a stock solution of 800 μM 3 was prepared in M9 minimal media and filter
sterilized. A 96-well plate was filled with 50 μL of M9 minimal media per well. Into the first
column, 50 μL of oxidized pre-acinetobactin stock was added, and columns were serially diluted
down to 1.56 μM. An inoculum was made by adding 200 μL of 0.5 McFarland (A. baumannii
ATCC 19606TT s1) to 29.8 mL of M9 minimal media supplemented with 200 μM 2,2’-dipyridyl
and 20 μM acinetobactin. Inoculum (50 μL) was added to each well for a final concentration of
100 μM 2,2’-dipyridyl, 10 μM acinetobactin, and a serial dilution of 200-0.78 μM oxidized pre213

acinetobactin. Growth promotion or inhibition was determined as compared to a control with 100
μM 2,2’-dipyridyl, 10 μM acinetobactin, and 0 μM oxidized pre-acinetobactin. All experiments
were performed in triplicate.
For the biological evaluation of the Fe3+-complex of oxidized pre-acinetobactin, 200 μM
stocks of acinetobactin-Fe3+ and oxidized pre-acinetobactin-Fe3+ were prepared in M9 minimal
media and filter sterilized. A 96-well plate was filled with 50 μL of M9 minimal media per well.
Into the first column, 50 μL of either acinetobactin-Fe3+ stock or oxidized pre-acinetobactin-Fe3+
stock was added, and columns were serially diluted down to 0.39 μM. An inoculum was made by
adding 200 μL of 0.5 McFarland standard (A. baumannii ATCC 19606TT s1) to 29.8 mL of M9
minimal media supplemented with 300 μM 2,2’-dipyridyl. Inoculum (50 μL) was added to each
well for a final concentration of 150 μM 2,2’-dipyridyl and a serial dilution of 50-0.19 μM
acinetobactin and oxidized pre-acinetobactin. Growth promotion was determined as compared to
a control with 125 μM 2,2’-dipyridyl, 0 μM acinetobactin-Fe3+ and 0 μM oxidized preacinetobactin-Fe3+. All experiments were performed in triplicate.
For MIC evaluation of oxidized pre-acinetobactin, stock solutions of 800 μM oxidized preacinetobactin and ciprofloxacin were prepared in M9 minimal media and filter sterilized. Eight 96well plates were filled with 50 μL of M9 minimal media per well. For the first column of each
plate, 50 μL of either oxidized pre-acinetobactin stock or ciprofloxacin stock was added, and
columns were serially diluted down to 1.56 μM. Seven separate inocula were prepared by diluting
200 μL of appropriate 0.5 McFarland standard (E. coli ATCC 25922, A. baumannii ATCC
19606TT, A. baumannii ATCC 19606T t6, A. baumannii ATCC 19606T t7, or A. baumannii
ATCC 19606T s1) in either plain M9 minimal media (all bacterial strains) or M9 minimal media
supplemented with 20 μM Fe(acac)3 (just A. baumannii ATCC 19606T and A. baumannii ATCC
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19606T s1). Inocula (50 μL) were added to each well of separate plates for a final concentration
of either 0 μM or 10 μM Fe3+ and a serial dilution of 200-0.78 uM oxidized pre-acinetobactin and
ciprofloxacin. Growth was measured by endpoint OD600. All experiments were performed in
triplicate.
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Determination of KFe
Stock solutions of 100 μM pre-acinetobactin 1, acinetobactin 2, and oxidized pre-acinetobactin 3 were
prepared in 10 mM HEPES buffer and a UV-Vis scan was recorded. Next 120 μM EDTA was added and
absorbance at 500 nm was measured over 800 minutes. Iron-binding affinity (KFe) was determined using
the following calculations.
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[EDTA]T = total EDTA added

Fluorescence Quenching Titration
A solution of 570 μM oxidized pre-acinetobactin 3 in methanol was prepared and a fluorescence
emission spectra was recorded (λexcitation = 330 nm). To determine stoichiometry of the complex
between 3 and iron (III), Fe(acac)3 was added 0.0438 equivalents at a time (1 μL of 10 μM
Fe(acac)3 added by Hamilton syringe) and emission spectra were recorded at 380 nm after each
addition. Peak fluorescence (Abs380nm) was plotted against iron (III) equivalents.
Computational Studies
All calculations were performed using Spartan ’16. Oxidized pre-acinetobactin 3 and preacinetobactin 1 were modeled in Spartan. The lowest energy conformations were obtained using
the minimize energy function. The 3’-4’-9-8 dihedral (see Table 5.1 for atom numbers) was
constrained in both molecules as the energy profile was created investigating the rotation around
the oxazole-carbonyl bond. The energy profile was run at ground state in the gas state with
molecular mechanics MMFF. The energy was calculated in kJ/mol as the heterocycle-carbonyl
bond rotated 360 degrees over 25 steps. The energy was plotted as against the 25 conformations.
Compound Characterization
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Benzyl 2-(2,3-dihydroxyphenyl)-5-methyloxazole-4-carboxylate (8)
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2-(2,3-dihydroxyphenyl)-5-methyloxazole-4-carboxylic acid (9)
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N-(2-(1H-imidazol-4-yl)ethyl)-N-(benzyloxy)-2-(2,3-dihydroxyphenyl)-5-methyloxazole-4carboxamide (11)
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N-(2-(1H-imidazol-4-yl)ethyl)-2-(2,3-dihydroxyphenyl)-N-hydroxy-5-methyloxazole-4carboxamide (3)

223

224

HRMS – OxPreA (3)
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Table 5.1. 2D NMR characterization data of oxidized pre-acinetobactin (3) in DMSO-d6.

Oxidized Pre-Acinetobactin (3)
Atom
2
3
5
6
7
9
2’
4’
5’
6’
1’’
2’’
3’’
4’’
5’’
6’’

13C

1H

(ppm),
Multiplets in Hz

COSY
1H-1H
3 bond

HMBC
1H-13C
2-3 bond

HSQC

(ppm)

134.8
24.9
48.1

6.86 (s, 1H)
7.54 (s, 1H)
2.88 (t, 2H)
3.93 (s(br), 2H)

7
6
5’’
6’’
5’’

7
5’
4’’,6’’
5’’
2’’,5’’
3’’,4’’
2’,2’’,4’’

5
6
6’
4’’
5’’
6’’

157.8
128.0
151.5
11.5
110.7
145.3
146.2
118.2
119.6
116.1

2.50 (s, 3H)

6.92-6.95 (m, 1H)
6.80 (t, 1H)
7.23 (dd, 1H)
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OxPreAcb (TFA salt)
OxPreAcb (3) was re-purified by preparatory HPLC upon reviewer request. Prep HPLC
was performed with a mobile phase of 0.1% trifluoroacetic acid in (A) water and (B) acetonitrile
(gradient of 0% B to 95% B in 17 min, 95% B to 100% B in 2 min, hold 100% B for 8 min). See
1H NMR and LC-MS below. This batch of OxPreA was higher purity and reproduced the irondependent growth inhibitory effects on A. baumannii (Figure 5.3).
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5.7 Figures and Tables

Figure 5.1. Structures of pre-acinetobactin (PreAcb, 1), acinetobactin (Acb, 2), and oxidized preacinetobactin (OxPreAcb, 3).
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Figure 5.2. OxPreAcb (3) competes with Acb (2) to inhibit A. baumannii growth. Growth curves
of A. baumannii ATCC 19606T in M9 minimal medium supplemented with 125 μM 2,2’-dipyridyl
(DIP) and gradient concentrations of Acb (A.), 125 μM DIP and gradient concentrations of
OxPreAcb (B.), 100 μM DIP, 10 μM Acb, and gradient concentrations of OxPreAcb (C.). Error
bars represent s.d. for three independent trials.
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Figure 5.3. Oxidized pre-acinetobactin (3) is a potent inhibitor of Acinetobacter baumannii
ATCC 19606T growth in iron (III) controlled M9 minimal media. By reviewer request, the
target compound was isolated to a greater degree of purity to ensure that extra signals from the
NMR were not responsible for biological activity. Re-purified compound was then tested under
new conditions to give an MIC90 reading. Compound 3 totally inhibited growth at 1.56 μM under
these conditions.
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Figure 5.4. Growth inhibition by OxPreAcb (3) is attenuated by iron. OD600 taken at 42 hrs of A.
baumannii ATCC 19606T and 19606T s1 (Acb biosynthesis mutant) grown in M9 minimal
medium supplemented with gradient concentrations of either OxPreAcb (3) (black bars) or
ciprofloxacin (grey bars). No DIP was added to the media. (A.) Wild-type A. baumannii ATCC
19606T. (B.) Wild-type ATCC 19606T supplemented with 10 μM Fe(acac)3. (C.) ATCC 19606T
s1. (D.) ATCC 19606T s1 supplemented with 10 μM Fe(acac)3. Error bars represent s.d. for three
independent trials.
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p-value (s1)

0.4929*
0.002**
0.0213*
0.0450*
0.0474*
0.0084**
0.0252*
0.4204
0.0053**
0.2244
0.1018

0.4452
0.4935
0.0871*
0.1042
0.5530
0.6228
0.0095**
0.0211*
0.0941
0.0837
0.0006***

0.0001***
0.0127*
0.1401
0.7185
0.3827
0.2429
0.0068**
0.4948
0.2769
0.0001***
0.2460

p-value (t6)

p-value (t7)

p-value (s1)

0.0015**
0.0495*
0.0016**
0.0001***
0.0001***
0.0006***
0.0006***
0.0256*
0.7008
0.2917

0.0017**
0.7924
0.0112*
0.0363*
0.0005***
0.0052**
0.0432*
0.5659
0.5602
0.6997

0.3074
0.004**
0.0072**
0.0001***
0.001**
0.0005***
0.0023**
0.0033**
0.1355
0.1963

All p-values are relative to the wild type strain at equal concentration of added molecule.
* indicates a difference that is statistically significant.
** indicates a difference that is very statistically significant.
*** indicates a difference that is extremely statistically significant.
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Figure 5.5. OxPreAcb (3) promotes the growth of A. baumannii when complexed with iron (III).
Endpoint OD600 measurements taken of bacterial growth of wild-type and mutants of A. baumannii ATCC
19606T in M9 minimal media. (A.) Media supplemented with gradient concentrations of oxidized preacinetobactin (3). Media contains 0 μM 2,2’-Dipyridyl. Measurements taken at 42 hours. (B.) Media
supplemented with gradient concentrations of oxidized pre-acinetobactin (3) Fe(III)-Complex. Media
contains 150 μM 2,2’-Dipyridyl. Measurements taken at 48 hours. Error bars represent standard deviations
for three independent trials. All p-values and statistical significance are provided below in table format.
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OxPreAcb

Figure 5.6. The antibiotic effect of oxidized pre-acinetobactin (3) is bacteriostatic. Images of
96 well microplates at 42 hours (top) and 72 hours (bottom) showing dose dependent and
bacteriostatic antibiotic effect of serially diluted oxidized pre-acinetobactin (3) against A.
baumannii ATCC 19606T with a ciprofloxacin control. Wells in control rows contain no
ciprofloxacin and no oxidized pre-acinetobactin. Growth curve analysis and regrowth studies of
cells treated with OxPreAcb suggest no loss of viable A. baumannii cells upon treatment with
OxPreAcb.
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Figure 5.7. Oxidized pre-acinetobactin (3) is bacteriostatic towards multiple strains of
pathogenic A. baumannii, as well as environmental Acinetobacter and pathogenic E. coli.
Endpoint OD600 measurements taken of bacterial growth in M9 minimal media supplemented with
gradient concentrations of either oxidized pre-acinetobactin (3) or ciprofloxacin. (A.)
Acinetobacter baumannii ATCC 17978. (B.) Acinetobacter baumannii ATCC 19961. (C.)
Acinetobacter baylyi ATCC 33305. (D.) Escherichia coli ATCC 29522.
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Figure 5.8. Oxidized pre-acinetobactin (3) forms a stable 2:1 complex with iron (III). Graph
shows the peak absorbance at 380 nm of emission spectra (λex = 330 nm) of 3 (570 μM) with
increasing quantities of Fe(acac)3.
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Figure 5.9. Pre-acinetobactin, acinetobactin, and oxidized pre-acinetobactin all form
colored, high-affinity complexes with iron(III). (A.) UV-Vis spectra of 100 μM preacinetobactin (1) complexed with iron (III) in 10 μM HEPES buffer. (B.) UV-Vis spectra of 100
μM oxidized pre-acinetobactin (3) complexed with iron (III) in 10 μM HEPES buffer. (C.) Kinetic
single-wavelength (500 nm) scan of 100 μM pre-acinetobactin (1) complexed with iron (III) in
HEPES supplemented with 120 μM EDTA. Black line represents average of two independent
measurements and grey area represents standard deviation. Log(KFe) calculations provided in
Equations 1–11. (D.) Kinetic single-wavelength (500 nm) scan of 100 μM oxidized preacinetobactin (3) complexed with iron (III) in HEPES supplemented with 120 μM EDTA. Black
line represents average of two indpendent measurements and grey area represents standard
deviation. Log(KFe) calculations provided in Equations 1–11. The apparent KFe values for the 2:1
PreAcb, Acb, and OxPreAcb iron(III) complexes were 27.4 ± 0.2, 26.2 ± 0.1, and 26.5 ± 0.3,
respectively.
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A.

B.

C.

Figure 5.10. Oxidized pre-acinetobactin is more rigid than pre-acinetobactin. Gas phase
minimum energy calculation structures of (A.) pre-acinetobactin (red) overlaid with oxidized preacinetobactin (blue), (B.) pre-acinetobactin, and (C.) oxidized pre-acinetobactin. Pre-acinetobactin
forms a stable intramolecular H-bond between the C2-hydroxyl group of the phenyl ring with the
oxazoline nitrogen. Oxidized pre-acinetobactin forms a stable H-bond between the hydroxyl group
of the hydroxamic acid and the oxazole nitrogen.
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adopts a planar geometry causing reduced flexibility, which may contribute to antibiotic properties.
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Figure 5.12. Oxidation of pre-acinetobactin oxazoline to the corresponding oxazole restricts
rotation about the heterocycle-carbonyl bond through the introduction of A 1,3 strain. (A.)
Energy coordinate diagram for rotation around the oxazoline-carbonyl bond in pre-acinetobactin
1. (B.) Energy coordinate diagram for rotation around the oxazole-carbonyl bond in oxidized preacinetobactin 3.
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Figure 5.13. Hypothetical model for the mechanism of action of OxPreAcb growth inhibition
of A. baumannii. Biosynthesis of PreAcb takes place in the cytoplasm. Efflux of PreAcb to the
extracellular space provides a mixture of PreAcb and Acb after isomerization spontaneously
occurs. PreAcb and Acb form stable complexes (PreAcb)2Fe(III) and (Acb)2Fe(III), respectively,
that are transported to the periplasmic space by the outer membrane receptor BauA with assistance
of the ExbB/ExbD/TonB complex. The periplasmic binding protein BauB shuttles
(PreAcb)2Fe(III) and (Acb)2Fe(III) to the ABC-transporter BauCDE for transport to the cytoplasm.
The flavin reductase BauF is predicted to reduce Fe(III) to Fe(II) and provide PreAcb/Acb for the
next siderophore cycle. OxPreAcb is competitive with Acb and inhibits the growth of A.
baumannii. The mechanism of competition with Acb and growth inhibition is unknown.
Competition for transport could take place at the level of BauA on the outside of the cell or BauB
on the inside of the cell. Raymond proposed a shuttle mechanism for siderophore transport in
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Gram-negative bacteria that argues for the involvement of both an iron-bound siderophore and an
iron-free siderophore that undergoe metal swapping.15 The iron-free OxPreAcb might interfere
with this siderophore shuttle process, but more fundamental studies of this membrane transport
paradigm are required to test this hypothesis. Additionally, OxPreAcb might inhibit siderophore
biosynthesis or iron assimilation processes by a competitive mechanism resulting from the
structural similarity of OxPreAcb to PreAcb and Acb. Lastly, OxPreAcb was shown to strongly
chelate iron(III) so a general mechanism of metalloenzyme inhibition or disruprtion of metal
homeostasis might be at play. This type of more general mechanism might account for the growth
inhibitory activity of OxPreAcb against non-Acb producing bacteria like E. coli.16

Figure 5.14. Structures of pre-acinetobactin (PreAcb), acinetobactin (Acb), OxPreAcb,
pyochelin, yersiniabactin, and escherichelin. OxPreAcb and escherichelin both contain rigid
aromatic heterocycles and inhibit the growth of pathogenic bacteria producing structurally similar
siderophores with non-aromatic heterocycles.
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Chapter 6: Iron Binding Proves to be Crucial
in Siderophore Cycling Disruption by Oxidized
Pre-Acinetobactin in Acinetobacter baumannii
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6.1 Preface
The abstract of this chapter was adapted in part from [Bohac, T. J., Shapiro, J. A.,
Wencewicz, T. A.] abstract for ACS national meeting Boston, August 2018. This chapter was
adapted in part from manuscript in preparation [Bohac, T. J., Shapiro, J. A., Fang, F, Giblin, D. E.
& Wencewicz, T. A.]. TJB synthesized all compounds and performed all compound
characterization. JAS performed MIC evaluation of compounds. LF performed growth studies with
gallium complex. DEG performed DTF computational work. TAW served as principal investigator
and oversaw experimental design and completion.

6.2 Abstract
The rise of antibiotic resistance is driving exploration of non-canonical antibiotic
approaches, including neutralization of virulence factors. Multi-drug resistant (MDR) Gramnegative pathogens, including Acinetobacter baumannii, are of particular concern because of the
small number of clinically useful antibiotics available for use. We have previously reported a new
method for blocking iron acquisition in MDR A. baumannii as an antivirulence strategy using rigid
oxazole analogs of the siderophore acinetobactin. All genome sequenced clinical isolates of MDR
A. baumannii to date possess the capacity for acinetobactin biosynthesis and utilization.
Acinetobactin is a primary iron scavenging molecule for A. baumannii that is found in two isomeric
forms, pre-acinetobactin and acinetobactin, composed of either an oxazoline or isooxazolidinone
core, respectively. By oxidizing the oxazoline of pre-acinetobactin to an oxazole, we stabilized
this isomeric form providing a molecule that is still capable of forming high affinity 2:1
siderophore:iron(III) complexes and gains cell entry via the acinetobactin uptake pathway. Here
we report a comprehensive investigation of acinetobactin structure-function relationships for the
oxazoline, oxazole, and isooxazolidinone isomeric forms and show that iron chelation and receptor
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binding are critical for biological activity. The oxazole acinetobactin analog is a potent growth
inhibitor (MIC values as low as 1µM) of the CDC panel of MDR A. baumannii clinical isolates
and represents a new lead antivirulence molecule for disrupting siderophore-mediated iron
acquisition in this deadly pathogen.

6.3 Introduction
Previously, as discussed in Chapter 5, we have synthesized oxidized pre-acinetobactin
(OxPreAcb) by conversion of the phenolate-oxazoline moiety to a phenolate-oxazole. 1 We showed
that this small structural change resulted in a drastic change in bioactivity, from a growth promotor
as PreAcb to a growth inhibitor as OxPreAcb. We hypothesized that this planar structure would
be more rigid due to A1,3 strain and that this rigidity may contribute to the antibiotic properties
demonstrated by OxPreAcb. There have been few reports of oxidized siderophore-variants as
potential antimicrobials2 —particularly as it relates to A. baumannii. Therefore, studies probing
specific structure-activity relationships of these interesting small molecules are of great interest.
In this study, we shed light on how OxPreAcb functions and what moieties are critical to inhibitory
function. This work establishes structure activity relationships of OxPreAcb that are crucial to
further optimization of the drug-like properties of OxPreAcb. We report the synthesis and
biological evaluation of a library of OxPreAcb analogs. These analogs demonstrate a direct
correlation between iron binding and the ability to inhibit growth.

6.4 Results and Discussion
Previous work by our group investigated the structure activity relationship of analogs of
pre-acinetobactin and acinetobactin.3, 4 A panel of ten pre-acinetobactin and nine corresponding
acinetobactin analogs were synthesized. These analogs explored the effect of hydroxyl group
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positioning on the aromatic catechol on the left hand side of the molecule, the chain length and
influence of the imidazole group on the right hand side of the molecule, and the role of the
hydroxamate hydroxyl group on bioactivity and iron binding. The features of these analogs probed
the ability of the compound to bind iron, the ability to promote growth and the rate of
isomerization. The findings of this study highlighted the necessity of the 2’-hydroxyl group for
both iron (III) binding as well as growth promotion in the pre-acinetobactin form, while the
hydroxamate hydroxyl group and the presence of the imidazole ring were seen to influence the
rate of isomerization. In the acinetobactin form, both the 2’- and 3’- hydroxyl groups were crucial
in iron (III) binding and growth promotion ability of the compound (Figure 6.1).
Equipped with the knowledge from our SAR studies on pre-acinetobactin and
acinetobactin, we aimed to investigate OxPreAcb in a similar manner. The three parts of the
OxPreAcb molecule that were of interest to us were: (1) the necessity and positioning of the
hydroxyl groups on the aromatic ring of OxPreAcb, (2) the necessity of the imidazole ring, and (3)
the necessity of the hydroxamate hydroxyl group. We probed the role of these moieties through
the synthesis of OxPreAcb and 8 structural analogs generated from various commercially available
substituted benzaldehydes (Scheme 6.1). The modularity and convergent nature of the synthesis
allows for ease of diversification, as starting with various commercially available benzaldehydes
provides diversification around the left hand aromatic ring, while compounding of various amines
affords diversification on the right hand side of the molecule. Starting with the corresponding
benzaldehyde, the addition of L-threonine benzyl ester, followed by the oxidation of the
intermediate oxazoline, provided the corresponding oxazole benzyl esters. Hydrogenolysis of the
benzyl ester afforded the corresponding carboxylic acids that when exposed to EDC, HOBt
coupling with various amines, in the presence of facilitating base, afforded compound 2, along
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with the benzyl protected OxPreAcb 1 and compounds 3-9. Final deprotection of these
intermediates with H2 and Pd/C delivered title compounds 1, 3-9 in good yield (38-63%).
It has been hypothesized that OxPreAcb utilizes the Acb uptake pathway and that the
ability of OxPreAcb to bind iron (III) is instrumental to the mode of action. Therefore, with the
panel of analogs in hand, the ability of each analog to bind iron (III) was explored through a chrome
azurol S assay (CAS) (Figure 6.2). Compounds 1 and 3-6 demonstrated iron binding ability. As
compound 3 lacks the imidazole group on the right hand side of the molecule, and is instead
replaced with a butane group, its ability to bind iron(III) demonstrates that the presence of the
imidazole group is not necessary for metal chelation. Compounds 3-6 each contain a hydroxyl
group in the 2’- position, while compounds 5 and 6 contain an additional hydroxyl group in the
5’- or 4’- position respectively. The ability for all three of these compound to bind iron(III)
indicated the necessity for the 2’- hydroxyl group, while the presence or position of an additional
hydroxyl group seems no have no influence on metal bonding (Table 6.1). Taken collectively, all
the compounds with iron binding capabilities contained both a 2’-hydroxyl group, as well as the
hydroxamate hydroxyl group, deeming these groups crucial for metal chelation ability. These
results complement our group’s previous finding that the oxidized system of OxPreAcb adopts a
planar geometry and was predicted to bind iron with these two hydroxyl moieties. We
hypothesized that this binding mode was favored over binding iron through the 2’-hydroxyl and
the carbonyl oxygen due to A1’3 strain induced between the methyl group and the hydroxamate
substituents (hydroxyl group or imidazole ring) (Figure 6.3). This A1’3 strain is not as severe in
the natural pre-acinetobactin siderophore due to the trans orientation between the methyl and
hydroxamate groups.
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To test the inhibitory effect of our analogs, MIC90 values were obtained through growth
studies in iron restricted minimal media. Briefly, OxPreAcb analogs were serially diluted in M9
media supplemented with 100µm DIP. MIC 90 values were read as the lowest concentration at
which no visible growth was observed. Compounds 2 and 7-9 all provided MIC values >200;
analog 2 does not contain the hydroxymate hydroxyl group, while analogs 7-9 are the 3’-OH,
benzyl and 2,3-dimethoxy analogs, respectively. Interestingly, these four analogs are all of the
analogs with a negative CAS result and inability to bind iron(III) (Table 6.1). This finding
indicates that iron binding is crucial to the mode of action leading to growth inhibition. Compounds
1 and 3-6 all inhibited growth with MIC values as low as 0.78 µM, again correlating directly with
the ability of the molecule to chelate metal. Compound 3 demonstrated that the presence of the
imidazole ring is not required for iron binding (positive CAS result) nor for growth inhibition (MIC
value 1.56µM), signifying the right hand side of the molecule as a potential site for further
derivatization.
With these compounds in hand, we sought to explore the ability of these analogs to utilize
and interact with the siderophore uptake pathway. Preacintobactin and acinetobactin are known to
be transported through TonB-dependent outer membrane transport protein, BauA. Recently,
Naismith and coworkers resolved an interesting crystal structure of a holo-PreAcb/Acb complex
bound to BauA.5 Once in the periplasm, periplasmic siderophore binding protein, BauB, directs
the siderophore-iron complex to the inner membrane ABC-transport protein, BauCDE. As
discussed in Chapter 2, a crystal structure of Acb2Fe-BauB complex highlighted the binding mode
of Acb-iron and matched that was predicted by DFT calculations. 6 With expressed and purified
BauB in hand, we performed fluorescence quenching assays of the small molecule to BauB to
determine BauB binding affinities for the natural compound along with the analogs (Figures 6.4,
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6.5 & Table 6.1). All molecules possessing a substituent in the 2’- position of the ring on the right
hand side of the molecule were able to bind BauB with nM affinities; notably, molecules 7 and 8
which lack a 2’- substituent failed to bind BauB. This finding indicates the necessity of a
substituent (hydroxyl or methyl ester) to be the 2’- position of the right hand catechol ring, which
is likely needed for hydrogen bounding to the protein binding site. We determined the binding
affinities for both the iron free (apo) and iron bound (holo) forms of the natural siderophores Acb
and Fims, in addition to OxPreAcb and analogs, as relevant references to natural BauB binding.
In the holo form, OxPreAcb has the lowest BauB binding affinity, suggesting that OxPreAcb can
interact with and can potentially outcompete with the natural siderophores for the siderophore
pathway.
With lead compound OxPreAcb in hand, we sought to investigate the how effective this
compound inhibited the growth of clinically relevant bacterial strains; thus, we performed growth
studies of OxPreAcb against 13 clinical strains of A. baumannii obtained from the CDC ARBANK. These clinical isolates have various number of resistances genes (5-14 antibiotic genes)
and serve as a representation of clinically revelant multidrug resistant A. baumannii. The MIC90’s
and susceptible – intermediate – resistant (S-I-R) interpretation of these isolates against 21
common antibiotics are obtained by the CDC and listed in Figure 6.6. OxPreAcb showed
inhibition of all 13 strains as low as 1.56µM at 17 hours and as low as 6.25µM at 40 hours (Table
6.2), demonstrating the potential for OxPreAcb to treat clinical multidrug resistant infections. The
increase in MIC90 values at 17 hours to 40 hours and the growth recovery over time is consistent
with our previous hypothesis that OxPreAcb works in a bacteriostatic manner.
We determined the relative cytotoxicity using a lactose dehydrogenase (LDH) release assay
of OxPreAcb to healthy stable cell type, mammalian cells, and found OxPreAcb to be non251

cytotoxic, with LDH release of 1.379% at 100µM concentration OxPreAcb (Figure 6.7).
Cytotoxicity was determined through average lactate dehydrogenase release in madin-darby
canine kidney cells. This low toxicity is encouraging and serves as grounds to warrant further
investigation and optimization of OxPreAcb and oxidized siderophore scaffolds as a general ant
virulence approach.
To help elucidate the mechanism of action of OxPreAcb, we sought to determine whether
disruption of the siderophore is in fact the target or if OxPreAcb plays a role in general disruption
of metal homeostasis or metalloenzyme inhibition within the cell. In order to explore this
possibility, the OxPreAcb-Ga complex was synthesized. Gallium has been reported to have
antibacterial activity when conjugated to both protoporphyrin IX (potent activity against Gramnegative and Gram-positive bacteria)7 as well as siderophores such as deferoxamine mesylate
(activity against P. aeruginosa).8 Further, as gallium serves as a mimic of iron, gallium fails to be
reduced in cells and therefore upon reaching the cytoplasm, siderophore-gallium conjugates would
fail to be reduced, thus preventing release of free metal and recycling of the siderophore. Initial
growth studies of OxPreAcb-Ga against A. baumannii ATCC17978 in M9 minimal media with
supplemented DIP showed complete growth inhibition at all concentrations (Figure 6.8). This
inhibition of activity by OxPreAcb-Ga, however, can be recovered in a dose-dependent manner
upon the addition of Fim-Fe, Acb2-Fe or OxPreAcb-Fe. This growth recovery upon siderophore
addition indicates that OxPreAcb-Ga was not merely a general toxic effect from the presence of
Ga but instead points to pathway competition of OxPreAcb-Ga and A. baumannii siderophore and
supports the theory that OxPreAcb disrupts the siderophore pathway, as opposed to disrupting
metal homeostasis (Figure 6.9 & 6.10). Further evidence that OxPreAcb utilizes the siderophore
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pathway is shown in the ability of OxPreAcb-Ga binding to BauB with similar affinity to that of
the natural siderophores (Figure 6.11).

6.5 Outlook and Conclusions
In summary, we generated, characterized, and evaluated eight structural analogs of
previously reported OxPreAcb to identify structure-activity-relationships related to iron binding,
growth inhibition, and periplasmic binding protein affinity (BauB). Studies show a direct
correlation between inhibition and ability to bind iron. Additionally, the right hand portion of the
molecule was identified as a potential site for further diversification, as the presence of the
imidazole tail did not have an effect on iron binding ability nor growth inhibition ability.
Moreover, growth inhibitions studies with (OxPreAcb) 2-Ga and corresponding growth recovery
promoted by known, iron-bound A. baumannii siderophores suggests a competition of OxPreAcb
with the natural system (Figure 6.12). BauB binding assays highlight the ability of OxPreAcb
analogs to bind to this protein, provided the analog possesses a substituent (hydroxyl or methoxy)
in the 2’-position. In conclusion, through the presented studies, we have identified promising
candidates, with low cytotoxicity and potent inhibitory activity across a panel of highly resistant
A. baumannii clinical isolates, which merit further study and evaluation as lead compounds for the
treatment of MDR A. baumannii infections.

6.6 Materials and Methods
Strains, Materials, and Instrumentation
Growth studies for the oxidized pre-acinetobactin analog panel were conducted using A.
baumannii ATCC 19606T provided by Dr. Luis Actis. Growth studies for oxidized preacinetobactin against clinical strains were conducted using A. baumannii AR-BANK #0273,
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#0275, #0278, #0284, #0287, #0290, #0293, #0296, #0299, #0302, #0305, #0308, #0311 from the
Antimicrobial Resistance Bank (collected by the CDC and FDA), provided to us by Dr. Gautam
Dantas. Precultures and 96-well plate A. baumannii growth assays were performed in filtersterilized M9 minimal media. Samples for LC-MS were prepared in 0.45 μM PTFE mini-UniPrep
vials from Agilent. All preparatory HPLC was performed using a Beckman Coulter SYSTEM
GOLD 127P solvent module and 168 detector with a Phenomenex Luna 10u C18(2) 100A column,
250 × 21.20 mm, 10 μm with guard column. Prep HPLC was performed with a mobile phase of 5
mM ammonium acetate in (A) water and (B) acetonitrile, and data were processed using 32 Karat
software, version 7.0. All LC-MS was performed on an Agilent 6130 quadrupole LC-MS with
G1313 autosampler, G1315 diode array detector, and 1200 series solvent module. A Phenomenex
Gemini C18 column, 50 × 2 mm, 5 μm with guard column was used for all LC-MS separations.
LC-MS mobile phases were 0.1% formic acid in (A) water and (B) acetonitrile, and data were
processed using G2710 ChemStation software. NMR was performed on a Varian Unity Inova-600
MHz instrument with a cold probe. Bacterial growth studies were performed using polystyrene 96well plates with polystyrene lids.
CAS Assay
CAS agar plates were prepared as described previously.1,3,4 Wells were made in the solid
agar, and 50 μL each of 100 μM solutions of oxidized pre-acinetobactin analogs in M9 minimal
media (diluted from calibrated DMSO-d6 stocks) were pipetted into the wells. Color change was
observed after 4 hours.
A. baumannii Growth Studies in Minimal Media
M9 minimal media was made as described previously. 3
Analog Panel:
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Solutions of 800 μM oxidized pre-acinetobactin analogs in M9 media were filter sterilized.
96-well plates were filled with 50 μL of M9 minimal media per well. Into the first column, 50 μL
of analog was added and columns were serially diluted down to 0.39 μM. An inoculum was made
by adding 200 μL of a 0.5 McFarland standard of A. baumannii ATCC 19606T to 29.8 μL of 200
μM 2,2’-dipyridyl in M9 minimal media. Inoculum (50 μL) was added to each well for a final
concentration of 100 μM 2,2’-dipyridyl and a serial dilution of 200 μM-0.39 μM analog. An MIC 90
was read visually as the concentration at which no growth was observed and recorded at 72 hours.
Clinical Strain Panel:
A solution of 800 μM oxidized pre-acinetobactin in M9 media was filter sterilized. 96-well
plates were filled with 50 μL of M9 minimal media per well. Into the first column, 50 μL of
oxidized pre-acinetobactin was added and columns were serially diluted down to 0.39 μM. For
each AR-BANK strain described in the above section, an inoculum was made by adding 200 μL
of a 0.5 McFarland standard to 29.8 μL of 200 μM 2,2’-dipyridyl in M9 minimal media. Inoculum
(50 μL) was added to each well for a final concentration of 100 μM 2,2’-dipyridyl and a serial
dilution of 200 μM-0.39 μM analog. An MIC 90 was read visually as the concentration at which no
growth was observed and recorded at 17 hours and 40 hours.
OxPreAcb-Ga growth studies in A. baumannii ATCC 17978:
For biological assessment of OxPreAcb-Ga under iron-restrictive conditions, stock
solutions of 10 mM of OxPreAcb-Ga were prepared in DMSO. A 96-well plate was filled with 50
μL of M9 minimal media per well. These stock solution were diluted adding 20 μL of 10 mM
OxPreAcb-Ga stock to 180 μL of M9 minimal media, affording a 1 mM stock solutions. 50 μL of
OxPreAcb-Ga 1 mM stock solutions were added to the first row of a 96 well plate. Compound was
serially diluted down the plate to 7.8 μM. An inoculum was made by adding 100 μL of 0.5
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McFarland standard (A. baumannii ATCC 17978) to 4.0 mL of M9 minimal media supplemented
with 350 μM 2,2’-dipyridyl. Inoculum (50 μL) was added to each well for a final concentration of
175 μM 2,2’-dipyridyl and a serial dilution of 250-7.8 μM OxPreAcb-Ga. Growth promotion
was determined as compared to a control with 175 μM 2,2’-dipyridyl, 0 μM OxPreAcb-Ga.
All experiments were performed in triplicate.
Combination studies of OxPreAcb-Ga and Fim-Fe, Acb-Fe or OxPreAcb-Fe:
For the biological evaluation of combinations of OxPreAcb-Ga and Fim-Fe, Acb-Fe
or OxPreAcb-Fe, a 96-well plate was filled with 50 μL of M9 minimal media per well. 2.5 μL of
10 mM OxPreAcb-Fe or Fim-Fe was added into 197.5uL M9 minimal media to make 125uM stock
solution. For Acb-Fe, 3.3uL of 7.6mM Acb-Fe was added into 196.7uL M9 minimal media to
make 125 uM stock solution. 50uL of Fim-Fe, Acb-Fe or OxPreAcb-Fe was added to the first row
of of a 96 cell plate. Compounds were serially diluted down the plate to 0.975μM. 4.68 uL of 10
mM OxPreAcb-Ga was added to 115.32 uL M9 minimal media to make 0.39 uM stock solution.
2uL of 0.39 uM OxPreAcb stock solution was added to each well of 96-well plate. An inoculum
was made by adding 100 μL of 0.5 McFarland standard (A. baumannii ATCC 17978) to 4.0 mL
of M9 minimal media supplemented with 350 μM 2,2’-dipyridyl. Inoculum (50 μL) was added to
each well for a final concentration of 175 μM 2,2’-dipyridyl, 7.8uM OxPreAcb-Ga and a serial
dilution of 31.25-0.975μM iron compounds. Growth promotion was determined as compared to
a control with 175 μM 2,2’-dipyridyl, 0 μM OxPreAcb-Ga. All experiments were performed in
triplicate.
BauB Fluorescence Quenching Studies
BauB fluorescence quenching experiments were performed as previously reported. 6
Briefly, a 183 μM bead of protein BauB-ss was thawed and diluted ten-fold in TBS buffer to afford
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a 18.3 μM stock solution. This stock solution was then diluted again to provide a 400 nM stock
solution. 300 μL of the 400 nM stock solution was transferred to a fluorescence cuvette. A stock
solution of 400 nM protein and 16 μM small molecule was made.
An emission spectrum was taken at each concentration as an average of 3 scans. Excitation
wavelength of 280 nm, fluorescence observed between 300 and 400 nm. Slit width was set to 10
nm with a scan speed of 400. Fluorescence at 320 nm was tracked as a function of small molecule
concentration. All measurements were performed in duplicate.
Fluorescence spectra were taken of 400 nM protein with the following concentrations of
small molecule: 0 nM, 106.8 nM, 212.8 nM, 318.0 nM, 422.4 nM, 684.0 nM, 1196.0 nM, 1688.0
nM, 2644.0 nM and 3536.0 nM.
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Compound Synthesis

Compound
17, 24, 31
18, 25, 32
19, 26, 33
20, 27, 34
21, 28, 35
22, 29, 36
23, 30, 37

R2

R1
2,3-di-OH
2-OH
2,5-di-OH
2,4-di-OH
4-OH
H
2,3-di-OMe

Compound

R1

38

2,3-di-OH

OBn  OH (OxPreA, 1)

2

2,3-di-OH

H (2)

39

2,3-di-OH

OBn  OH (3)

40

2-OH

OBn  OH (4)

41

2,5-di-OH

OBn  OH (5)

42

2,4-di-OH

OBn  OH (6)

43

4-OH

OBn  OH (7)

44

H

OBn  OH (8)

45

2,3-di-OMe

OBn  OH (9)
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R3

Compound 12 was synthesized and characterized as previously reported by our group. 3

Compound 13 was synthesized through the N-Boc removal of N-Boc-O-benzylhydroxylamine
(12). 20mg of 12 was dissolved in 5 mL of neat TFA. Reaction stirred for 1 hr, monitored by LCMS. Upon verification of completion, TFA was removed by rotary evaporation under reduced
pressure to afford the TFA salt of O-benzylhydroxylamine 13 in quantitative yield. Compound 13
was used without purification or characterization.

Compound 15 was synthesized and characterized as previously reported by our group. 4

Compound 16 was synthesized through the N-Boc removal of N-Boc-O-benzylhydroxylamine
(15). 20mg of 15 was dissolved in 5 mL of neat TFA. Reaction stirred for 1 hr, monitored by LCMS. Upon verification of completion, TFA was removed by rotary evaporation under reduced
pressure to afford the TFA salt of O-benzylhydroxylamine 16 in quantitative yield. Compound 16
was used without purification or characterization.
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General Procedure A. The synthesis of oxazole benzyl esters 24-30 was adapted from a
previously reported, one-pot synthesis of oxazoles.9 Briefly, L-throenine benzyl ester oxalate (3.34
mmol), potassium carbonate (6.68 mmol), and N,N’-dimethylacetamide (8.3 mL) were stirred
under argon. To the resultant mixture was added various benzaldehyde (3.34 mmol), the solution
stirred at room temperature, under argon, for 12 hrs. After 12 hrs, the reaction was cooled to 0°C,
and bromotrichloromethane (10.02 mmol) and 1,8-diazabicyclo[5.4.0]undec-7-ene (10.02 mmol)
were added. The solution stirred at 0°C for 2 hrs, at which point the reaction was removed from
the ice bath and warmed to rt. The mixture stirred at rt for an additional 10 hrs [monitored by LCMS]. The reaction was diluted with DD-H2O (3x original volume) and extracted with MTBE (3 x
15 mL) and EtOAc (3 x 15 mL). The organic layers were combined, washed with brine, and dried
over Na2SO4. The product was concentrated by rotary evaporation to yield desired compound. The
crude product was then purified as needed by prep HPLC (gradient of 0% B to 95% B for 17 min
then hold at 100% B for 8 minutes) to provide the title compound. NMR matched previous reports. 1
R1

O
N

OH

O

General Procedure B. Oxazole carboxylic acids 31-37 were synthesized through the
hydrogenation of oxazole benzyl esters 24-30. Briefly, oxazole benzyl esters 24-30 (20 mg) were
dissolved in MeOH (2 mL) 10% P/C (2 mg) was added at rt. The vial was purged with H 2 and
allowed to stir under H2 atm (1 atm) for 1 hr [monitored by LC-MS]. Once complete, as judged by
LC-MS, the solid catalyst was removed via syringe filtration, and the solution was concentrated
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under reduced pressure to provide pure carboxylic acids 31-37 in quantitative yield. These
compounds were used without purification or characterization.

General Procedure C. Compounds 2, 38-45 were synthesized through the coupling of oxazole
carboxylic acids 31-37 and amines 10, 13 and 16. Carboxylic acids 31-37 (0.25 mmol) were
dissolved in DMF (8 mL) under argon. Amines 10, 13 or 16 (0.38 mmol) were added. To the
stirring solution was added EDC (1.28 mmol) and HOBt (1.28 mmol). Et 3N was added to the
reaction dropwise until a pH of ~9 was obtained. The reaction stirred under argon for 12 hrs
(monitored by LC-MS), at which point the reaction mixture was concentrated by rotary
evaporation and purified by prep HPLC (gradient of 0% B to 95% B in 17 minutes, 95% B to
100% B in 2 minutes, hold 100% B for 8 minutes) to yield title compound 2, 38-45. Compound 2
was characterized by HRMS and 2D-NMR.

General Procedure D. OxPreA and analogs (1-9) were synthesized through hydrogenation of
oxazole amides 38-45. Oxazole amides 38-45 was stirred in MeOH with ~1/10 mass equivalent of
10% Pd/C under H2 atmosphere (1 atm). Upon confirmation of reaction completion by LC-MS (~1
hr), the solid catalyst was removed through syringe filtration and the solution was concentrated by
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rotary evaporation to afford desired compounds 1-9 in quantitative yield. Characterized by HRMS
and 2D-NMR.

Compound 17 was synthesized and characterized as previously reported in our group. 1

Compound 18 was synthesized by general procedure A starting with 2-hydroxybenzyaldehyde.
1

H NMR (600 MHz, Chloroform-d) δ 10.82 (s, 1H), 7.77 (dd, J = 7.9, 1.7 Hz, 1H), 7.46 (d, 2H),

7.40 (t, J = 7.5 Hz, 2H), 7.36 (d, 2H), 7.07 (d, J = 8.4, 0.8 Hz, 1H), 6.94 (t, J = 8.0, 7.4, 0.9 Hz,
1H), 5.37 (s, 2H), 2.70 (s, 3H). 13C NMR (151 MHz, Chloroform-d) δ 161.5, 159.4, 157.4, 155.3,
135.7, 132.8, 128.8, 128.5, 128.3, 127.0, 126.0, 119.5, 117.5, 110.4, 66.7, 12.2. LC-MS cald for
C18H16NO4 (M + H)+ 310.1074; found 310.1

Compound

19

was

synthesized

by

general

procedure

A

starting

with

2,5-

dihydroxybenzyaldehyde. 1H NMR (600 MHz, DMSO-d6) δ 10.03 (s, 1H), 9.25 (s, 1H), 7.47 (d, J
= 7.2 Hz, 2H), 7.42 (t, J = 7.4 Hz, 2H), 7.38 – 7.34 (m, 1H), 7.16 (d, J = 2.7 Hz, 1H), 6.91 – 6.84
(m, 2H), 5.36 (s, 2H), 2.67 (s, 3H).13C NMR (151 MHz, DMSO-d6) δ 160.8, 158.6, 155.9, 150.1,
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149.2, 135.8, 128.6, 128.2, 128.1, 126.3, 120.7, 117.9, 111.4, 110.2, 66.1, 11.9. LC-MS cald for
C18H16NO5 (M + H)+ 325.1023; found 326.1

Compound

20

was

synthesized

by

general

procedure

A

starting

with

2,4-

dihydroxybenzyaldehyde. 1H NMR (600 MHz, Chloroform-d) δ 7.65 (d, J = 8.7 Hz, 1H), 7.45 (d,
2H), 7.39 (t, J = 7.3 Hz, 2H), 7.35 (d, J = 7.3 Hz, 1H), 6.52 (d, J = 2.3 Hz, 1H), 6.45 (dd, J = 8.6,
2.3 Hz, 1H), 5.37 (s, 2H), 2.68 (s, 3H). 13C NMR (151 MHz, Chloroform-d) δ 161.8, 159.7, 159.7,
159.7, 159.3, 154.7, 135.8, 128.8, 128.5, 127.7, 126.8, 107.9, 103.7, 66.8, 12.2. LC-MS cald for
C18H16NO5 (M + H)+ 326.1023; found 326.1

Compound 21 was synthesized by general procedure A starting with 4-hydroxybenzyaldehyde.
1

H NMR (600 MHz, Chloroform-d) δ 7.90 (d, J = 8.9 Hz, 1H), 7.43 (d, J = 6.9 Hz, 1H), 7.38 –

7.28 (m, 4H), 6.87 (d, J = 8.9 Hz, 1H), 5.37 (s, 2H), 2.66 (s, 2H). 13C NMR (151 MHz, Chloroformd) δ 162.5, 160.2, 158.6, 158.4, 156.0, 135.9, 139.9, 128.7, 128.7, 128.6, 128.4, 116.0, 66.8, 12.4.
LC-MS cald for C18H16NO4 (M + H)+ 310.1074; found 310.1

Compound 22 was synthesized by general procedure A starting with benzyaldehyde. 1H NMR
(600 MHz, Chloroform-d) δ 8.09 – 8.00 (m, 2H), 7.52 – 7.46 (m, 2H), 7.45 – 7.40 (m, 3H), 7.38
(t, J = 7.2 Hz, 2H), 7.35 – 7.30 (m, 1H), 5.41 (s, 2H), 2.68 (s, 3H).
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13

C NMR (151 MHz,

Chloroform-d) δ 162.4, 159.8, 156.5, 135.9, 130.8, 128.8, 128.7, 128.7, 128.5, 128.4, 126.7, 66.7,
12.4. LC-MS cald for C18H16NO3 (M + H)+ 294.1125; found 294.1

Compound 23 was synthesized by general procedure A starting with 2,3 dimethoxybenzyaldehyde. 1H NMR (600 MHz, Chloroform-d) δ 7.55 (dd, J = 7.9, 1.5 Hz, 1H), 7.47 (d, J =
7.4 Hz, 2H), 7.37 (t, J = 7.3 Hz, 2H), 7.35 – 7.30 (m, 1H), 7.11 (t, J = 8.0 Hz, 1H), 7.02 (dd, J =
8.2, 1.5 Hz, 1H), 5.40 (s, 2H), 3.92 (s, 3H), 3.90 (s, 3H), 2.69 (s, 3H).

13

C NMR (151 MHz,

Chloroform-d) δ 162.5, 158.4, 156.8, 153.7, 148.0, 136.1, 128.7, 128.5, 128.5, 128.4, 124.4, 122.1,
121.6, 114.9, 66.6, 61.5, 56.2, 12.5. LC-MS cald for C 20H20NO5 (M + H)+ 354.1336; found 354.1

Compound 38 was synthesized and characterized as previously reported by our group. 1

Compound 39 was synthesized by general procedure C through EDC/HOBt mediated couple of
oxazole carboxylic acid 31 and O-benzylehydroxylamine 16 in the presence of facilitating base.
1

H NMR (600 MHz, DMSO-d6) δ 7.95 (s, 1H), 7.42 (s, 2H), 7.31 (s, 3H), 7.24 (dd, J = 7.9, 1.6

Hz, 1H), 6.95 (dd, J = 7.9, 1.5 Hz, 1H), 6.82 (t, J = 7.9 Hz, 1H), 4.99 (s, 1H), 4.94 (s, 1H), 3.88 –
3.72 (m, 2H), 1.69 – 1.54 (m, 2H), 1.38 – 1.24 (m, 2H), 0.94 – 0.76 (m, 3H). 13C NMR (151 MHz,
DMSO-d6) δ 158.1, 146.0, 145.1, 133.7, 129.4, 129.13 129.02 128.6, 128.6, 128.3, 119.7, 118.3,
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118.1, 116.4, 76.6, 19.3, 19.0, 13.6, 13.4. LC-MS cald for C 22H25N2O5 (M + H)+ 397.1758; found
397.2

Compound 40 was synthesized by general procedure C through EDC/HOBt mediated couple of
oxazole carboxylic acid 32 and O-benzylehydroxylamine 13 in the presence of facilitating base.
1

H NMR (600 MHz, DMSO-d6) δ 7.78 (dd, J = 7.8, 1.7 Hz, 1H), 7.50 (s, 1H), 7.44 – 7.39 (m, 1H),

7.35 (s, 2H), 7.31 (s, 3H), 7.06 (dd, J = 8.3, 1.1 Hz, 1H), 7.02 – 6.97 (m, 1H), 6.80 (s, 1H), 4.95
(s, 2H), 4.05 (t, J = 7.2 Hz, 2H), 2.88 (t, J = 7.2 Hz, 2H), 2.43 (s, 3H).

13

C NMR (151 MHz,

DMSO-d6) δ 172.1, 161.6, 157.2, 156.1, 152.2, 135.0, 134.8, 132.6, 129.3, 128.5, 128.4, 128.3,
126.9, 119.7, 118.1, 117.0, 111.0, 75.6, 25.1, 11.5. LC-MS cald for C 23H22N4O4 (M + H)+
418.1641; found 418.2

Compound 41 was synthesized by general procedure C through EDC/HOBt mediated couple of
oxazole carboxylic acid 33 and O-benzylehydroxylamine 13 in the presence of facilitating base.
1

H NMR (600 MHz, DMSO-d6) δ 7.49 (s, 1H), 7.36 – 7.28 (m, 5H), 7.15 (d, J = 2.8 Hz, 1H), 6.88

(d, J = 8.7 Hz, 1H), 6.86 (dd, J = 8.9, 2.8 Hz, 1H), 6.80 (s, 1H), 5.79 (s, 1H), 4.94 (s, 2H), 4.03 (t,
J = 7.2 Hz, 2H), 2.86 (t, J = 7.2 Hz, 2H), 2.41 (s, 3H). 13C NMR (151 MHz, DMSO-d6) δ 158.0,
157.6, 150.0, 149.0, 134.8, 129.3, 128.5, 128.4, 128.3, 120.3, 117.9, 111.4, 110.5, 56.6, 45.0, 27.9,
15.7. LC-MS cald for C23H22N4O5 (M + H)+ 434.1590; found 434.2
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Compound 42 was synthesized by general procedure C through EDC/HOBt mediated couple of
oxazole carboxylic acid 34 and O-benzylehydroxylamine 13 in the presence of facilitating base.
1

H NMR (600 MHz, DMSO-d6) δ 7.59 (d, J = 8.5 Hz, 1H), 7.49 (s, 1H), 7.36 – 7.28 (m, 5H), 6.79

(s, 1H), 6.43 (dd, J = 8.6, 2.2 Hz, 1H), 6.41 (d, J = 2.3 Hz, 1H), 5.78 (s, 2H), 4.93 (s, 2H), 4.02 (t,
J = 7.3 Hz, 2H), 2.86 (t, J = 7.3 Hz, 2H), 2.39 (s, 3H). 13C NMR (151 MHz, DMSO-d6) δ 161.6,
158.2, 158.0, 157.9, 134.8, 129.3, 128.5, 128.3, 127.9, 108.3, 102.8, 102.6, 56.7, 45.6, 28.0, 15.7.
LC-MS cald for C23H22N4O5 (M + H)+ 434.1590; found 434.2

Compound 43 was synthesized by general procedure C through EDC/HOBt mediated couple of
oxazole carboxylic acid 35 and O-benzylehydroxylamine 13 in the presence of facilitating base.
1

H NMR (600 MHz, DMSO-d6) δ 7.76 (d, J = 8.7 Hz, 2H), 7.49 (s, 1H), 7.41 (s, 1H), 7.34 (s, 2H),

6.88 (d, J = 8.7 Hz, 2H), 5.77 (d, J = 6.4 Hz, 3H), 5.04 (s, 2H), 4.09 (s, 2H), 2.89 – 2.83 (m, 2H),
2.44 (s, 3H). 13C NMR (151 MHz, DMSO-d6) δ 160.0, 158.1, 158.0, 134.7, 129.0, 128.4, 128.3,
127.8, 117.3, 116.0, 56.8, 37.6, 28.0, 15.7. LC-MS cald for C 23N22N4O4 (M + H)+ 418.1641; found
418.2
N

O
N
O

NH

N
OBn

Compound 44 was synthesized by general procedure C through EDC/HOBt mediated couple of
oxazole carboxylic acid 36 and O-benzylehydroxylamine 13 in the presence of facilitating base.
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1

H NMR (600 MHz, DMSO-d6) δ 7.96 – 7.92 (m, 2H), 7.55 – 7.49 (m, 3H), 7.50 (s, 1H), 7.41 (s,

2H), 7.33 (s, 3H), 6.81 (s, 1H), 5.06 (s, 2H), 4.11 (s, 2H), 2.89 (t, 2H), 2.47 (s, 3H). 13C NMR (151
MHz, DMSO-d6) δ 135.3, 134.7, 131.0, 130.8, 129.2, 129.2, 129.1, 128.4, 128.3, 126.4, 126.1,
126.0, 125.9, 75.7, 51.7, 24.9, 11.6. LC-MS cald for C 23H22N4O3 (M + H)+ 402.1692; found 402.2
MeO

N

O

OMe
N
O

NH

N
OBn

Compound 45 was synthesized by general procedure C through EDC/HOBt mediated couple of
oxazole carboxylic acid 37 and O-benzylehydroxylamine 13 in the presence of facilitating base.
1

H NMR (600 MHz, DMSO-d6) δ 7.48 (s, 1H), 7.43 – 7.36 (m, 2H), 7.36 – 7.31 (m, 3H), 7.23 (dd,

J = 8.2, 1.8 Hz, 1H), 7.19 (t, J = 7.9 Hz, 1H), 6.79 (s, 1H), 5.79 (s, 1H), 5.03 (s, 2H), 4.13 (s, 2H),
3.86 (s, 3H), 3.78 (s, 3H), 2.87 (t, J = 7.5 Hz, 2H), 2.47 (s, 3H). 13C NMR (151 MHz, DMSO-d6)
δ 162.1, 158.0, 155.9, 153.4, 147.0, 135.4, 134.7, 129.1, 128.4, 128.3, 124.6, 121.0, 120.8, 115.1,
60.7, 56.8, 51.7, 28.0, 15.7. LC-MS cald for C 25H27N4O5 (M + H)+ 463.1976; found 463.2
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6.7 Figures and Tables
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Figure 6.1: SAR analysis of pre-acinetobactin and acinetobactin2

Scheme 6.1: Synthetic route for OxPreAcb and analogs. *note: compound 2 lacks a
hydroxymate hydroxyl group and thus does not require a final de-protection step
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Right Side

Left Side

O

Figure 6.2: CAS assay determination of iron binding ability of OxPreAcb and analogs
COMPOUND

MIC

CAS

Acb
Acb-Fe
PreAcb
PreAcb-Fe
FimsA
FimsA-Fe
OxPreAcb, 1
OxPreAcb-Fe
OxPreAcb-Ga
2
3
4
5
6
7
8
9

>200
>200
>200
>200
>200
>200
1.56
>200
<0.78
>200
1.56
0.78
0.78
0.78
>200
>200
>200

+
+
+
+
+
+
+
+
+
+
+
+
+
-

BAUB BINDING
AFFINITY
302 ± 105
162 ± 81
383 ± 106
754 ± 155
355 ± 139
244 ± 93
198 ± 78
317 ± 172
293 ± 172
183 ± 112
218 ± 126
217 ± 212
260 ± 129
206 ± 138
No fit
No fit
143 ± 60

Table 6.1: MIC90 values (µM), CAS assay and BauB affinities for natural siderophores and
OxPreAcb derivatives
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Figure 6.3: The presence of the hydroxymate group in OxPreAcb is necessary for OxPreAcb
inhibition
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Figure 6.4: Fluorescence Quenching of BauB by OxPreAcb, OxPreAcb-Fe, PreAcb, PreAcb-Fe,
Acb, Acb-Fe, DFO-B and Kanamycin
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Figure 6.5: Fluorescence Quenching of BauB by OxPreAcb analogs
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Figure 6.6: CDC clinical isolates resistances to current antibiotics (S - susceptible, I – intermediate, R - resistant)
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CDC Isolate Strain

MIC90 (17 hrs)
µm

MIC90 (40 hrs)
µm

0273

1.56

6.25

0275

3.125

6.25

0278

3.125

6.25

0284

12.5

25

0287

3.125

6.25

0290

6.25

25

0293

0.78

6.25

0296

6.25

25

0299

No growth

12.5

0302

6.25

25

0305

3.125

12.5

0308

6.25

25

0311

6.25

25

Table 6.2: MIC90 values of OxPreAcb against CDC clinical isolates of A. baumannii
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Cytotoxicity (MDCK, LDH Release, n=3)
Positive Control

LDH Lysis Buffer

Test Compound

Concentration (µM)

Average LDH Release
SD
(%)

0

1.238%

0.535%

0.1

0.298%

0.222%

0.333

0.094%

0.094%

1

0.157%

1.102%

3.33

0.016%

0.267%

10

0.235%

0.163%

33.3

0.345%

0.380%

100

1.379%

0.190%

NA

100.000%

7.636%

OxPreAcb

Positive Control

Average % LDH Release
120%
100%
80%
60%
40%
20%
0%
0

0.1

0.333

1

3.33

Concentration (µM)

10

33.3

100

Positive
Control

Figure 6.7: Toxicity data Alliance Pharma
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Figure 6.8: OxPreAcb2Ga inhibits A. baumannii ATCC17978 growth. Growth curves of A.
baumannii in M9 minimal medium supplemented with 125 μM 2,2’-dipyridyl (DIP) and gradient
concentrations of OxPreAcb2Ga (A.), without error bars (B.) with error bars. Error bars represent
s.d. for three independent trials.
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Figure 6.9: Growth studies of A. baumannii ATCC17978 in the presences of 1. OxPreAcb-Ga
(7.8 μM) and Fims-Fe (31.25 μM, 0.975 μM) 2. OxPreAcb-Ga (7.8 μM) and (Acb) 2-Fe (31.25
μM, 0.975 μM) 3. OxPreAcb-Ga (7.8 μM) and OxPreAcb-Fe (31.25 μM, 0.975 μM) 4.
OxPreAcb (250 μM, 6.25 μM). 5. OxPreAcb-Ga (250 μM, 7.8 μM)
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OD600

Figure 6.10: 7.8 μM OxPreAcb-Ga with variable Fims-Fe, Acb-Fe and OxPreAcb-Fe growth
studies against A. baumannii ATCC17978. Growth in M9 minimal medium supplemented with
DIP. Error bars represent s.d. for three independent trials.
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Figure 6.11: Fluorescence quenching assay of BauB with OxPreAcb-Ga

Figure 6.12: OxPreAcb inhibits growth of A. baumannii by disruption of the siderophore
pathway, as shown by the ability of OxPreAcb to bind periplasmic siderophore binding protein,
BauB.
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Figure 6.13: UV-Vis spectra for apo-OxPreAcb analogs
Compound Characterization Data
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benzyl 2-(2-hydroxyphenyl)-5-methyloxazole-4-carboxylate (18)

281

benzyl 2-(2,5-dihydroxyphenyl)-5-methyloxazole-4-carboxylate (19)

282

benzyl 2-(2,4-dihydroxyphenyl)-5-methyloxazole-4-carboxylate (20)

283

benzyl 2-(4-hydroxyphenyl)-5-methyloxazole-4-carboxylate (21)

284

benzyl 5-methyl-2-phenyloxazole-4-carboxylate (22)

285

MeO

OMe
N

O
OBn

O

benzyl 2-(2,3-dimethoxyphenyl)-5-methyloxazole-4-carboxylate (23)

286

N-(benzyloxy)-N-butyl-2-(2,3-dihydroxyphenyl)-5-methyloxazole-4-carboxamide (39)

287

N-(2-(1H-imidazol-4-yl)ethyl)-N-(benzyloxy)-2-(2-hydroxyphenyl)-5-methyloxazole-4-carboxamide
(40)

288

N-(2-(1H-imidazol-4-yl)ethyl)-N-(benzyloxy)-2-(2,5-dihydroxyphenyl)-5-methyloxazole-4carboxamide (41)

289

N-(2-(1H-imidazol-4-yl)ethyl)-N-(benzyloxy)-2-(2,4-dihydroxyphenyl)-5-methyloxazole-4carboxamide (42)

290

N-(2-(1H-imidazol-4-yl)ethyl)-N-(benzyloxy)-2-(4-hydroxyphenyl)-5-methyloxazole-4carboxamide (43)

291

N-(2-(1H-imidazol-4-yl)ethyl)-N-(benzyloxy)-5-methyl-2-phenyloxazole-4-carboxamide (44)

292

N-(2-(1H-imidazol-4-yl)ethyl)-N-(benzyloxy)-2-(2,3-dimethoxyphenyl)-5-methyloxazole-4carboxamide (45)

293

N-(2-(1H-imidazol-4-yl)ethyl)-2-(2,3-dihydroxyphenyl)-5-methyloxazole-4-carboxamide – 11
HRMS cald for C16H17N4O4 (M + H)+ 329.1244; found 329.1245

Atom
2
3
5
6
7
9
2’
4’
5’
6’
1’’
2’’
3’’
4’’
5’’
6’’

13C

1H

(ppm)

(ppm),
Multiplets in Hz

134.8
27.9
37.6

6.85 (s, 1H)
7.57 (d, 1H)
2.76 (t, 2H)
3.47 (q, 2H)

157.6
128.8
151.4
11.3
110.7
145.1
146.3
118.3
119.5
116.3

COSY
1H-1H
3 bond

HMBC
1H-13C
2-3 bond

HSQC

7

5
6

2.66 (s, 3H)

5’

6’

6.65 (dd, 1H)
6.80 (t, 1H)
7.23 (dd, 1H)

4’’, 6’’
5’’
2’’, 5’’
3’’, 4’’
2’, 2’’, 4’’

4’’
5’’
6’’

7
6

5’’
6’’
5’’

294

295

296

297

LC_MS and HRMS for 1

298

N-butyl-2-(2,3-dihydroxyphenyl)-N-hydroxy-5-methyloxazole-4-carboxamide – 2
HRMS cald for C15H19N2O5 (M + H)+ 307.1288; found 307.1286

Atom

13C

(ppm)
1
2
3
4
5
6
2’
4’
5’
6’
1’’
2’’
3’’
4’’
5’’
6’’

34.1
27.5
21.2
1.32
157.8
128.0
151.5
11.5
110.8
145.2
146.1
118.3
126.4
115.5

1H

(ppm),
Multiplets in Hz

COSY
1H-1H
3 bond

HMBC
1H-13C
2-3 bond

HSQC

2.98 (m, 2H)
1.65 (m, 2H)
1.48 (m, 2H)
1.32 (m, 3H)

4
3, 5
4, 6
5

4
3, 5
4, 6
5

3
4
5
6

2.54 (s, 3H)

5’

6’

6.94 (dd, 1H)
6.80 (t, 1H)
7.23 (dd, 1H)

4’’, 6’’
5’’
2’’, 5’’
3’’, 4’’
2’, 2’’, 4’’

4’’
5’’
6’’

5’’
6’’
5’’

299

300

301

302

LC_MS and HRMS for 2

303

N-(2-(1H-imidazol-4-yl)ethyl)-N-hydroxy-2-(2-hydroxyphenyl)-5-methyloxazole-4-carboxamide – 3
HRMS cald for C16H17N4O4 (M + H)+ 329.1244; found 329.1241

Atom

13C

(ppm)
2
3
5
6
7
9
2’
4’
5’
6’

157.3
128.7
151.6
11.5

1’’
2’’
3’’
4’’
5’’
6’’

110.6
156.1
117.0
132.5
119.8
126.4

134.7
24.5

1H

(ppm),
Multiplets in Hz
6.85 (s, 1H)
7.54 (s, 1H)
2.88 (t, 2H)
3.93 (s(br), 2H)

COSY
1H-1H
3 bond

4’’
3’’
4’’, 6’’
3’’

HSQC

5
6

7
6

2.50 (s, 3H)
*under DMSO peak
7.05 (d, 2H)
7.42 (t, 1H)
7.01 (t, 1H)
7.79 (d, 1H)

HMBC
1H-13C
2-3 bond

4’, 5’

6’

1’’, 5’’, 2’’
6’’, 2’’
1’’, 3’’, 6’’
2’’, 4’’, 2’

3’’
4’’
3’’
6’’

304

305

306

307

LC_MS and HRMS for 3

308

N-(2-(1H-imidazol-4-yl)ethyl)-2-(2,5-dihydroxyphenyl)-N-hydroxy-5-methyloxazole-4-carboxamide – 4
HRMS cald for C16H17N4O5 (M + H)+ 345.1193; found 345.1190

Atom

13C

1H

(ppm)

(ppm),
Multiplets in Hz

134.7
21.2
45.7

6.86 (m, 3H)
7.53 (s, 1H)
2.87 (t, 2H)
3.91 (s (br), 2H)

2
3
5
6
7
9
2’
4’
5’
6’

158.2
128.0
149.1
11.5

1’’
2’’
3’’
4’’
5’’
6’’

110.2
126.4
126.6
120.3
150.0
117.9

COSY
1H-1H
3 bond

7
6

2.50 (s, 3H)
Under DMSO peak
6.86 (m, 3H)
6.86 (m, 3H)
7.14 (d, 1H)

4’’
3’’

HMBC
1H-13C
2-3 bond

HSQC

7

5
6

5’

6’

2’’, 4’’
3’’

3’’
4’’
6’’

309

310

311

312

LC_MS and HRMS for 4

313

N-(2-(1H-imidazol-4-yl)ethyl)-2-(2,4-dihydroxyphenyl)-N-hydroxy-5-methyloxazole-4-carboxamide – 5
HRMS cald for C16H17N4O5 (M + H)+ 345.1193; found 345.1190

Atom
2
3
5
6
7
9
2’
4’
5’
6’
1’’
2’’
3’’
4’’
5’’
6’’

13C

1H

(ppm)

(ppm),
Multiplets in Hz

134.7
28.0
45.2

6.85 (s, 1H)
7.53 (s, 1H)
2.09 (t, 2H)
3.91 (s(br), 2H)

158.0
128.2
150.4
11.4
102.4
158.0
102.8
161.6
108.3
127.5

COSY
1H-1H
3 bond

HMBC
1H-13C
2-3 bond

HSQC

7

4
6

2.47 (s, 3H)

5’

6’

6.40 (d, 1H)

3’’
2’’, 4’’

3’’

6.43 (dd, 1H)
7.59 (d, 1H)

7
6

6’’
5’’

6’’, 4’’

5’’
6’’

314

315

316

317

LC_MS and HRMS for 5

318

N-(2-(1H-imidazol-4-yl)ethyl)-N-hydroxy-2-(4-hydroxyphenyl)-5-methyloxazole-4-carboxamide – 6
HRMS cald for C16H17N4O4 (M + H)+ 329.1244; found 329.1242

Atom
2
3
5
6
7
9
2’
4’
5’
6’
1’’
2’’
3’’
4’’
5’’
6’’

13C

1H

(ppm)

(ppm),
Multiplets in Hz

134.7
28.0
45.2

6.88 (m, 3H)
7.50 (s, 1H)
2.88 (t, 2H)
4.02 (s (br), 2H)

158.0
127.2
158.1
11.4

2.43 (s, 3H)

117.5
115.9
160.0
115.9
117.5

COSY
1H-1H
3 bond

7
6

HMBC
1H-13C
2-3 bond

HSQC

7

5
6

5’

6’

7.77 (d, 2H)
6.88 (m, 3H)

3’’
2’’

3’’
2’’

2’’
3’’

6.88 (m, 3H)
7.77 (d, 2H)

6’’
5’’

6’’
5’’

5’’
6’’

319

320

321

322

LC_MS and HRMS for 6

323

N-(2-(1H-imidazol-4-yl)ethyl)-N-hydroxy-5-methyl-2-phenyloxazole-4-carboxamide – 7
HRMS cald for C16H17N4O3 (M + H)+ 313.1295; found 313.1295

Atom

13C

(ppm)

1H

(ppm),
Multiplets in Hz

COSY
1H-1H
3 bond

2
3
5
6
7
9
2’
4’
5’
6’
1’’
2’’
3’’
4’’

157.7
127.8
156.6
11.52
130.7
129.2
125.8
129.3

7.54 (m, 4H)
7.95 (m, 2H)
7.54 (m, 4H)

3’’
2’’, 4’’
3’’, 5’’

5’’
6’’

125.8
129.2

7.95 (m, 2H)
7.54 (m, 4H)

4’’, 6’’
5’’

134.7

6.80 (s (br), 1H)
7.54 (m, 4H)
2.89 (t, 2H)
4.02 (s (br), 2H)

HMBC
1H-13C
2-3 bond

7
6

2.45 (s, 3H)

HSQC

6
7

5’

6’

3’’, 4’’
2’’, 4’’, 5’’
2’’, 3’’, 5’’,
6’’
3’’, 4’’, 6’’
4’’, 5’’

2’’
3’’
4’’
5’’
6’’

324

325

326

327

LC_MS and HRMS for 7

328

N-(2-(1H-imidazol-4-yl)ethyl)-2-(2,3-dimethoxyphenyl)-N-hydroxy-5-methyloxazole-4-carboxamide- 8
HRMS cald for C18H21N4O5 (M + H)+ 373.1506; found 373.1502

Atom

13C

(ppm)
2
3
5
6
7
9
2’
4’
5’
6’
1’’
2’’
3’’
4’’
5’’
6’’
7’’
8’’

134.6
28.0

1H

(ppm),
Multiplets in Hz
6.85 (s (br), 1H)
7.48 (s (br), 1H)
2.87 (m, 2H)
4.08 (s (br), 2H)

COSY
1H-1H
3 bond

HMBC
1H-13C
2-3 bond

HSQC

5
7
6

158.0
11.4
121.1
153.4
147.0
120.8
124.6
60.8
55.8

2.47 (s, 3H)

7.20 (m, 2H)
7.40 (dd, 1H)
7.20 (m, 2H)
3.78 (s, 3H)
3.86 (2, 3H)

5’’
6’’
5’’

5’

6’

5’’, 6’’
4’’, 6’’
4’’, 5’’
3’’
2’’

4’’
5’’
6’’
7’’
8’’

329

330

331

332

LC_MS and HRMS for 8

333
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Chapter 7: Fimsbactin analogs as mimics of
the natural Fimsbactin system
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7.1 Preface
This chapter was adapted in part with from [Bohac, T. J., Fang, L., Banas, V. S., Giblin,
D. E. & Wencewicz, T. A. manuscript in preparation] TJB performed the synthesis,
characterization and evaluation of the compounds. LF performed all growth and competition
studies. VSB assisted in the synthesis of the analogs. DEG performed all DFT calculations. TAW
served as principal investigator and oversaw experimental design and completion.

7.2 Abstract
Herein, we report the synthesis of three structural and functional Fimsbactin siderophore
mimics. We report the growth promotion abilities and iron binding affinities of the three analogs
to be comparable to that of natural Fimsbactin A. We determined siderophore charge has little, if
any, effect on metal and BauB binding or growth promotion. Through growth recovery and
siderophore binding protein, BauB, affinities studies, we observed that the Fimsbactin mimics
utilize the siderophore transport pathway and can compete with natural siderophores acinetobactin
and Fimsbactin A. Equipped with this knowledge, further mimics and siderophore-antibiotic
conjugates can be synthesized to continue to exploit the A. baumannii siderophore transport
pathways as a Trojan horse strategy for antibiotic delivery.

7.3 Introduction
While antibiotic resistance is on the rise for both Gram-negative and Gram-positive
pathogens, those infections caused by Gram-negative bacteria are often more difficult to treat. 1
Due to the presence of a second outer cell membrane, many traditional antibiotics that are effective
against Gram-positive pathogens fail to permeate the outer membrane of Gram-negative
pathogens, rendering them ineffective.2 Thus, unique strategies for targeted antibiotic delivery are
of increasing interest to combat multi-drug resistant Gram-negative infections. 2 In particular,
337

Trojan horse delivery strategies which employ siderophores as vehicles of antibiotic delivery have
gained interest over the past few decades.2 Siderophore-antibiotic conjugates have shown promise
against both Gram-positive and Gram-negative pathogens, and siderophore-antibiotic conjugate
Cefiderocol of Shionogi has recently proceeded to phase III clinical trials for the treatment of a
range of MDR Gram-negative pathogens.3
In particular, our laboratory focuses on the study of one such multi-drug resistant pathogen,
Acinetobacter baumannii¸ which produces a cocktail of three siderophores. These siderophores,
acinetobactin4, Fimsbactin5 and baumannoferrin6, support cell growth through the acquisition of
essential metal nutrients. On-going work in our lab has sought to elucidate the mechanisms by
which A. baumannii siderophores interact and promote growth. Building upon the body of research
targeting the biosynthesis and biological function of Acb and Fims, we sought to expand these
studies to include synthetically simpler siderophore mimics as probes of the natural system.
Leading in the synthesis, discovery and evaluation of Trojan horse siderophore-antibiotic
conjugates, the Miller group synthesized a Fimsbactin structural mimic (Fim analog 1, 2),
containing three bidentate binding moieties consistent with natural Fimsbactin A: two catechols
and one hydroxymate moiety (Figure 7.1). Unlike the natural system, this structural mimic does
not contain any stereo-centers; thus, represents as a synthetically simpler target molecule. To date,
numerous antibiotics have been conjugated to this structural mimic, including ciprofloxacin 2,7,
carbacephalosporin,2 daptomycin,8 and vancomycin.9 Interestingly, while both Fimsbactin analogconjugated carbacephalosporin and daptomycin showed extremely low MIC values (as low as
0.2µM) against A. baumannii¸ conjugates with flouroquinolones (ciprofloxacin) afford little to no
inhibition against A. baumannii (MIC >125µM).2,8 Given that beta-lactam antibiotics target
penicillin binding proteins (PBP) located in the periplasm, while fluoroquinolones target DNA
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gyrase located in the cytoplasm, the lack of growth inhibition by the Fimsbactin mimicciprofloxacin target suggests the Fimsbactin structural mimic fails to reach the cytoplasm of the
cell. Correspondingly, it has been hypothesized that the natural Fimsbactin siderophores are
reduced in the periplasm of the cell and never reach the cytoplasm. This hypothesis is further
supported by the absence of an inner membrane transport protein in the A. baumannii Fimsbactin
gene cluster.11 However, the mechanism of action of transport and delivery via Fimsbactin analog
antibiotic conjugates still remains unknown. In this regard, we sought to explore if this Fimsbactin
analog serves as both a structural analog and functional mimic of the natural Fimsbactins, which
utilizes the natural Fimsbactin transport pathways that support bacterial virulence. This chapter
includes the synthesis and biological study of three structural Fimsbactin mimics (Figure 7.2) and
evaluates their ability to serve as possible siderophore-like scaffolds for antibiotic delivery.

7.4 Results and Discussion
To achieve our established goals, we first synthesized compound 1 in 8 steps starting from
commercially available starting materials (Figure 7.3)2, which, after troc-deprotection, possesses
a terminal primary amine for further coupling/diversification. Previous work in our group has
highlighted the role of siderophore charge in bacteria siderophore utilization [in particular, of
danoxamine analogs of S. aureus9]. This led us to explore the influence of charge on the structural
Fimsbactin mimic system. To this end, we synthesized previously reported Fimsbactin analog 1
(2) - negatively charged at neutral pH, Fimsbactin analog 2 (3) – neutral charge at neutral pH, and
Fimsbactin analog 3 (4) – positively charges at neutral pH. Fimsbactin analog 1 (2) was obtained
in two steps from compound 1 via the removal of the troc-protecting group and addition of succinic
anhydride, followed by global benzyl de-protection via hydrogenylsis. Similarly, Fimsbactin
analogs 2 and 3 (3, 4) were synthesized via troc-deprotection of compound 1 with activated zinc,
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followed by the addition of acetic anhydride or Cbz-beta-alanine-N-hydroxysuccinimide ester,
respectively; global benzyl/benzylcarbamate de-protection then affords title compounds 3 and 4,
in good overall yield.
With these analogs in hand, we first sought to investigate the role of siderophore-mimic
charge on growth promotion abilities. In both the apo- and holo- forms, all three analogs were seen
to promoted growth in a dose dependent manner—with higher growth promotion in the holo- form
than in the apo- variant (Figure 7.4, 7.5). There was no apparent effect of charge on growth
promotion, as all three analogs promoted growth at a similar rate. As all three analogs promoted
growth in the holo- form, we sought to explore the effect of charge on iron binding affinity in
reference to the natural Fimsbactin system. We were excited to find that all three fimbactin analogs
bind iron with similar affinities as the natural system (logK Fe = 27.1) (Table 7.1)—with the
neutrally charged analog (3) possessing a slightly higher binding affinity (logK Fe = 28.5) than the
positively charged analog (4) (logKFe = 27.3).

These results implied that the structural

modification of Fimsbactin A to afford simpler analogs—provided the metal-binding functional
groups are maintained—allows for the easy generation of viable Fims-like probes.
Due to the similarities in the iron binding and growth promotion of the Fimsbactin analogs
to natural Fimsbactin A, we next sought to investigate if the analogs utilize the siderophore
transport pathway as a means of gaining outer membrane permeability. To explore this possibility,
we synthesized gallium loaded Fimsbactin analog compounds and tested their effect on the whole
cell growth of A. baumannii. As expected, all three gallium complexes inhibited whole cell growth.
Gallium mimics the iron-siderophore contacts but is not reduced in the periplasm or cytosol—
therefore inhibiting essential iron acquisition. We next set out to identify if growth could be
recovered via the addition of natural siderophore iron complexes, FimFe and AcbFe, which would
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indicate that the Ga-Fims analog complexes utilize the siderophore pathway. Indeed, dosedependent growth recovery was observed with the addition of FimFe and AcbFe, demonstrating
that the analogs compete with Fimsbactin and Acb uptake pathways (Figures 7.6-7.9). Greater
growth recovery was observed in the FimsFe/Fim-Ga competition studies, suggesting direct
competition of the analog with Fims-specific transport and illustrating that the Fimsbactin analog
are in fact functional, as well as structural, mimics. Fimsbactin analog-Ga competition with Acb
is consist with our previous findings10 that natural Fims compete with natural Acb, as well, since
previous studies have shown that natural Fimsbactin can compete with Acb for periplasmic binding
protein, BauB.11 Thus, to evaluate if the Fimsbactin analogs could also bind BauB, we performed
BauB fluorenscene quenching assays with both the apo- and holo- forms of each analog (Table
7.1, Figure 7.10). BauB-binding was observed for all analog forms and apparent binding affinities
were consistent with natural Fimsbactin A, further supporting that the Fimsbactin analogs serve as
functional Fimsbactin mimics.
The DFT-computed energy minimized structure of holo-Fimsbactin analog 1 (2), was
strikingly similar to that of the computed holo-Fimsbactin A structure (Figure 7.11A and 7.11B).
Both structures bind iron in a hexadentate manner, with the catecholate ligands and hydroxamate
ligand occupying the same sites. An overlap of these two structures highlight these commonalities
(Figure 7.11C). Both these energy-minimized structures contain a tetrahedral center, denoted with
a star in Figure 7.1; this center forces the geometry of the binding moieties of the Fimsbactin
analog to occupy the same 3-dimensional positions as in the natural system, thus providing further
evidence of the ability of the analog to mimic natural Fimsbactin A. Moreover, the DFT energy
minimized structure of [FimFe]- was strikingly similar to the experimentally observed cis[Acb2Fe]- complexed to BauB.12 Since the minimized structure of [FimFe]- appears to occupy
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similar 3-dimensional space as BauB-bound [Acb2Fe]- (as depicted in Figure 7.11), we
hypothesize that the [FimsbactinFe]- analog will also bind BauB in a similar fashion—as the
energy minimized structure of the [FimsbactinFe] - analog overlays well with the [FimFe]structure. These findings are consistent with the ability of the Fimsbactin analogs to compete with
both natural Fimsbactin and natural Acb in BauB binding and indicate the viability of the
simplified analogs to serve as functional mimics of the natural system. Moreover, the structural
simplification of more complex siderophore systems may prove useful in the facile generation of
functional siderophore-like probes and new simplified scaffolds for antibiotic-conjugate drug
delivery systems. However, it must be noted that the analogs cannot be hydrolyzed. As discussed
in chapter 4, the potential ability of the natural Fimsbactin A siderophore to be hydrolyzed to
fimsbactin F may play a vital role in the interworking of the Fimsbactin system.

7.5 Outlook and Conclusions
In summary, we completed the synthesis of three simplified structural Fimsbactin analogs.
Through whole cell growth promotion studies and iron binding assays, we demonstrated that all
three analogs promote growth and bind iron in a similar manner as the natural Fimsbactin A
siderophore—independent of analog formal charge. Moreover, we determined that all three
analogs utilize the siderophore transport pathway through growth recovery competition assays
with gallium bound analogs and iron bound Fimsbactin and acinetobactin. In particular, the
observed competition between the Fimsbactin analogs and acinetobactin highlights the importance
of sideorphore competition for periplasmic binding protein, BauB, binding as it relates to growth
promotion. BauB binding assays confirmed that the generated Fimsbactin bind BauB with similar
affinities as the natural siderophores, Fimsbactin and acinetobactin. Taken collectively, these
results suggest that the simplified Fimsbactin analogs serve as both structural and functional
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Fimsbactin mimics and may be useful for the generation of “siderophore”-antibiotic conjugates
for targeted drug delivery.

7.6 Materials and Methods
Strains, Materials, and Instrumentation
Growth studies for the Fimsbactin analogs were conducted using A. baumannii ATCC
19606T provided by Dr. Luis Actis. Precultures, and 96-well plate A. baumannii growth assays
were performed in filter-sterilized M9 minimal media. Samples for LC-MS were prepared in 0.45
μM PTFE mini-UniPrep vials from Agilent. All preparatory HPLC was performed using a
Beckman Coulter SYSTEM GOLD 127P solvent module and 168 detector with a Phenomenex
Luna 10u C18(2) 100A column, 250 × 21.20 mm, 10 μm with guard column. Prep HPLC was
performed with a mobile phase of 5 mM ammonium acetate in (A) water and (B) acetonitrile, and
data were processed using 32 Karat software, version 7.0. All LC-MS was performed on an Agilent
6130 quadrupole LC-MS with G1313 autosampler, G1315 diode array detector, and 1200 series
solvent module. A Phenomenex Gemini C18 column, 50 × 2 mm, 5 μm with guard column was
used for all LC-MS separations. LC-MS mobile phases were 0.1% formic acid in (A) water and
(B) acetonitrile, and data were processed using G2710 ChemStation software. NMR was
performed on a Varian Unity Inova-600 MHz instrument with a cold probe. Bacterial growth
studies were performed using polystyrene 96-well plates with polystyrene lids. BauB affinity
studies were conducted using a fluorescence cuvette (HellmaAnalytics High Precision Cell cuvette
made of Quartz SUPRASIL; light path 10 x 2 mm). Emission spectra were recorded at λ emission =
300–400 nm using a PerkinElmer LS 55 Luminescence Spectrometer (slit width 10 nm; scan speed
400 nm/min) at excitation = 280 nm. Fluorescence intensity at 320 nm was plotted versus substrate
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concentration (nM) and apparent Kd was calculated using nonlinear regression and a one binding
site model in GraphPad Prism v7.0b

A. baumannii Growth Studies in Minimal Media
M9 minimal media was prepared as described previously. 13,14,15
Growth studies
For biological assessment of Fimsbactin analogs under iron-restrictive conditions, stock
solutions of 10 mM each analog were prepared in DMSO. A 96-well plate was filled with 50 μL
of M9 minimal media per well. These stock solution were diluted adding 5 μL of 10 mM
Fimsbactin analog stock to 195 µL of M9 minimal, affording 250 µM stock solutions. 50 µL the
Fimsbactin analog 250 µM stock solutions were added to the first row of a 96 well plate.
Compound was serially diluted down the plate to 1.95 μM. An inoculum was made by adding 100
μL of 0.5 McFarland standard (A. baumannii ATCC 17978) to 4.0 mL of M9 minimal media
supplemented with 350 μM 2,2’-dipyridyl. Inoculum (50 μL) was added to each well for a final
concentration of 175 μM 2,2’-dipyridyl and a serial dilution of 62.5-1.95 μM Fimsbactin analog.
Growth promotion was determined as compared to a control with 175 μM 2,2’-dipyridyl, 0 μM
Fimsbactin analog. All experiments were performed in triplicate.
For the biological evaluation of the Fe3+-complex of 250 μM stocks of each Fimsbactin
anlog-Fe3+ were prepared in M9 minimal media. A 96-well plate was filled with 50 μL of M9
minimal media per well. Into the first row, 50 μL of Fimsbactin analog-Fe 3+ stock was added, and
rows were serially diluted down to 1.95 μM. An inoculum was made by adding 100 μL of 0.5
McFarland standard (A. baumannii ATCC 17978) to 4.0 mL of M9 minimal media supplemented
with 350 μM 2,2’-dipyridyl. Inoculum (50 μL) was added to each well for a final concentration of
175 μM 2,2’-dipyridyl and a serial dilution of 62.5-1.95 μM Fimsbactin analog-Fe 3+. Growth
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promotion was determined as compared to a control with 175 μM 2,2’-dipyridyl, 0 μM Fimsbactin
analog-Fe3+. All experiments were performed in triplicate.
Growth studies with Gallium:
For the biological evaluation of the Ga-complex of 125 μM stocks of each Fimsbactin
anlog-Ga were prepared in M9 minimal media. A 96-well plate was filled with 50 μL of M9
minimal media per well. Into the first row, 50 μL of Fimsbactin analog-Ga stock was added, and
columns were serially diluted down to 0.9765 μM. An inoculum was made by adding 100 μL of
0.5 McFarland standard (A. baumannii ATCC 17978) to 4.0 mL of M9 minimal media
supplemented with 350 μM 2,2’-dipyridyl. Inoculum (50 μL) was added to each well for a final
concentration of 175 μM 2,2’-dipyridyl and a serial dilution of 31.25-0.9765 μM Fimsbactin
analog-Ga. To all wells in the first 3 columns, 2 μL of 195 μM FimA-Fe was added to afford a
final concentrations of 3.9 μM of FimA-Fe. To all the wells in the next 3 columns, 2 μL of 195
μM Acb-Fe was added to afford a final concentrations of 3.9 μM of Acb-Fe. Growth promotion
was determined as compared to a control with 175 μM 2,2’-dipyridyl, 0 μM Fimsbactin analogGa and also compared to an additional control of a 175 μM 2,2’-dipyridyl, and a serial dilution of
31.25-0.9765 μM Fimsbactin analog-Ga. All experiments were performed in triplicate.
BauB Fluorescence Quenching Studies
BauB fluorescence quenching studies were performed as previously reported. 11,12 Briefly,
a bead of protein BauB-ss was thawed and diluted to provide a 400 nM stock solution. 300 μL of
this 400 nM stock solution was transferred to a fluorescence cuvette. A stock solution of 400 nM
protein and 16 μM small molecule was made. An emission spectrum was taken at each
concentration as an average of 3 scans. Excitation wavelength of 280 nm, fluorescence observed
between 300 and 400 nm. Slit width was set to 10 nm with a scan speed of 400. Fluorescence at
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320 nm was tracked as a function of small molecule concentration. All experiments were
performed in duplicate as independent trials. Increasing concentrations of small molecule were
added without altering protein concentration. Measurements at the following concentrations of
small molecule were taken: 0, 106.8, 212.8, 318, 422.4, 684, 1196, 1688, 2644, 3536 nM
DFT Calculations.
Stable holo-siderophore complexes with ferric iron were calculated using density
functional theory16,17 (DFT) in a similar manner as described previously.12 Monte Carlo/MMFF
molecular mechanics/dynamics was used to explore conformer spaces. Initial structure
optimization was performed by using the PM3d semi-empirical algorithm (Spartan Linux v10,
WaveFunction, Inc.). We employed DFT (Density Functional Theory, Gaussian 09, Gaussian Inc.)
for calculations using the PBE0 hybrid functional (PBE1PBE in Gaussian parlance) with basis sets
Def2-SVP and Def2-TZVP. Minima were optimized at the level PBE0/Def2-SVP and single-point
energies were calculated at level PBE0/Def2-TZVP, with scaled thermal-energy corrections from
B3LYP/6-31G(d,p).18 Solvent-based single-point energies were calculated at the same level using
the CPCM polarizable conductor calculation model for water and the Universal Force Field for
atomic radii.19 DFT functionals and basis sets were chosen for efficiency and compatibility with
ferric complexes.20,21,22

346

Determination of KFe
Stock solutions 100 µM Fimsbactin analog iron complexes were prepared in 10 mM
HEPES buffer and a UV-Vis scan was recorded. Next 120 µM EDTA was added and absorbance
at 500 nm was measured over 800 minutes. Iron-binding affinity (KFe) was determined using the
following calculations.
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[EDTA]T = total EDTA added
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Synthetic procedures:

Compound 1 was synthesized and characterized as previously reported by Miller and colleagues
following synthetic scheme 1.2 Briefly, 2,3 dihydroxybenzoic acid was benzyl protected with
benzylbromide and subsequent saponification afforded 2,3(bisbenzyloxy)benzoic acid (93%, 17.4
grams). An N,N’-carbonyldiimidazole (CDI)-mediated coupling reaction of spermidine and
2,3(bisbenzyloxy)benzoic acid afforded N’N8-bis(2,3-bis(benzyloxy)benzoyl)spermidine (91%,
6.87 grams). Addition of succinic anhydride in the presence of catalytic DMAP in DCM afforded
4-((4-(2,3-bis(benzyloxy)benzamido)butyl)(3-(2,3-bis(benzyloxy)benzamido)propyl)amino)-4oxobutanoic acid, S1 (93%, 3.79 grams). Correspondingly, boc protection of 5-amino-1-pentanol
(87%, 15.4 grams) followed by Mitsunobu amination with N-troc-O-benzyl-hydroxylamine
provided 2,2,2-trichloroethyl (benzyloxy)(5-((tert-butoxycarbonyl)amino)pentyl)carbamate, S2
(73%, 3.96 grams). The free amine of S2 was synthesized via the removal of boc-protecting group
of S2 by trifluroacetic acid. Subsequent EDC-mediated coupling with S1 in the presence of
facilitating base, triethyl amine and catalytic DMAP provided compound 1 (76%, 3.86 grams).
NMR characterization was consistent previously reports.
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Benzyl protected - Fimsbactin analog 1 was synthesized and characterized as previously
reported.2 Briefly, activated zinc was added to a stirring solution of compound 1 in a 1:1 mixture
of THF:AcOH at room temperature under argon atmosphere. To the stirring reaction mixture was
added succinic anhydride, dropwise, slowly. When the reaction was complete (as determined by
LC-MS, ~ 3 hours), the mixture was filtered to remove insoluble zinc, and the solvent removed
under reduced pressure. The resultant crude oil was dissolved in EtOAc and washed with water (2
times) and brine (2 times), dried over magnesium sulfate, filtered over cotton, and concentrated
under reduced pressure. The crude mixture was separated by preparative high performance liquid
chromatography (C18-silica, 0B to 95B gradient 17 minutes, 95B to 100B gradient 8 minutes, 5
mM ammonium acetate buffer) to afford benzyl-protected Fimsbactin analog 1 (60 mg) NMR
(Figures 7.13 & 7.14) analysis was consistent with previous reports.

Fimsbactin Analog 1. To a stirring solution of benzyl-protected Fimsbactin analog 1 dissolved in
MeOH under argon atmosphere was added ~1/10 mass equivalent of 10% Pd/C as a solid in one
portion. The flask was purged with H2, and the resultant solution stirred under hydrogen
atmostphere (1 atm) for approximately 1 hour. Upon confirmation of reaction completion by LC350

MS (~1 hr), the reaction mixture was filtered to remove insoluble palladium catalyst, and the
solution was concentrated under reduced pressure to afford Fimsbactin Analog 1 (10 mg). ESI LCMS, HR-MS and NMR (Figures 7.15-7.18) analysis of Fimsbactin Analog 1 were consistent with
previous reports

Benzyl protected - Fimsbactin analog 2. Activated zinc (6 mg) was added to a stirring solution
of compound 1 (6 mg) in a 1:1 mixture of THF:AcOH at room temperature under argon
atmosphere. To the stirring reaction mixture was added acetic anhydride (4.9 mg), slowly. When
the reaction was complete (as determined by LC-MS, ~ 3 hours), the mixture was filtered to
remove insoluble zinc, and the solvent removed under reduced pressure. The resultant crude oil
was dissolved in EtOAc and washed with water (2 times) and brine (2 times), dried over
magnesium sulfate, filtered over cotton, and concentrated under reduced pressure. The crude
mixture was separated by preparative high performance liquid chromatography (C18-silica, 0B to
95B gradient 17 minutes, 95B to 100B gradient 8 minutes, 5 mM ammonium acetate buffer) to
afford compound 3 (6 mg). NMR analysis of benzyl protected Fimsbactin analog 2 are shown in
Figures 7.19 & 7.20.
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Fimbactin Analog 2. To a stirring solution of compound benzyl protected Fimsbactin analog 2
dissolved in MeOH under argon atmosphere was added ~1/10 mass equivalent of 10% Pd/C as a
solid in one portion. The flask was purged with H2, and the resultant solution stirred under
hydrogen atmostphere (1 atm) for approximately 1 hour. Upon confirmation of reaction
completion by LC-MS (~1 hr), the reaction mixture was filtered to remove insoluble palladium
catalyst, and the solution was concentrated under reduced pressure to afford Fimsbactin Analog 2
(8.6 mg). Figures 7.21-7.24

Benzyl/Cbz protected - Fimsbactin analog 3. Activated zinc (6 mg) was added to a stirring
solution of compound 1 (4.4 mg) in a 1:1 mixture of THF:AcOH at room temperature under argon
atmosphere. To the stirring reaction mixture was added Cbz-beta-alanine-N-hydroxysuccinimide
ester (113 mg), slowly. When the reaction was complete (as determined by LC-MS, ~ 3 hours),
the mixture was filtered to remove insoluble zinc, and the solvent removed under reduced pressure.
The resultant crude oil was dissolved in EtOAc and washed with water (2 times) and brine (2
times), dried over magnesium sulfate, filtered over cotton, and concentrated under reduced
pressure. The crude mixture was separated by preparative high performance liquid
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chromatography (C18-silica, 0B to 95B gradient 17 minutes, 95B to 100B gradient 8 minutes, 5
mM ammonium acetate buffer) to afford Benzyl/Cbz protected - Fimsbactin analog 3 (5 mg). NMR
analysis is shown in Figures 7.25 & 7.26.

Fimsbactin Analog 3. To a stirring solution of Benzyl/Cbz protected - Fimsbactin analog 3
dissolved in MeOH under argon atmosphere was added ~1/10 mass equivalent of 10% Pd/C as a
solid in one portion. The flask was purged with H2, and the resultant solution stirred under
hydrogen atmostphere (1 atm) for approximately 1 hour. Upon confirmation of reaction
completion by LC-MS (~1 hr), the reaction mixture was filtered to remove insoluble palladium
catalyst, and the solution was concentrated under reduced pressure to afford Fimsbactin Analog 3
(4.2 mg). ). NMR analysis is shown in Figures 7.27-7.30.
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7.7 Figures and Tables

Figure 7.1: Natural Fimsbactin A and synthetic Fimsbactin Analogs. Common metal binding moieties are
highlighted – catechol (blue) and hydroxymate (red). Each compound contains a similar tetrahedral center
denoted with a *.
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Figure 7.2: Naturally produced siderophore Fimsbactin A and three synthetic analogs. Each
analog contains a different sidechain substituent which are negatively, neutral and positively
charged, respectively, as neutral pH.

Figure 7.3: Three Fimsbactin structural analogs are synthesized via divergent synthesis from
common compound 1
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Compound
Fimsbactin A12
Fims analog 1
Fims analog 2
Fims analog –
3

BauB Binding Affinity
(apo/holo)
354.8 ± 139.3/
244.4 ± 93.3
393.3 ± 63.3/
350.3 ± 143.5
259.3 ± 55.4/
215.9 ± 30.3
239.4 ± 103.2/
286.3 ± 106.9

LogKFe
27.1 ± 0.2
27.9 ± 0.1
28.5 ± 0.4
27.3 ± 0.1

Table 7.1: Iron affinities and periplasmic siderophore binding protein, BauB, binding affinities

OD600

for both iron-bound and iron-free Fimsbactin analogs and natural Fimsbactin A.

Figure 7.4: Influence of apo- and holo-fimsbactin analogs on A. baumannii growth. Bar graphs
depict the growth of A. baumannii ATCC 17978 determined by measuring the optical density at
600 nm (OD600) as a function of time in the presence of 15.625 µM concentration of either the
apo- or holo- form of each Fimsbactin analog. Error bars represent standard deviations from the
mean for three independent trials. ****p < 0.0001. Full growth curves at variable concentration
seen in Figure 7.5.
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Figure 7.5: Influence of apo- and holo-fimsbactin analogs on A. baumannii growth. Line graphs
depict the growth of A. baumannii ATCC 17978 determined by measuring the optical density at
600 nm (OD600) as a function of time in the presence of variable concentration of either the apoor holo- form of each Fimsbactin analog. Error bars represent standard deviations from the mean
for three independent trials.
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Figure 7.6: Growth inhibition by each Fimsbactin analog-Ga complex and the growth recovery of
variable Fimsbactin analog-Ga (0.975µM or 31.25µM) and 3.9µM Fimsbactin A-Fe or Acb-Fe.
Bar graphs depict the growth of A. baumannii ATCC 17978 determined by measuring the optical
density at 600 nm (OD600) as a function of time. Error bars represent standard deviations from the
mean for three independent trials. ****p < 0.0001, ns: non-significant. Full growth curves at
variable concentration seen in Figure 7.7, 7.8 and 7.9.
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Figure 7.7: (a) Dose dependent growth inhibition by Fimsbactin analog 1-Ga complex (b)
3.9µM Fim-Fe and variable Fimsbactin analog 1-Ga complex (c) 3.9µM Acb-Fe and variable
Fimsbactin analog 1-Ga complex .Line graphs depict the growth of A. baumannii ATCC 17978
determined by measuring the optical density at 600 nm (OD600) as a function of time. Error bars
represent standard deviations from the mean for three independent trials.
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Figure 7.8: (a) Dose dependent growth inhibition by Fimsbactin analog 2-Ga complex (b)
3.9µM Fim-Fe and variable Fimsbactin analog 2-Ga complex (c) 3.9µM Acb-Fe and variable
Fimsbactin analog 2-Ga complex .Line graphs depict the growth of A. baumannii ATCC 17978
determined by measuring the optical density at 600 nm (OD600) as a function of time. Error bars
represent standard deviations from the mean for three independent trials.
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Figure 7.9: (a) Dose dependent growth inhibition by Fimsbactin analog 3-Ga complex (b)
3.9µM Fim-Fe and variable Fimsbactin analog 3-Ga complex (c) 3.9µM Acb-Fe and variable
Fimsbactin analog 3-Ga complex .Line graphs depict the growth of A. baumannii ATCC 17978
determined by measuring the optical density at 600 nm (OD600) as a function of time. Error bars
represent standard deviations from the mean for three independent trials.

361

Figure 7.10: Fluorescence quenching by Fimsbactin analogs and their respective iron complex of
N-His6-BauB. Graphs depict intrinsic tryptophan fluorescence quenching (y-axis; excitation = 280
nm; emission = 340 nm) of 400 nM N-His6-BauB in the presence of variable siderophore
concentrations (x-axis). Apparent Kd values were calculated using a single-binding mode curvefitting model in GraphPad Prism version 7.0b. Error bars represent standard deviations for two
independent trials.
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Figure 7.11: Structural comparison of FimFe and Fimsbactin analog 1 complexes. DFT
calculated structures of the monoanionic (a) 1:1 [FimFe] - and (b) 1:1 [Fimsbactin analog 1-Fe]complexes (c) Overlay of both structures highlighting similarity of geometry and placement of
ligands.
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Figure 7.12: UV-Vis spectra of Fimsbactin analog 1, 2 and 3 iron complexes
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Figure 7.13. 1H-NMR (600 MHz, CDCl3) spectrum of benzyl-protected compound 2,
Fimsbactin Analog 1. The x-axis is chemical shift given in parts per million (ppm). The y-axis is
arbitrary peak intensity.
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Figure 7.14. 13C-NMR (151 MHz, CDCl3) spectrum of benzyl protected compound 2,
Fimsbactin Analog 1. The x-axis is chemical shift given in parts per million (ppm). The y-axis is
arbitrary peak intensity.
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Figure 7.15. 1H-NMR (600 MHz, CD3OD) spectrum of compound 2, Fimsbactin Analog 1. The
x-axis is chemical shift given in parts per million (ppm). The y-axis is arbitrary peak intensity.
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Figure 7.16. 13C-NMR (151 MHz, CD3OD) spectrum of compound 2, Fimsbactin Analog 1. The
x-axis is chemical shift given in parts per million (ppm). The y-axis is arbitrary peak intensity.
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Figure 7.17. Diode array optical absorbance detection (DAD) and extracted ion chromatograms
(EICs) for fimsbactin analog 1 [M+H]+ ions from LCMS analysis using ESI ionization in positive
ion mode. The x-axis represents retention time (min) for all chromatograms.
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Figure 7.18. High-resolution ESI MS (positive ion mode) of Fimsbactin analog 1
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Figure 7.19. 1H-NMR (600 MHz, CDCl3) spectrum of benzyl-protected compound 3, Fimsbactin
Analog 2. The x-axis is chemical shift given in parts per million (ppm). The y-axis is arbitrary
peak intensity.
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Figure 7.20. 13C-NMR (151 MHz, CDCl3) spectrum of benzyl-protected compound 3, Fimsbactin
Analog 2. The x-axis is chemical shift given in parts per million (ppm). The y-axis is arbitrary
peak intensity.
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Figure 7.21. 1H-NMR (600 MHz, CD3OD) spectrum of compound 3, Fimsbactin Analog 2. The
x-axis is chemical shift given in parts per million (ppm). The y-axis is arbitrary peak intensity.
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Figure 7.22. 13C-NMR (151 MHz, CD3OD) spectrum of compound 3, Fimsbactin Analog 2. The
x-axis is chemical shift given in parts per million (ppm). The y-axis is arbitrary peak intensity.
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Figure 7.23. Diode array optical absorbance detection (DAD) and extracted ion chromatograms
(EICs) for fimsbactin analog 2 [M+H]+ ions from LCMS analysis using ESI ionization in positive
ion mode. The x-axis represents retention time (min) for all chromatograms.
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Figure 7.24. High-resolution ESI MS (positive ion mode) of Fimsbactin analog 2
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Figure 7.25. 1H-NMR (600 MHz, CDCl3) spectrum of benzyl/cbz-protected compound 4,
Fimsbactin Analog 3. The x-axis is chemical shift given in parts per million (ppm). The y-axis is
arbitrary peak intensity.
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Figure 7.26.

13

C-NMR (151 MHz, CDCl3) spectrum of benzyl/cbz-protected compound 4,

Fimsbactin Analog 3. The x-axis is chemical shift given in parts per million (ppm). The y-axis is
arbitrary peak intensity.
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Figure 7.27. 1H-NMR (600 MHz, DMSO-d6) spectrum of compound 4, Fimsbactin Analog 3. The
x-axis is chemical shift given in parts per million (ppm). The y-axis is arbitrary peak intensity.
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Figure 7.28.

13

C-NMR (151 MHz, DMSO-d6) spectrum of compound 4, Fimsbactin Analog 3.

The x-axis is chemical shift given in parts per million (ppm). The y-axis is arbitrary peak intensity.
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Figure 7.29. Diode array optical absorbance detection (DAD) and extracted ion chromatograms
(EICs) for fimsbactin analog 3 [M+H]+ ions from LCMS analysis using ESI ionization in positive
ion mode. The x-axis represents retention time (min) for all chromatograms.
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Figure 7.30. High-resolution ESI MS (positive ion mode) of Fimsbactin analog 3
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Chapter 8: Conclusions and Future
Directions
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8.1 Preface
This chapter was written by T. Bohac. Initial work towards some of the future directions
has been conducted by TJB, VSB and LF.

8.2 Summary of Dissertation
Taken collectively, this dissertation aims to further expand the fundamental knowledge of
pathogenic virulence factors in the hopes of combating the rise in anti-microbial resistance –
particularly as it relates to the multi-drug resistant pathogen A. baumannii. This dissertation
focuses on nutrient acquisition, metal in particular, via small secondary metabolites called
siderophores. A. baumannii is known to synthesize three classes of siderophores, acinetobactin,
Fimsbactin and baumannoferrin. This dissertation is two-part in that it begins with furthering the
current knowledge of the natural system and ends with applying this knowledge to the design and
synthesis of antimicrobial compounds for potential therapeutic applications.
Chapter one of this dissertation provides an in-depth discussion of iron acquisition in
pathogens, as well as an overall of the current knowledge of the siderophores of A. baumannii.
Chapter two expands upon the knowledge of siderophore acinetobactin, as we discuss a crystal
structure of Acb2Fe bound to periplasmic siderophore binding protein, BauB. We identify key
binding residues and interactions and perform fluorescence quenching assays with a panel of
acinetobactin and pre-acinetobactin analogs to further probe these key binding interactions.
Chapter three discusses the isolation and characterization of siderophore Fimsbactin A. By
performing siderophore competition studies between natural acinetobactin and Fimsbactin A, we
were surprised to see an inhibitory effect at high concentrations of Fimsbactin A, demonstrating
the importance of concentration and balance in the growth-promoting siderophore cocktail.
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Moreover, studies on protein binding and ligand displacement showed that Fimsbactin A can
compete with acinetobactin for siderophore transport protein BauB. We proposed that this finding
was important in understanding the role of siderophore cocktail biosynthesis and production, as
strains containing the Fims biosynthetic gene cluster maintain low concentrations of Fims in
infectious conditions. Furthermore, many strains of A. baumannii do not contain the Fimsbactin
biosynthetic gene cluster but produce high quantities of acinetobactin, thus eliminating any
deleterious competition caused by dual production.
Chapter four attempts to examine the seemingly redundancy of multiple siderophores in A.
baumannii, we isolated and characterized Fimsbactin F and explored additional siderophore
combination studies. In addition, we investigated metal preference among natural and synthetic
siderophores to explore their role in metal homeostasis.
Chapter five and six explore the ability to induce subtle structural changes through
oxidation and aromatization of cyclic moieties to transform a growth promoting siderophore,
acinetobactin, into a growth inhibitor “siderophore-like” analog, oxidized acinetobactin. We show
iron binding to be crucial for inhibition, and findings support that inhibition occurs through the
disruption of the siderophore transport pathway. We highlighted OxPreAcb effectiveness against
a panel of CDC multi-drug resistant A. baumannii clinical isolates, and concurrent mammalian
cytotoxicity studies showed that OxPreAcb was non-cytotoxic, even at high concentrations,
making it an ideal candidate for further development in in vivo infection models.
Finally, studies presented in Chapter seven examined a currently used Fimsbactin structural
mimic and generated 2 new related analogs. We hypothesized that these mimics would serve as
effective vehicles for antibiotic drug delivery, through Trojan horse siderophore-antibiotic
conjugates, and studies were designed to validate the effectiveness of the structural analogs to
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behave in a similar manner to the natural system. In this regard, we were able to confirm that the
three Fimsbactin mimics serve as both structural and functional Fimsbactin mimics and that net
charge has little to no effect on the ability of each mimic to function as a siderophore. Taken
collectively, this work highlights the ability to simplify structurally complex siderophore systems,
while maintaining biological viability, and serves as a reference for further development of
siderophore probe molecules—particularly in regards to Trojan horse antibiotic delivery.

8.3 Future Directions
While this dissertation extended previous work, it also laid the foundation for future work.
While there are many many ideas and future directions that stem from the work discussed in this
dissertation, herein I will highlight a few areas that I view as interesting and instrumental in the
future of this project.
Baumannoferrin synthesis and evaluation
In order to truly understand the interworking of a siderophore cocktail in A. baumannii, the
third siderophore, the baumannoferrins, must be synthesized or isolated. While no total synthesis
of the baumannoferrins has been reported, synthesis of siderophores containing fragments similar
to the baumannoferrins have been reported in the synthesis of staphyloferrin B by Nolan (2015) 1
and in the synthesis of acinetoferrin by Phanstiel (1998).2 Using similar methods developed in
these two works, a proposed total synthesis of the baumannoferrins could be accomplished through
the route seen in Figure 8.1.
The proposed synthesis commences with isolation of benzyl ester 4 in three steps starting
from (S)-malic acid 1, as previously reported by Nolan (2015).1 Dioxolanone 2 is afforded through
the stereoselective acetyl protection of malic acid 1 with trimethylacetaldehyde. Allylation by
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allyl bromide, with lithium hexamethyldisilazide (LiHMDS) as facilitating base, provides 3 in
moderate yield. Subsequent ring-opening transesterification affords the resulting acid 4. In turn,
amine 7 could be generated from the EDC-mediated coupling of carboxylic acid 5, derived from
2-oxo-pentanedioic acid.3 and amino-acid derivative 6, derived from Bn-protected Boc-protected
of 2, 4-diamino-butyric acid.
Coupling of amine 7 with acid 4, using EDC and Hunig’s base, would provide amide 8.
Oxidative cleavage of the terminal olefin of 8 with ruthenium (III) chloride in the presence of
sodium periodate would afford terminal carboxylic acid 9. EDC-mediated coupling of acid 9 with
compound tert-butyl (3-aminopropyl)(benzyloxy)carbamate 10, in the presence of facilitating base
(N,N-diisopropylethylamine, DIPEA), would generate compound 11. Subsequent Pd-catalyzed
hydrogenation and treatment with TFA would provide hydroxamine 12. The diversification of
baumannoferrin analogs can be achieved at in the final step of the synthesis, where various acid
chlorides can be coupled with hydroxamine 12 to provide the corresponding hydroxamides.
Through exploration of derivatives, necessity of a double bond in the structure could be probed or
additional degrees of unsaturations can be installed to evaluate the importance of tail structural
rigidity. Additionally, since it has been hypothesized that the baumannoferrins are able to integrate
with the lipid membrane and experience membrane “flip-flop”, based upon a “flip-flop” motion
observed by structurally similar siderophore acinetoferrin (Figure 8.2), we can identify the optimal
chain length of the hydrophobic lipid chain through analog synthesis. 4 In the case of the synthesis
of baumannoferrin A (13), hydroxamine 12 can be treated with 2-decenoyl chloride (derived from
2-decenoic acid) with facilitating base to afford the title product (13).
With the baumannoferrins in hand, we could explore structure activity relationships as
aforementioned. Further, we could perform biological evaluation of the baumannoferrins through
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growth assays, metal binding and affinity studies and protein binding assay. Moreover, with preacinetobactin, acintobactin and Fimsbactin already isolated/synthesized, combination studies with
all three siderophore classes of A. baumannii would allow for a more holistic representation of the
natural system.
Further derivatization of OxPreAcb and Click Chemistry
In Chapters 5 and 6, the synthesis and evaluation of oxidized pre-acinetobactin (OxPreAcb)
and analog was discussed in depth. With the strong inhibitory nature of this lead compound, further
evaluation and exploration of this compound is merited. While 8 structural analogs of OxPreAcb
have been synthesized and evaluated, discussed in Chapter 6, further diversification and SAR of
OxPreAcb can be explored around the right hand of the molecule with changes to the imidazole
tail (Figure 8.3), as this position was seen to be non-crucial for iron binding nor growth inhibition.
Further diversification can be explored at the oxazole ring system (Figure 8.3), to date no SAR
around this system has been explored.
While we have seen that OxPreAcb can interact with BauB and the siderophore transport
pathway, further exploration of the mechanism of action of this molecule is desirable. One analog
of OxPreAcb that can allow for vast diversification and serve many function is an OxPreAcb
alkyne with the alkyne moiety on the right hand side of the molecule in place of the imidazole ring
(Figure 8.4). This alkyne moiety then can undergo click chemistry with different azide molecules,
resulting in formation of a triazole moiety along with attachment of different groups as seen in
Figure 8.4. One route can use click chemistry with azide-antibiotic groups to observe where the
OxPreAcb molecule reaches inside the cell, as well as to observe the inhibitor-antibiotic effect on
inhibition. As discussed in Chapter 7, work by many, including Wencewecz et al., highlighted the
utility of employing siderophore-antibiotic conjugates as a means of Trojan horse drug delivery. 5
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While a siderophore is innately growth promoting, siderophore-antibiotic conjugates have been
seen to reach MIC’s as low as 0.2 µM against A. baumannii6; since OxPreAcb in itself is inhibitory,
OxPreAcb-antibiotic conjugates serve as an attractive target molecule. Further, following work by
Wencewicz at el, through attachment of beta-lactams antibiotics (penicillin binding protein target
– periplasm) and fluoroquinolones antibiotics (DNA gyrase target – cytoplasm), we can investigate
where the OxPreAcb molecule reaches in the cell based upon MIC values and effectiveness of
these two conjugates.5 In the same vain, click chemistry between the OxPreAcb-alkyne and
fluorophore-azides can allow for imaging and cellular localization studies and possible
identification of the ultimate intracellular location of the OxPreAcb-fluorphore conjugate.
While we have evidence that OxPreAcb interacts with periplasmic siderophore binding
protein, BauB, we can use the OxPreAcb-alkyne molecule to further probe the interactions of
OxPreAcb on the protein level. Through bacteria feeding studies, incubation allows the OxPreAcbalkyne to interact with target proteins, which, after cell lysis and click conjugation with an affinity
tag, could be isolated and characterized through MS-MS proteomics.
We have previously showed that OxPreAcb binds to iron in a 2:1 stoichiometry. 7
Synthetically derived OxPreAcb dimers, using click chemistry between the OxPreAcb-alkyne
molecule and an OxPreAcb-azide molecule, serve as interesting target compounds. These dimers
can be synthesized of various lengths, as well as of various forms of connectivity (head to head,
tail to head, etc.). Subsequent iron binding and metal titration studies with the generated dimer
library would allow for the determination of metal-ligand stoichiometry—in hopes of identifying
a candidate which binds iron in a 1:1 ligand-metal conformation. Such a system would decrease
the entropy cost associated with iron binding and enhance the ability of the molecule to outcompete
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the natural acinetobactin system. Outcompeting the natural siderophore systems would then
provide a means to more potently inhibit the growth of MDR A. baumannii.
Extending oxidation to other known siderophores with oxidizable groups
Previous work by the Henderson group highlighted the ability of nature to synthesize an
antimicrobial secondary metabolite, esherichelin, which is structurally similar to a known growth
promoting siderophore, pyrochelin.8 The most noteworthy difference between these two
compounds is the degree of unsaturation within the S,N-containing heterocycle, which is a thiazole
in escherichelin and a thiazoline in pyrochelin. As discussed in Chapters 5 and 6, our group was
able to extend this “oxidation strategy” to the acinetobactin system of A. baumannii by
synthesizing an oxidized variant of the natural siderophore. This variant, coined OxPreAcb,
contained an oxazole in the place of the natural oxazoline and served as a growth inhibitor as
opposed to a growth promoter.7 Pyrochelin and pre-acinetobactin are two of a plethora of known
siderophores with oxidizable heterocyclic groups; some of these siderophores include agrobactin,
anguibactin, and mycobactin (Figure 8.5). With the structural similarity to pre-acinetobactin,
anguibactin, produced by the fish pathogen Vibrio anguillarum, presents as a suitable target
molecule for synthesis and evaluation by our group. Additionally, a recent publication by Abe et
al reports the isolation of the hinduchelins A-D. 9 These compounds contain a central oxazole,
serving as yet another example of a siderophore-like oxidized system further supporting the
incorporation of these motifs in future synthetic strategies to biologically active small molecules.
Our group has been recently working towards the synthesis of both the natural anguibactin
siderophore, as well as the oxidized version of the molecule. Unlike pre-acinetobactin, anguibactin
is hypothesized to not undergo isomerization to a post-isomerized form (Figure 8.6).10,

11

However, this hypothesis has never been experimentally confirmed in the context of a synthetic
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strategy. Thus, our group targeted the synthesis of natural anguibactin in order to evaluate its
biological activity and explore its possible pH-dependent isomerization. While current efforts are
focused on optimization of the synthesis, initial synthetic efforts commenced with EDC/HOBt
mediated coupling of 2,3-dihydroxybenzoic acid and L-cysteine-methyl ester in the presence of
facilitating to afford coupled compound 1 (Figure 8.7). Compound 1 is then cyclized to afford the
corresponding thiazoline-methyl ester 2. Concurrently, histamine 3 is converted to the
corresponding halogenated salt 4 which then through an SN2 reaction with N-boc-O-benzyl-amine
provides N-boc-O-benzyl-histamine 5. Thiazoline-methyl ester 2 is then saponified with lithium
hydroxide to afford the free acid. Hydrogenation of N-boc-O-benzyl-histamine 5 with palladium
on carbon followed by treatment with trifluoroacetic acid provides free amine, N-(2-(1H-imidazol4-yl)ethyl)hydroxylamine, 7. EDC/HOBt mediated coupling between free acid and free amine in
the presence of facilitating bases yields title compound, anguibactin. Interestingly, with HPLC
prep purifying the title compound, anguibactin (m/z 348), we observed a new peak appearing over
time. This new peak (m/z 332) we hypothesize is in fact due to isomerization of anguibactin,
followed by hydrolysis of the newly formed thiocarbonyl forming des-methyl-acinetobactin
(Figure 8.8). We hypothesis that the isomerization is indeed occurring and due to the subsequent
addition of water, may have gone overlooked previously. Future studies are needed to isolate, fully
characterize, and monitor isomerization conditions and determine isomerization rates of the
anguibactin system.
The synthesis of oxidized anguibactin (OxAng) is also currently being pursued and
optimized in our lab. Similarly to the synthesis of OxPreAcb, the synthesis of OxAng commences
with a one pot, two-step reaction of coupling 2,3-dihydroxybenzaldehyde and L-cysteine-methylester, cyclization and oxidation by DBU to afford the thiazole-methyl-ester 1 (Figure 8.9). As
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previously discussed N-boc-O-benzylhydoxyhistamine 4 can be synthesized in 2 steps starting
from histamine 2. Saponification of thiazole-methyl-ester with lithium hydroxide afforded free
acid 5 while treatment of doubly protected amine 4 with TFA provides free amine 6. HATU
coupling of acid 5 and amine 6 yields the title compound-benzyl-ester protected 7, which upon
deprotection with boron trichloride and tetra-n-butylammonium bromide, affords OxAng 8.
Upon successful synthesis of both anguibactin and OxAng, biological evaluation of these
compounds can explore whether the oxidation of a known siderophore can result in inhibition in a
third system. Provided OxAng has an inhibitory effect, this strategy of siderophore oxidization as
a potential anti-virulent approach should be optimized and extended as a general strategy of
combating multi-drug resistant pathogens.
Fimbactin (A and F) analogs and antibiotic conjugates
As discussed in chapters 3 and 4, we now have a method for isolating natural Fimsbactin
A, as well as natural Fimsbactin F, from A. baumannii culture. Isolating these compounds opens
the door for numerous derivatization and conjugation chemistry. Using a semi-synthetic approach,
isolation of Fimsbactin A and F followed by oxidation of the oxazoline ring, using methods such
as the DBU oxidation that was seen to be successful with the OxPreAcb system, might allow for
the synthesis of yet another two oxidized siderophore systems (Figure 8.10). Further, Fimsbactin
F contains an alcohol moiety that can serve as a handle for potential further chemistry (Figure
8.11). Like with the OxPreAcb-alkyne system, further diversification can include attachment of
fluorophores and/or antibiotics to both investigate the target location of Fimsbactin F inside the
cell, as well as serve as a Trojan horse scaffold. Moreover, the alcohol handle on Fimsbactin F
may allow for quick diversification through the addition of varies acyl chlorides. Addition of a
molecule such as 4-chlorobenzoyl chloride can serve as a probe molecule to investigate the
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relationship/interconversion, if any, between Fimsbactin A and Fimsbactin F. Synthesizing this
analog, feeding it to the bacteria, and then performing HRMS can allow us to detect formation, if
any, of the free 4-chlorobenzoic acid. If detected that may indicate that Fimsbactin A is cleaved
by an esterase to yield Fimsbactin F.
Fimsbactin A can also be obtained through total synthesis as shown in Figure 8.12. Crude
final compound was obtained, however there was racemization at the denoted carbon. This
synthetic strategy could be optimized to allow for diversification to allow for the synthesis of
various fimsbactin analogs.
DFT computational calculations and BauB crystal structures
With extremely fruitful collaborations with both the Gulick group (State University of New
York at Buffalo) and Dr. Daryl Giblin (WUSTL Chemistry), we are currently continuing our
efforts to further expand upon on previous work. Efforts continue to crystalize periplasmic
siderophore binding protein, BauB, and other siderophore transport proteins with our current panel
of natural and synthetic compounds. Further structural evidence and interactions at the protein
level will allow for more targeted structure diversification work, as well as provide insight to the
inter-workings of the natural siderophore transport pathways. DFT and computational work
continues to explore lowest energy confirmation of natural and synthetic compounds, as well as to
explore metal interactions and metal complex formations to extend upon our work with various
metal titration/preference of various siderophore systems.
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8.5 Figures

Figure 8.1. Proposed synthetic route towards the total synthesis of the baumannoferrins.
Highlighted in red shows a site of potential diversification which can allow for rapid derivatization
of variable chain length and degrees of unsaturation.
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Figure 8.2. Structures of Baumannoferrin A and structurally similar Acinetoferrin. Shared
structural features are highlighted in red.

Figure 8.3. OxPreAcb structure. Blue circles represent areas for potential site for further
diversification.

Figure 8.4. OxPreAcb-alkyne molecule can allow for rapid functionalization via click chemistry
to explore the location of OxPreAcb in the cell, protein the molecule interacts with, potential
optimization of the molecule as an inhibition through dimerization and a potential Trojan horse
vehicle inhibitor-antibiotic system.
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Figure 8.5. Structures of siderophores with oxidizable groups highlighted in green. Groups in red
denote the two oxidized moiety in “siderophore-like” molecules that have been shown to be
inhibitory in their respective pathogens.

Figure 8.6. Anguibactin, a siderophore from Vibrio anguillarum is thought to not be able to
undergo spontaneous isomerization as is seen in the case of pre-acinetobactin from A. baumannii
isomerizing to acinetobactin. Initial research by group, however, suggests potential isomerization
followed by addition of water to the thiocarbonyl to afford acinetobactin des-methyl.
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Figure 8.7. Synthetic route to the total synthesis of anguibactin
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synthetic anguibactin.
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Figure 8.9. Synthetic route towards the total synthesize of OxAng

Figure 8.10. Potential semi-synthetic route to synthesis of Ox-FimA and Ox-FimF
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Figure 8.12. Synthetic efforts towards the synthesis of Fimsbactin A. Crude compound was
obtained but there was racemization of stereochemistry at the denoted carbon. Further optimization
is needed.
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